Investigating Murine Double Minute-2 Pro-Angiogenic Function in Health and Disease: An Integrative Approach from Rodent and Human Skeletal Muscle to Primary Endothelial Cells by Aiken, Julian Alexander
Investigating Murine Double Minute-2 pro-angiogenic function in 
health and disease: an integrative approach from rodent and human 
skeletal muscle to primary endothelial cells 
 
JULIAN AIKEN 
 
A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE STUDIES 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 
GRADUATE PROGRAM IN KINESIOLOGY & HEALTH SCIENCE 
YORK UNIVERSITY 
TORONTO, ONTARIO 
APRIL 2018 
 
© Julian Aiken, 2018 
 
Abstract 
Capillaries are essential for overall skeletal muscle health, transporting nutrients and oxygen as 
well as removing waste from muscle cells. Angiogenesis is the process of capillary growth from 
pre-existing capillaries, and is regulated by a balance of pro- and anti-angiogenic factors. Our 
laboratory has demonstrated that Murine Double Minute-2 (Mdm2) is essential for skeletal muscle 
capillary maintenance as well as for exercise-induced angiogenesis. The aim of my research was 
to further investigate Mdm2 function in both physiological (exercise) and pathological (diabetes) 
contexts at the tissue level of the skeletal muscle and in primary endothelial cells. I first contributed 
to show that Mdm2 protein levels are elevated following a prolonged exercise training program in 
human skeletal muscle (academic research paper 1). Next, I investigated the response of Mdm2 
to an acute bout of exercise, which itself represents a powerful pro-angiogenic stimulus (academic 
research paper 2). Muscle contractile activity stimulates Mdm2 phosphorylation on its serine 166 
concomitant with increased pro-angiogenic vascular endothelial growth factor-A (VEGF-A). 
Mdm2 phosphorylation was found to be dependent on VEGF-A signaling, demonstrating for the 
first time that Mdm2 and VEGF-A can interact in a complex regulatory loop. In vitro experiments 
show that VEGF-A-dependent activation of Mdm2 leads to increased migratory activity of 
endothelial cells. This effect appeared to be a result of enhanced Mdm2-FoxO1 binding, resulting 
in the inhibition of FoxO1-dependent regulation of thrombospondin-1 expression, a potent anti-
angiogenic molecule. I further explored this relationship between VEGF-A and Mdm2 in academic 
research paper 3, demonstrating that VEGF-driven Mdm2 phosphorylation was dependent on 
extracellular signal related kinases 1/2 (ERK1/2) - p90 ribosomal s6 kinase (p90RSK) in primary 
human endothelial cells. Finally, academic research paper 4 provided evidence that Mdm2 is a 
clinically relevant protein in type 1 diabetes (T1D), a highly understudied disease in the context of 
ii
skeletal muscle angio-regulation. Mdm2 protein abundance was lowered in muscles from T1D 
animals alongside increases in key anti-angiogenic Mdm2 targets and significant capillary 
regression. Taken together, my dissertation research clearly identifies Mdm2 as a master regulator 
of angio-adaptation at the level of the skeletal muscle and endothelial cells in both health and 
disease.   
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1. INTRODUCTION & LITERATURE REVIEW 
1. The skeletal muscle microvasculature  
1.1 The importance of the skeletal muscle microvasculature 
 The skeletal muscle tissue accounts for 40% of our body weight and is essential for a 
variety of functions including metabolic regulation and locomotion [1]. The basal metabolism of 
the skeletal muscle tissue requires roughly 20% of total cardiac output and with acute exercise 
blood flow to the muscle tissue can increase by 20 fold or more during maximal exercise [2-5]. In 
order to ensure proper functioning, active muscle cells must be supplied with adequate oxygen and 
nutrient delivery along with the removal of metabolic wastes. The vascular system is composed of 
blood vessels ranging in size from large arteries and veins and smaller arterioles and venules 
(macrovasculature) to the capillaries (microvasculature). Capillaries are our smallest blood vessels 
with an average diameter of around 5µm [6,7]. The capillary network serves as the site of gas and 
nutrient exchange in all bodily tissues including the skeletal muscle [8,9]. In the skeletal muscle, 
capillaries are intimately associated with muscle fibers, running parallel and longitudinally to the 
fibers, with short lateral branches forming vascular networks. In 1919, a pioneering theory was put 
forth by August Krogh that describes each capillary as supplying a cylindrical area of muscle with 
oxygen and nutrients which travel from the bloodstream, out of the capillary, and to the muscle 
cells [10]. As oxygen has a limited diffusion distance, the density and distribution of capillaries 
surrounding muscle fibers determines the oxygenation and the metabolic capacity of the muscle 
tissue [11] . The oxygen capacity of the skeletal muscle is largely predicted by the capillarization 
of the tissue and is a direct determinant of exercise capacity, since exercise requires large increases 
in blood flow to working muscle groups [2]. Indeed, it is well documented that more oxidative 
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muscle types have a greater capillary density [12]. Since each individual capillary has the capacity 
to supply only a limited surface area of muscle, we can appreciate that the loss of capillaries can 
likely result in loss of muscle function. All blood vessels, including our capillaries, are made up 
of endothelial cells and, as such, it is the regulation and activity of the endothelial cell itself that 
largely determines overall microvascular function. 
1.2 Skeletal muscle capillary plasticity 
 The skeletal muscle capillary network shows remarkable plasticity, adapting to both 
physiological and pathological conditions by capillary expansion or regression. In healthy adults, 
endothelial cells are usually quiescent, and do not divide, with cell turnover time in the hundreds 
of days [13]. However, in response to pathological stimuli such as tumor growth and wound repair, 
or physiological stimuli such as menstruation and exercise training, endothelial cells begin to 
proliferate and migrate to form new capillaries [2].  
1.2a Vasculogenesis 
The de novo formation of the vascular network is termed vasculogenesis, and is one of the 
first steps in embryo development [14]. This process entails the aggregation of hemangioblasts, 
which are blood and endothelial precursor cells, forming the first vascular structures termed blood 
islands [15]. The formation of a primary capillary plexus is achieved through the fusion of multiple 
blood islands [15]. Maturation of this primary plexus involves cell proliferation, migration and 
angiogenesis, which is discussed in subsequent sections. Interestingly, vasculogenesis is not 
restricted to the developing embryo, as it also can occur in adults in response to acute and chronic 
ischemic conditions that result in hypoxia such as vascular disease, wound healing, tumor growth, 
retinopathy, and during exercise [16]. The process whereby endothelial precursor cells lead to 
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adult neovascularization is termed postnatal vasculogenesis, and is driven by bone-marrow derived 
endothelial progenitor cells (EPCs) [17,18]. An elevation in circulating EPCs that are released 
from the bone marrow travel to ischemic, hypoxic, or injured tissue and differentiate into mature 
endothelial cells [18]. Indeed, a number of studies demonstrate that exercise-induced hypoxia and 
muscle ischemia increase the amount of circulating EPCs and promote neovascularization [16,19-
22]. 
1.2b Arteriogenesis 
 Arteriogenesis is the process through which existing arteries and arterioles are enlarged in 
both diameter and wall thickness leading to an overall larger blood vessel involving the 
remodelling of endothelial cells, vascular smooth muscle cells (VSMC), and fibroblasts [2,23]. 
While older literature also refers to arterial collateralization and capillary arterialization as 
arteriogenesis, these are separate processes whereby new arterial conduit vessels are formed to 
bypass an occlusion, or existing mature capillaries are surrounded by vascular smooth muscle cells, 
respectively [2]. The purpose of arteriogenesis is to increase the blood flow capacity of a resistance 
vessel (a vessel that has the ability to dilate or constrict in order to regulate blood flow to 
downstream tissues). Since arteriogenesis cannot compromise the vessel’s ability to dilate and 
constrict, thickening of the vascular wall (due to VSMC and extracellular matrix remodelling) 
must also occur in addition to increases in diameter [2]. The velocity of blood flow, elevated 
internal pressure, and the total volume of blood a resistance vessel experiences directly dictates 
the size of that vessel, as this exposes the endothelium to greater shear stress (the physical drag 
endothelial cells experiences as blood rushes past in the vessel lumen [23]. Prolonged exercise 
training can induce arteriogenesis by intermittently increasing the shear stress experienced by the 
arterial endothelium during exercise bouts as exercise increases heart rate, stroke volume and thus 
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cardiac output. Indeed, it has been demonstrated that the size of major vessels is tightly associated 
with the level of exercise training or disuse of a specific downstream muscle group [24]. 
1.2c Angiogenesis  
The process whereby new capillaries are formed from pre-existing ones is termed 
angiogenesis. Angiogenesis is essential for a number of physiological processes including organ 
and tissue regeneration and repair, during wound healing, menstruation and pregnancy, and 
exercise training [25-28]. There are two distinct processes in which new capillaries are formed 
from pre-existing ones, termed ‘sprouting’ and ‘intussusceptive’ (splitting) angiogenesis, 
respectively. Sprouting angiogenesis first involves the activation of endothelial cells, a degradation 
of the basement membrane and extracellular matrix (the structural area surrounding the capillary), 
endothelial cell proliferation, migration and subsequent lumen formation [29-31]. The second 
phase sees the new vessel mature and differentiate through the recruitment of associated cell types 
such as pericytes, the addition of extracellular matrix around the sprout, and re-entry into the 
capillary bed to form a capillary loop [29-31]. Sprouting angiogenesis is observed in response to 
muscle activity as is seen during chronic electrical stimulation [32]. Alternatively, intussusceptive 
angiogenesis involves the insertion of endothelial cell projections, or pillars, within the lumen of 
the vessel eventually splitting the original lumen into new vessels [33,34], and occurs in response 
to elevated blood flow [7]. Splitting angiogenesis is understood as being a more energy efficient 
form of new capillary formation, as it requires less endothelial cell proliferation and does not 
require basement membrane degradation to occur [23]. Refer to figure 1.1 for a schematic 
overview of sprouting versus intussusceptive angiogenesis. Increased capillary branching results 
in greater surface area and increased capillary-muscle interface [2]. This adaptation allows for 
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increased blood residence time and therefore increased oxygen and substrate exchange time in 
combination with decreased diffusion lengths [2]. 
 
 
Figure 1.1 The difference between sprouting and intussusceptive angiogenesis. Sprouting 
angiogenesis involves the proliferation and migration of endothelial cells to form a vascular sprout 
leading to a new capillary. Intussusceptive angiogenesis occurs when tissue pillars project into an 
existing lumen to form new, separate lumens. Both sprouting and intussusceptive angiogenesis 
leads to increased branching of the capillary network, while capillary regression, or pruning, leads 
to fewer capillaries.  
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1.3 Measurements of skeletal muscle angiogenesis / capillary regression  
 The capillary density (CD) is commonly measured to determine the extent of skeletal 
muscle perfusion, and is given by the cross-sectional counting of the total number of capillaries in 
a given surface area of muscle. Occasionally, the CD is wrongfully used as a true indicator of 
angiogenesis. Since the CD can increase or decrease as a result of muscle atrophy or hypertrophy, 
respectively, with no actual capillary growth or regression occurring, it cannot be used as a 
measurement of true angiogenesis. Instead, the CD could be considered a way to appreciate blood 
perfusion to the muscle, as it reflects the amount of capillaries present in a given surface area of 
muscle tissue. A true indication of skeletal muscle angiogenesis is the capillary-to-fiber (C/F) ratio, 
which is given by taking the ratio of capillaries to muscle fibers in a cross-sectional area of a 
muscle biopsy. The C/F ratio is not affected by muscle atrophy or hypertrophy, and therefore is a 
reliable measurement to assess skeletal muscle capillarization and angiogenesis. 
1.4 Exercise-induced skeletal muscle angiogenesis  
The process of skeletal muscle angiogenesis in response to exercise training, termed 
exercise-induced angiogenesis, is a main focus of this dissertation. It is well documented that 
exercise training leads to improved blood flow capacity to working muscle groups [35]. Several 
mechanisms contribute to establish this exercise-induced adaptation (i.e. increased cardiac output 
and arteriogenesis), with muscle capillarity being an important determinant of the overall blood 
flow capacity of the skeletal muscle. As previously stated, the capillary network matches oxygen 
and nutrient delivery to the metabolic needs of muscle cells. Thus, in response to repetitive muscle 
contractile activity, the capillary network must adapt to the increase in metabolic demand of active 
muscle cells [1]. Angiogenesis, therefore, plays a critical role in muscle adaptation to exercise 
training [2]. In humans, endurance exercise training is a strong driving force for skeletal muscle 
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angiogenesis, with training programs lasting between 4 to 24 weeks in duration leading to 10-25% 
increased muscle capillarity in most cases [36]. Indeed, it is well documented that aerobic 
endurance exercise leads to skeletal muscle angiogenesis in response to numerous exercise 
modalities [1]. Aerobic exercise may induce increased muscle capillarization independent of 
changes in fiber size, however the cross-sectional area of muscle fibers typically remains unaltered 
and the changes in capillary density and capillary-to-fiber ratio are unidirectional [36]. In contrast, 
heavy resistance exercise in which skeletal myocytes undergo hypertrophy can lead to decreases 
in capillary density, due to increased muscle cross-sectional area [37]. Resistance programs that 
incorporate higher repetition exercises may prevent such a loss in capillary density [2,29]. Indeed, 
several studies show an increase in the capillary-to-fiber ratio in response to resistance exercise 
training, preserving the capillary density and therefore the perfusion of the muscle [38-40]. 
Furthermore, a study from Gavin and colleagues [41] shows that the response of angio-adaptive 
growth factors are similar in magnitude and timing in response to resistance versus aerobic 
exercise.  
Exercise can promote skeletal muscle angiogenesis through several specific mechanisms 
that provide stimulus for the growth of skeletal muscle capillaries. The physical environment of 
the microvasculature is an important determinant of whether the capillary network is maintained, 
expands, or regresses. Physical forces are always present at the level of the endothelium, and all 
blood vessels are exposed to mechanical stimuli from both the surrounding area such as stretch 
and muscle contraction and from intravascular stresses such as blood pressure and shear stress 
[42]. All of these mechanical forces have the ability to contribute to the formation of new 
capillaries in response to exercise.  
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As stated previously, shear stress is a mechanical stress defined as the physical drag 
endothelial cells experience as blood rushes past in the vessel lumen [23]. Unlike arterioles, 
capillaries lack the ability to regulate their diameter due to the absence of vascular smooth muscle 
cells surrounding the vessel. Therefore, the adaptation of the capillary network to shear stress 
differs to the process of arteriogenesis. Instead of an enlargement of the vessel, the capillary 
network can expand by angiogenesis to allow a greater amount of blood to flow through the muscle 
tissue due to increased capillary surface area, mainly through intussusceptive vs. sprouting 
angiogenesis [42,43]. Shear stress is sensed by endothelial cells by mechanotransducers present 
on the cell surface such as G-proteins, cell-matrix and cell-cell adhesion molecules, ion channels, 
and tyrosine kinases (such as the vascular endothelial growth factor receptor 2 [VEGFR2]) 
[36,44,45]. When mechanoreceptors sense shear stress they become activated and initiate 
downstream signaling through mitogen activated protein kinases (MAPKs) and 
phosphatidylinositide 3-kinase (PI3K)-Akt signaling [44,45]. Shear stress induces alterations in 
gene expression by increasing the activity of a number of transcription factors including early 
growth response protein 1 (Egr-1), activator protein-1 (AP-1), specificity protein 1 (Sp1), and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [44,46] that bind to 
common promoter regions in target genes termed shear stress responsive elements (SSREs) [44,47] 
with subsequent expression of growth factors and molecules involved in angiogenesis such as 
endothelial nitric oxide synthase (eNOS), nitric oxide (NO), VEGFR2, vascular endothelial growth 
factor-A (VEGF-A; see following section discussing VEGF-A), transforming growth factor-β 
(TGF-β), platelet derived growth factor-B (PDGF-B), and fibroblast growth factor-2 (FGF-2) 
[2,43,44,46,48-50].  
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Skeletal muscle endothelial cells are also exposed to additional mechanical forces not 
present in other tissues due to the contractile properties of muscle fibers. Zhou et al [51] 
demonstrated in rodents that extirpating the tibialis anterior resulting in increased stretch and 
overload of the synergist muscle, extensor digitorum longus, led to capillary growth by sprouting 
in the overloaded muscle. Indeed, muscle stretch leads to sprouting angiogenesis whereas shear 
stress favors splitting angiogenesis [42,43]. Both increased blood flow [52,53] and increased 
muscle stretch [54] have been shown in human models of passive exercise (i.e. no active work 
being performed) through motor-driven passive flexion and extension on the leg. Passive exercise 
has been shown to increase pro-angiogenic factor expression [52], and while 4 weeks of passive 
exercise did not result in overt angiogenesis, a higher proportion of proliferating endothelial cells 
were detected [54], suggesting that passive stretch has the ability to initiate the angiogenic process. 
The passive stretch model requires minimal metabolic demand, therefore isolating and 
highlighting the importance of purely mechanical forces to the angiogenic process in the skeletal 
muscle. 
In addition to mechanical forces, the skeletal muscle may experience exercise-induced 
local hypoxia, which could serve a strong pro-angiogenic stimulus. Reduced oxygen levels 
available to the muscle tissue is a result of elevated oxygen consumption in the active muscle 
compared to resting [55]. The O2 cascade is defined as the transport of oxygen from the air we 
breathe to the utilization of oxygen in the mitochondria. This transport system involves the lungs, 
heart, vascular circulation, and the muscle tissue [56]. As oxygen is transported along this 
anatomical pathway, the partial pressure of oxygen (PO2) steadily declines. The PO2 of the air we 
breathe is approximately 149 mmHg, yet falls to 105 mmHg in lung alveoli, 103 mmHg in arterial 
circulation, 44 mmHg on average at the level of the capillaries, and 34 mmHg inside muscle cells 
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in humans [57]. A bout of exercise strongly alters PO2 at every point along this pathway, and 
results in comparative hypoxia at the level of the myocyte versus resting conditions. In response 
to maximal knee extensor exercise, alveolar (120 mmHg) and arterial (115 mmHg) PO2 are 
elevated due to increased respiration, however, the mean capillary PO2 (37.5 mmHg) and 
intramyocyte PO2 (3.1 mmHg) are reduced [57,58]. It can be appreciated that endothelial cells at 
the level of the capillary bed perhaps experience mild hypoxia during exercise (44 mmHg resting 
versus 37.5 mmHg during exericse), however the drop in PO2 at the level of the myocyte is 
profound (34 mmHg resting versus 3.1 mmHg during exercise), representing a dramatic hypoxic 
state compared to rest. Correspondingly, it has been reported that myoglobin oxygen saturation is 
shifted from ~100% saturation at rest to ~50% saturation during exercise in the human leg [56,58]. 
This alteration in myoglobin saturation was observed as rapidly as 30 seconds after the onset of 
exercise, and returns to resting values in less than 1 minute of exercise cessation [56,58].  
The cellular response to hypoxia is largely sensed by the transcription factor hypoxia 
inducible factor-1 (HIF-1) which consists of two subunits, the oxygen sensitive HIF-1α (which is 
stabilized by low cellular oxygen levels, and rapidly degraded in normoxia) and the constitutively 
active HIF-1β [55]. In the hypoxic state, HIF-1α is stabilized and shuttles from the cytoplasm to 
the nucleus where it heterodimerizes with the β subunit subsequently interacting with hypoxia 
responsive elements (HRE) in target genes that promote increases in oxygen transport such as 
VEGF-A (stimulates angiogenesis) and erythropoietin (EPO; stimulates erythropoiesis), while 
concomitantly upregulating glucose receptors and glycolytic enzymes [55,59,60]. Indeed, Jiang et 
al [61] show that HIF-1α protein accumulation is attributable to oxygen levels, and that lower 
oxygen levels stimulated increased HIF-1α-DNA binding in HeLa cells. Localized muscle hypoxia 
is a pro-angiogenic stimulus, as stabilization of HIF-1α in a specific area of muscle tissue can lead 
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to increased myocyte expression and release of the pro-angiogenic VEGF-A which can serve as a 
chemoattractant toward which endothelial cells from existing vessels can migrate in order to form 
new capillaries. Indeed, it has been documented that exercise increases HIF-1α protein 
immediately following and up to 6 hours post-exercise in human skeletal muscle, corresponding 
to increased VEGF-A and EPO mRNA levels [62]. As the adaptation of the muscle to exercise is 
established (i.e. exercise-induced angiogenesis), the response of HIF-1α is attenuated, as the 
observed increase in HIF-1α expression in response to an acute bout of exercise was lost following 
4 weeks of training in human skeletal muscle [63]. Interestingly, it has been shown that HIF-1α 
regulation is possible aside from hypoxic stress by insulin and insulin-like growth factors, platelet-
derived growth factor, and epidermal growth factor as well as the activation of the signaling 
cascades PI3K/Akt and RAS/ERK1/2 [59,60]. 
Often, when exercise-induced angiogenesis is discussed, we are referring to the outcome, 
or the end result, following a period of exercise training when an increased abundance of skeletal 
muscle capillaries is visualized. However, one single acute bout of exercise by itself is a very 
strong pro-angiogenic stimulus, modifying the expression levels of various angio-adaptive factors 
and stimulating endothelial cell activation in skeletal muscle. When repeated chronically, such as 
during exercise training, these pro-angiogenic signals will ultimately lead to the formation of 
mature capillaries. These singular acute bouts of exercise may be considered the ‘dynamic phase’ 
of the angiogenic process. Over time, the expression levels of these angio-adaptive factors will be 
modified as the adaptation to exercise is established. Refer to figure 1.2 for a schematic depicting 
the possible responses of pro- and anti-angiogenic molecules in response to a bout of exercise that 
would favor capillary growth, and to figure 1.3 for a schematic depicting the temporal response of 
pro-angiogenic factors in response to repeated acute bouts of exercise leading to microvascular 
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adaption. The following section entitled “molecular regulation of skeletal muscle angiogenesis” 
will provide details regarding the balance between key pro- and anti-angiogenic factors.   
 
 
Figure 1.2 A single bout of exercise is a powerful stimulus to alter the angio-adaptive balance 
between anti- and pro-angiogenic molecules. In response to a bout of exercise, the angiogenic 
balance can be shifted favoring capillary growth by either lowering anti-angiogenic factors (1), 
elevating pro-angiogenic molecules (2), a combination of both (3), or an increase in both with a 
larger elevation in the pro-angiogenic factors.  
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 Figure 1.3 Singular acute bouts of exercise are very strong pro-angiogenic stimuli, modifying the 
expression levels of various angio-adaptive factors and stimulating endothelial cell activation in 
skeletal muscle. These singular acute bouts of exercise may be considered the ‘dynamic phase’ of 
the angiogenic process. Over time, as exercise bouts are repeated chronically (exercise training) 
the capillary network can expand by the process of exercise-induced angiogenesis. 
 
1.5 Skeletal muscle capillary regression 
 Several conditions exist which lead to skeletal muscle capillary loss, including, but not 
limited to, muscle disuse, obesity, diabetes, chronic increases in blood pressure, chronic heart 
failure or chronic obstructive pulmonary disease (COPD) [64-66]. Researchers have employed 
numerous methodologies to induce skeletal muscle capillary regression in animal models including 
immobilization casting, nerve crushing, hindlimb or whole body suspension and motor nerve 
conduction blockage [65,66]. Capillary regression as a product of disuse in humans has also been 
studied in patients with bedrest, inflammatory myopathies, neurogenic disorders, mitochondrial 
myopathies, space flight and peripheral vascular diseases [66]. One theory that attempts to explain 
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capillary regression in the skeletal muscle tissue as a result of disuse is the over-exposure of muscle 
cells to oxygen, termed hyperoxia. Muscle fibers that are in a state of relative disuse become over-
perfused with oxygen, resulting in capillary regression to match the metabolic demands of the 
muscle tissue with supply from the microvasculature. Persistent hyperoxia can lead to 
vasoconstriction of arterioles leading to decreased blood flow through capillaries and therefore 
oxygen delivery to the muscle tissue. However, vasoconstriction itself may not be sufficient to 
restore proper oxygenation to the muscle, and capillary regression is required [65]. Overall, it is 
poorly understood the process through which skeletal muscle capillaries regress in response to 
various disease states. Due to the unique nature of each respective pathology, the mechanisms 
governing molecular changes leading capillary rarefication are vast, and require intensive research 
for each specific disease.  
 Capillary regression as a result of muscle disuse has been widely shown in the literature. 
Malek and colleagues [67] demonstrate the plasticity of the skeletal muscle microvasculature in 
response to exercise training with subsequent detraining. Rats were subjected to 10 weeks of 
treadmill exercise training, which as expected, resulted in increased muscle capillarity in the soleus 
and plantaris muscles. However, animals that underwent the exercise training but were then 
confined to their cages for just 7 days following the exercise period (i.e. detraining) had 
significantly lower capillary-to-fiber ratio and capillary density compared to the trained group. 
These findings highlight the rapidity that capillary regression can occur, as well as demonstrating 
that adaptations to exercise stimulus are not permanent and the capillary network adapts rapidly to 
the demands of muscle cells. Similar findings have been recorded by Huttemann et al [68] as the 
C/F ratio was increased following 5 weeks of treadmill training in mice plantaris muscle but 14 
days detraining reversed this effect. Olenich and colleagues [69] demonstrated that mice allowed 
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to exercise voluntarily for 3 weeks underwent exercise-induced angiogenesis with significant 
elevations in C/F ratio in the gastrocnemius, plantaris, and soleus muscles, however after just 7 
days of detraining muscle capillarity was similar to pre-training levels. Similar findings have been 
described in human subjects in response to detraining, as 8 weeks of bicycle ergometer training 
led to a 20% increase in C/F ratio and capillary density in the vastus lateralis muscle of subjects, 
however 8 weeks of detraining reversed the C/F ratio similar to pre-exercise levels [70]. 
Additionally, a 6.3% reduction in capillary density was observed after 15 days without training in 
endurance runners [71]. Muscle disuse has also been demonstrated in rodent models of tail 
suspension which results in hindlimb unloading (mimicking space flight and muscle disuse due to 
the removal of natural physical forces and gravity experienced by the suspended muscles) [72]. 
Previous results from our laboratory have shown significant capillary regression in the soleus 
muscle following 9 days of hindlimb unloading [73]. Similarly, Wagatsuma et al [74] showed that 
10 days of hindlumb unloading led to a 19.5% reduction in the amount of capillaries around a 
muscle fiber in the gastrocnemius muscle.  
2. Molecular regulation of skeletal muscle angiogenesis 
2.1 The angio-adaptive balance 
In response to metabolic and mechanical stresses, the growth of the capillary network is 
dependent on the expression level of various molecules that operate to either suppress or stimulate 
capillary growth. The angio-adaptive balance can be defined as the relative abundance, activity, 
and interplay between pro- and anti-angiogenic molecules. The growth, or alternatively, the 
regression of the skeletal muscle capillary network involves a shift in the angio-adaptive balance 
that is determined by alterations in expression of key stimulators and inhibitors of angiogenesis. 
Figure 2.1 (adapted from [64]) depicts a non-exhaustive list of identified pro- (stimulators) and 
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anti- (inhibitors) angiogenic molecules, respectively. Regular elevations in the expression of pro-
angiogenic factors, reductions in the expression of anti-angiogenic factors, or a combination of 
both, can lead to expansion of the capillary network in response to training (refer to figure 1.2). 
As we can appreciate, there exists an extensive catalogue of angio-adaptive regulators. How do we 
determine which factors are the most important for skeletal muscle capillary regulation? By 
modulating the expression of such proteins in animal models, researchers have identified key pro- 
and anti-angiogenic factors. VEGF-A and Thrombospondin-1 (TSP-1) are the most widely studied 
pro- and anti-angiogenic factors, respectively. It has been extensively demonstrated that VEGF-A 
and TSP-1 are essential regulators of skeletal muscle angiogenesis, in addition to capillary 
regulation in a variety of tissues and organs. Our laboratory has established that the VEGF-A/TSP-
1 ratio is a good indicator of the angiogenic microenvironment of the skeletal muscle 
[64,73,75,76]. The VEGF-A/TSP-1 ratio is defined as the comparative and relative expression 
level between VEGF-A and TSP-1. Since VEGF-A and TSP-1 represent essential regulatory 
molecules on either side of the angio-adaptive balance, the VEGF-A/TSP-1 ratio provides a key 
insight into the overall environment favoring either capillary maintenance, growth, or regression. 
The following section will provide a background review of the literature describing the regulatory 
role of VEGF-A and TSP-1 in skeletal muscle capillarity. 
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Figure 2.1: Diagram depicting the balance between stimulators and inhibitors of angiogenesis in 
the skeletal muscle. The figure lists key pro- and anti-angiogenic molecules. Adapted from [64] 
 
2.2 Vascular endothelial growth factor-A 
VEGF-A is a potent pro-angiogenic factor that is, amongst other functions, responsible for 
the growth of capillaries within the skeletal muscle. VEGF-A has been shown to be important for 
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both splitting and sprouting angiogenesis in the skeletal muscle [77]. VEGF-A is expressed by a 
number of different cell types including endothelial cells, myofibers, fibroblasts, macrophages, 
and satellite cells [7]. Several splice variants of VEGF-A exist, however in the skeletal muscle, the 
VEGF-A165 isoform is the most abundant physiologically active [36]. The pro-angiogenic effect 
of VEGF-A occurs by binding to tyrosine kinase receptors including VEGF-A receptor 1 and 2 
(VEGFR1 and 2) along with neuropilin-1 which serves as a co-receptor for VEGFR2, and it is 
VEGFR2 that is the most important for skeletal muscle angiogenesis [36]. Binding of VEGF-A to 
its receptors leads to a cascade of intracellular signaling pathways including the activation of 
extracellular signal regulated kinase 1/2 (ERK1/2) and Akt in endothelial cells which regulate a 
variety of cellular processes important for angiogenesis such as endothelial cell survival, 
proliferation, and gene expression [78,79].  
VEGF-A mRNA and protein expression can be increased in response to an acute bout of 
exercise within human skeletal muscle [80] and interstitial VEGF-A protein levels are significantly 
elevated during and following exercise [81]. VEGF-A mRNA expression appears to be transiently 
elevated between 1 and 6 hours during post-exercise rest, returning to pre-exercise levels within 
24 hours [36,82,83]. Indeed, VEGF-A mRNA expression was found to be elevated 2-4 fold at the 
end of a single exercise bout in rat muscle and remained elevated 4 hours afterwards, returning to 
baseline within 8 hours post-exercise [82]. Gavin et al [84] showed that VEGF mRNA was 
significantly elevated in human vastus lateralis both 2 and 4 hours following an acute bout of cycle 
ergometer exercise.  Similarly, VEGF-A mRNA was increased in human muscle tissue by nearly 
two-fold following an acute bout of knee-extension exercise [85]. In accordance with increased 
mRNA expression, some studies have shown that VEGF-A protein levels are also elevated 
following a bout of exercise in human muscle [86], while others have shown no change at 1 or 2 
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hours post-exercise [87] or even a decrease immediately after an exercise bout [84] in human 
skeletal muscle. The differential response of VEGF-A protein and mRNA in response to acute 
exercise is further discussed in the following paragraph. While the results describing the response 
of VEGF-A protein to an acute bout of exercise appear somewhat controversial, studies show that 
basal VEGF-A protein levels are significantly higher early in an exercise training program at 10 
days in human muscle [86], and at 7 days in mouse muscle [88]. Basal elevations in VEGF-A 
protein also appear to be transient, as no difference in basal VEGF-A protein was observed after 5 
weeks of knee extension exercise compared to pre-exercise levels, despite increased basal VEGF-
A protein at 10 days [89]. Similarly, Hoier and colleagues [36] have observed no changes in resting 
VEGF-A protein following either moderate or high intensity cycling training for four weeks in 
humans. In addition to alterations in VEGF-A expression, exercise also triggers elevations in its 
receptors. Studies have shown increased VEGFR1 and VEGFR2 mRNA 2-6 hours post-exercise 
in human muscle tissue [84,90]. This dual up-regulation of VEGF-A and its receptors in response 
to exercise serves as a mechanism for increased VEGF-A sensitivity in the skeletal muscle.  
The secretion of VEGF-A by skeletal muscle cells is a mechanism through which the 
skeletal muscle can regulate its’ own vascular supply in response to repeated bouts of exercise, 
thereby improving oxygen and nutrient delivery to active muscle cells. As reviewed in the previous 
paragraph, while some studies observe increased VEGF-A protein [86], others have shown that 
VEGF-A protein levels do not necessarily increase in human skeletal muscle in response to an 
acute bout of exercise [84]. However, it is well documented that VEGF-A concentration in muscle 
interstitial space increases [81] suggesting that the localization and mobilization of VEGF-A is an 
important response to exercise stimulus. It has been described in humans that VEGF-A is stored 
in vesicles distributed throughout muscle cells [36], which relocate and accumulate in the 
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subsarcolemmal region of following exercise [87]. This shift in subcellular location of VEGF-A 
vesicles coinciding with a 5 fold increase in interstitial VEGF-A protein following exercise 
suggests that VEGF-A is stored within vesicles in muscle cells and it secreted into the extracellular 
fluid in response to exercise stimulus [87]. Interestingly, VEGF-A mRNA has been shown only 
be elevated during rest following an exercise bout [36,82-84] yet interstitial VEGF-A protein is 
significantly higher early after the onset of exercise [87,91] suggesting that vesicles are pre-stored 
with VEGF-A, and that the elevation in VEGF-A mRNA following exercise serves to replenish 
VEGF-A stores within the muscle cell.  
An interesting study from Birot et al [92] shows that the expression of VEGF-A could be 
fiber type-specific. In response to a 90 minutes exercise bout, VEGF-A protein levels were 
significantly higher in rat plantaris muscle compared to non-exercised muscle. Individual fibers 
were isolated from whole plantaris muscle, and were identified as either type I, IIa, IIx, or IIb 
according to the expression of myosin heavy chain isoforms. While pooled myofibers from 
exercised animals presented a marked increase in VEGF-A mRNA compared to controls, only 
type IIb fibers had elevated VEGF-A expression when observed individually. Furthermore, not all 
fibers expressed VEGF-A, with type IIb fibers presenting the highest proportion of fibers with 
VEGF-A mRNA detected. Taken together, this data suggests that VEGF-A is more abundantly 
produced by fast-twitch glycolytic fibers that present the largest diameter and have the lowest 
oxidative potential. Due to the metabolic capacity of these fibers, they may experience more 
exercise-induced local hypoxia compared with increasingly more oxidative fibers (i.e. type IIx, 
IIa, or I), thus leading to significantly more VEGF-A expression in response to an acute bout of 
exercise.   
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Although VEGF-A is produced and released by various cell types, the importance of 
myofiber-derived VEGF-A is evident in studies where myocyte VEGF-A production was 
genetically deleted. In order to delete VEGF-A in the muscle tissue, Tang and colleagues [93] 
utilized intramuscular injection of cre-recombinase in VEGF-AloxP(+/+) mice. VEGF-A deletion 
resulted in significantly reduced capillary-to-fiber ratio (-67%) and capillary density (-69%) in the 
gastrocnemius four weeks post-injection. Olfert et al [94] demonstrate that muscle-specific VEGF-
A deletion in mice led to a 48% decrease in the capillary-to-fiber ration and a significant reduction 
of 39% capillary density in the gastrocnemius muscle. In another eloquent study, Olfert and 
colleagues [95] showed that while wild-type mice increased capillary density by 59% in the 
gastrocnemius muscle, and improved both maximal running speed and time to exhaustion 
following a 6 week training period, myocyte-specific VEGF-A deletion fully abrogated exercise-
induced angiogenesis and exercise performance. Furthermore, muscle overload-induced 
angiogenesis was entirely lost in mice with myocyte deletion of VEGF-A [96]. Both the ligand 
and the receptor are important for VEGF-A induced angiogenesis, as Lloyd and colleagues [97] 
have shown in a rodent model that VEGFR2 blockage blunted skeletal muscle angiogenesis in 
response to training compared to control animals.  
The production of VEGF-A by myocytes is often a result of hypoxic and metabolic stress, 
which are strongly associated with exercise [36,92,98]. Indeed, hypoxia inducible factor-1α (HIF-
1α) is an important transcriptional regulator of VEGF-A. HIF-1α acutely senses low cellular 
oxygen levels and can bind to the hypoxia responsive element on the VEGF-A gene and upregulate 
the expression of VEGF-A in the skeletal muscle [99]. Additionally, both HIF-1α and hypoxia 
itself also play important roles in VEGF-A regulation at the post-transcriptional level by stabilizing 
VEGF-A mRNA and promoting mRNA translation [99]. Interestingly, it has been shown that 
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Murine Double Minute-2 (Mdm2) shuttles from the nucleus to the cytoplasm during hypoxia and 
can bind to VEGF-A mRNA increasing its stability and translation in cancer cells [100]. The 
Mdm2 molecule is the main focus of this dissertation, and will be discussed at length in the 
following section. VEGF-A expression is also regulated by the peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1α) [101], and it has been shown that PGC-1α knockout 
mice had up to an 80%  reduction in muscle VEGF-A protein which corresponded to a 20% 
decrease in muscle C/F ratio versus wild-type mice [102]. Furthermore, while wild-type mice had 
significantly more VEGF-A protein in the quadriceps following a 5 weeks exercise period, 
however this exercise-induced effect on VEGF-A was lost in the PGC-1α knockout mice [102]. 
PGC-1α appears to regulate expression of VEGF-A through the estrogen related receptor alpha 
(ERRα) pathway [103]. The platelet-derived growth factor (PDGF) has been shown to induce 
elevations in VEGF-A mRNA expression and protein secretion in cultured human vascular smooth 
muscle cells, and that PDGF-induced VEGF-A promoter activity was dependent on AP-1 [104]. 
Similarly, Wang et al [105] have shown that PDGF treatment in porcine aortic endothelial cells 
led to dose-dependent elevations in VEGF-A mRNA, and that PDGF stimulation led to increased 
VEGF-A protein in the conditioned media of cultured endothelial cells. Other studies suggest that 
VEGF-A expression could be regulated by both AP-1 and sirtuin-1 (SIRT-1) in response to 
exercise, as expression of these factors preceded the exercise-induced rise in VEGF-A mRNA in 
human skeletal muscle [87]. Finally, AMP-activated protein kinase (AMPK) could regulate 
VEGF-A expression and protein release from muscle cells as 5-aminoimidazole-4-carboxamide 
ribonucleotide (AICAR), a potent stimulator of AMPK activity, significantly elevated both VEGF-
A mRNA and protein secretion in cultured C2C12 myocytes, and that transfection of a dominant-
negative AMPK entirely reversed this effect [106]. 
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2.3 Thrombospondin-1 
Thrombospondin-1 is a well described endogenous inhibitor of angiogenesis in the skeletal 
muscle. A number of anti-angiogenic roles for TSP-1 have been identified in relation to endothelial 
cells including the inhibition of VEGF-A activity and suppression of its bioavailability, as well as 
inducing endothelial cell apoptosis and inhibiting migration [107]. It has been shown that TSP-1 
can prevent release of VEGF-A from the extracellular matrix, preventing the mobilization of 
VEGF-A and decreasing the amount of VEGF-A bound to its receptors [108]. Furthermore, TSP-
1 has been shown to bind directly to VEGF-A, a mechanism which can promote VEGF-A clearing 
from the extracellular space, again leading to decreased VEGF-A interaction with its receptors 
[109,110]. Not only can TSP-1 prevent VEGF-A interaction with its receptors, TSP-1 can also 
inhibit the phosphorylation (i.e. activation) of the VEGF-A receptor 2 (VEGFR2), therefore 
inhibiting VEGF-A signaling [111]. By binding to its high-affinity receptor CD47, which is 
constitutively associated with VEGFR2, TSP-1 can inhibit VEGFR2 phosphorylation and 
downstream signalling [112]. Through the activation of several intracellular kinases, TSP-1 has 
been shown to lead to endothelial cell apoptosis in cultured endothelial cells [113]. It has been 
reported that TSP-1 can inhibit cell cycle progression through binding to very-low density 
lipoprotein receptor (VLDLR) in the membrane of capillary endothelial cells [114]. TSP-1 has 
also been demonstrated to inhibit endothelial cell migration by binding to CD36, which serves as 
one of several TSP-1 receptors [115,116]. Indeed, TSP-1 is demonstrably a potent negative 
regulator of the skeletal muscle microvasculature, as global deletion of TSP-1 in mice resulted in 
a significantly higher skeletal muscle capillarity that corresponded to a 67% increase in exercise 
endurance capacity when compared to controls [117]. An elegant study from Audet and colleagues 
[118] shows that chronic (14 days) delivery of ABT-510, a mimetic of TSP-1 targeting the CD36 
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receptor, resulted in significant reductions in the C/F ratio in the gastrocnemius, soleus, and 
plantaris muscles of mice, while also suppressing VEGF-A protein expression in the 
gastrocnemius and soleus.  Interestingly, it appears that capillary regression as seen following an 
exercise training period with subsequent detraining is not a result of reduced VEGF-A expression, 
but rather an increase in basal TSP-1 expression [72] highlighting the importance of TSP-1 and 
the anti-angiogenic side of the angio-adaptive balance to influence capillary loss. Studies that have 
investigated skeletal muscle capillary loss in detrained muscle following an exercise period show 
that capillary rarefication corresponded with increased TSP-1 protein levels [68,69], despite 
elevated VEGF-A levels. Furthermore, our laboratory has shown in a model of hindlimb unloading 
that capillary regression occurred in the soleus muscle in combination with a decreased VEGF-
A/TSP-1 ratio due to elevations in TSP-1 but no alterations in VEGF-A [73]. However, capillary 
regression did not occur in the plantaris muscle where TSP-1 expression was unaltered in 
combination with elevated VEGF-A.  
Interestingly, TSP-1 expression is elevated following an acute bout of exercise, with this 
response being ablated following 3 days of training [119]. These findings suggest that the temporal 
response of key anti-angiogenic molecules to exercise allows for fine control of the angiogenic 
process by potentially initiating angiogenesis along with elevations in pro-angiogenic molecules. 
It can be hypothesized that the angiogenic “start” signal is given by a decrease in TSP-1 in response 
to short-term training, concomitant with increased VEGF-A. Similarly, our laboratory has shown 
that forkhead box protein O1 (FoxO1), a transcription factor for TSP-1 [120], is significantly 
elevated immediately after (mRNA) and during rest (mRNA and protein) following an acute bout 
of exercise in mice [121]. However, when animals were trained over the course of 14 days, FoxO1 
mRNA and protein expression was significantly attenuated, with TSP-1 protein levels following 
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the same pattern [121]. Interestingly, the anti-angiogenic signal of increased TSP-1 expression 
could possibly also serve as a natural angio-regulatory “brake” or “stop” signal following exercise-
induced angiogenesis. Following an exercise training period during which the skeletal muscle 
capillary network has sufficiently expanded to meet the demands of active muscle cells, no further 
capillary growth is necessary. Indeed, Olfert et al [119] described the reinstatement of TSP-1 
responsiveness to an acute bout of exercise following an 8 week training period, as TSP-1 mRNA 
increased 3 to 4 fold following exercise in the trained muscle.  
Observations regarding TSP-1 transcriptional control are largely varied and are found to 
be cell and tissue type-specific, highlighting the various localized functions TSP-1 can serve in 
different tissues and contexts [122]. Both the complex assembled on the promoter region of TSP-
1 and the promoter regions involved in the expression of TSP-1 can vary from one cell type to 
another [122]. TSP-1 transcriptional regulation has been most widely studied in the context of 
hyperglycemia. Wang et al [123] show that in response to high glucose, the upstream stimulatory 
factors (USFs) bind directly to the TSP-1 promoter in mesangial cells as observed by chromatin 
immunoprecipitation, while Dabir and colleagues [124] identified that the aryl hydrocarbon 
receptor (AhR) binds to the TSP-1 promoter region in human aortic endothelial cells in response 
to high glucose exposure. Additionally, a potentially significant role for TSP-1 in metabolic 
regulation has been demonstrated, with TSP-1 transcription found to be regulated by leptin in 
human aortic smooth muscle cells [125]. While no direct transcriptional mechanism was 
investigated, Negoescu et al [126] observed increased TSP-1 protein expression in cultured bovine 
adrenocortical cells by TGFβ treatment. In the context of this dissertation, TSP-1 expression has 
been suggested to be under the control of the transcription factor p53 in fibroblasts [127], and p53 
expression was significantly associated with TSP-1 levels in human tumors [128]. In addition, 
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Roudier et al [120] show that in primary skeletal muscle microvascular endothelial cells, FoxO1 
is a potent stimulator of TSP-1 expression. The authors show that deletion of FoxO1 in endothelial 
cells led to significant reductions in TSP-1 protein, while overexpression of FoxO1 drastically 
increased TSP-1 protein. Furthermore, chromatin immunoprecipitation showed that endogenous 
FoxO1 directly binds to promoter regions on TSP-1.  
3. Murine Double Minute-2  
 It can be appreciated that there exists a plethora of angio-adaptive molecules that regulate 
skeletal muscle capillary maintenance, growth, and regression (refer to figure 1.2). Amongst these, 
VEGF-A and TSP-1 have been clearly identified as essential pro- and anti-angiogenic molecules, 
respectively, that together influence the overall angiogenic microenvironment of the skeletal 
muscle. As researchers, we strive to identify novel signaling pathways and molecules that could 
deepen our understanding of skeletal muscle capillary control in response to physiological and 
pathological stimuli. The identification of a molecule that could regulate both sides of the angio-
adaptive balance (VEGF-A and TSP-1), and is indispensable for capillary growth and maintenance 
is undeniably intriguing. Our laboratory has identified Murine Double Minute-2 (Mdm2) as an 
essential regulator of skeletal muscle angio-adaptation. The following sections will provide 
background information on Mdm2 including a pioneering study from our laboratory which formed 
the foundation of my dissertation research.  
3.1 Murine Double Minute-2: novel regulator of the skeletal muscle capillary network 
 In 2012, our laboratory published novel findings that describe Mdm2 as a key player in 
skeletal muscle angio-regulation. Transgenic Mdm2Puro/∆7-9 mice express 60% less Mdm2 versus 
wild-type animals, and present a significant 20% reduction in skeletal muscle capillaries at rest 
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[75]. In addition, while wild-type animals underwent exercise-induced angiogenesis in response 
to a training program, such an adaptive response was fully abolished in the Mdm2 deficient mice. 
In line with this finding, it was shown that total Mdm2 protein levels were found to be significantly 
elevated in healthy rodent muscle in response to prolonged exercise training. Furthermore, 
Mdm2Puro/∆7-9  mice displayed the loss of a physiological response to acute exercise, as an acute 
bout of treadmill running induced expression of the pro-angiogenic VEGF-A in wild-type mice 
but not in Mdm2Puro/∆7-9 mice. Mdm2 deficiency also led to significant elevations in FoxO1 protein 
levels, corresponding with enhanced TSP-1 protein expression. These key alterations in potent 
anti-angiogenic factors could explain the observed skeletal muscle capillary loss that was found to 
be independent of p53. These transgenic animals also had significantly less endothelial cell 
outgrowth (cell migration) than wild-types in a 3D muscle explant assay, indicating that Mdm2 is 
essential for the pro-angiogenic activity of skeletal muscle endothelial cells.  
Taken together, these data identify Mdm2 as an essential regulator of rodent skeletal 
muscle angio-adaptation, both at rest (capillary maintenance) and in response to prolonged 
physical activity (exercise-induced angiogenesis). However, the molecular mechanisms through 
which Mdm2 exerts this pro-angiogenic effect remain largely unknown. It is the scope of my 
dissertation research to elucidate the angiogenic function of Mdm2.   
3.2 Murine Double Minute-2: relationship with p53 
 Existing literature has described a pro-angiogenic role of Mdm2, predominantly in a 
pathological context. Mdm2 is an E3 ubiquitin ligase that has implications during tumour growth 
[129]. Indeed, in tumors that overexpress the Mdm2 protein, angiogenesis is increased [130]. 
Mdm2 is often considered as an oncoprotein as it is most commonly known for its role as the main 
negative regulator of the tumor suppressor p53. The p53 protein is a transcription factor for many 
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target genes that exert anti-tumor effects by inducing cell cycle arrest and apoptosis [131]. 
Interestingly, p53 also promotes anti-angiogenic functions in endothelial cells by inhibiting the 
cell cycle and inducing apoptosis in these cells. It has been shown that p53 can exert anti-
angiogenic effects by inhibiting the expression of VEGF-A in both normal and cancer cells [132-
134]. Additionally, p53 has been shown to influence the expression of the anti-angiogenic TSP-1 
[127,135]. Mdm2 and p53 bind directly between their respective N-terminal domains which 
promotes translocation of p53 from the nucleus into the cytoplasm [136,137]. As a transcription 
factor, this has important consequences for p53 activity as translocation to the cytoplasm blocks 
p53 interaction with its transcriptional machinery. In addition, Mdm2 can ubiquitinate p53 through 
its E3 ligase activity located in its C-terminal RING-finger domain thereby tagging p53 for 
proteasomal degradation [137-140]. Therefore, Mdm2 pro-angiogenic activity could be explained 
through its ability to negatively regulate p53-dependent anti-angiogenic activity.  
 Mdm2 is often overexpressed in tumors, where it can bind to p53 leading to p53 
proteasomal degradation thus acting as a tumorigenic molecule [138]. Due to this pathological 
overexpression of Mdm2 and its subsequent effect on p53 abundance and activity, current anti-
cancer strategies aim to inhibit the binding of Mdm2 to p53 in order to restore p53 function in 
tumors [139,141-143]. The binding pocket between Mdm2 and p53 was identified to be located 
on residues Phe19, Trp23 and Leu26 in the N-terminal of p53 and a hydrophobic cleft in the N-
terminal of Mdm2, and a number of synthetic compounds have been shown to bind with higher 
affinity than p53 to this region of Mdm2, essentially competing for and blocking p53 binding with 
Mdm2 [137]. The first class of small-molecule inhibitors, termed nutlins were identified in 2004 
by Vassilev et al [144]. Since, the nutlins and their successors have have already undergone phase 
1 clinical trials to treat cancers where wild-type p53 is expressed [137].  Secciero et al [145] 
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demonstrated the potent anti-angiogenic function of nutlin-3, as treatment with nutlin-3 dose-
dependently prevented angiogenesis in mice with a subcutaneous matrigel plug, inhibited the 
formation of capillary-like structures in cultured endothelial cells, and significantly inhibited 
endothelial cell migration. As with other anti-cancer treatments, the delivery of nutlins and 
associated drugs are often administered systemically, raising concerns over potential side-effects 
in non-cancerous tissues, due to their highly potent anti-angiogenic effects. For this reason, one 
very important aim of my dissertation research was to investigate the physiological effect of Mdm2 
(in healthy cells and tissues) to highlight the complexity of Mdm2 function outside of the context 
of cancer therapy. 
3.3 Murine Double Minute-2: p53-independent effects  
In contrast to its p53-dependent effects, Mdm2 may also possess other mechanisms to exert 
its pro-angiogenic function. Interestingly, previous studies have described that the pro-angiogenic 
effect of Mdm2 may however be independent of p53. Mice overexpressing Mdm2 display a higher 
occurrence of angiosarcoma that is characterized by excessive endothelial cell proliferation, 
independent of p53 [146]. Furthermore, our laboratory has shown decreased skeletal muscle 
capillarization in mice deficient for Mdm2, independent of the p53 background [75]. Mdm2 could 
indeed interact with other transcription factors targeting various angio-adaptive genes. Among 
these angio-adaptive molecules is the pro-angiogenic VEGF-A. It has been shown that Mdm2 can 
promote VEGF-A expression through interaction HIF-1α, a transcription factor for VEGF-A [147-
149]. In addition, we and others have show by co-immunoprecipitation that Mdm2 can bind to and 
negatively regulate the transcription factor FoxO1 [150,151]. FoxO1 is a transcription factor that 
has been shown to promote an anti-angiogenic environment by stimulating the expression of its 
transcriptional target TSP-1 [120]. In mice that have had endothelial cell specific deletion of 
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FoxO1, the onset of exercise-induced angiogenesis occurred earlier than controls [121]. 
Interestingly, it has also been demonstrated that overexpression of FoxO1 led to a decrease in 
VEGF-A mRNA levels, suggesting FoxO1 could regulate not only TSP-1, but rather both sides of 
angio-adaptive balance (i.e. VEGF-A and TSP-1) [152]. Thus, the role of Mdm2 in the angiogenic 
process appears to be very complex, suggesting that Mdm2 may represent a novel ‘master 
regulator’ of several transcription factors influencing the angio-adaptive balance (FoxO1, HIF-1α, 
p53). These interactions affect both pro- and anti-angiogenic factors (VEGF-A, TSP-1), and the 
interplay between Mdm2 targets further highlights the complexity of the Mdm2-dependent 
angiogenic process. Post-translational modifications of the Mdm2 protein, such as phosphorylation 
(i.e. on its serine 166 [Ser166]) can enhance interactions between Mdm2 and its downstream 
targets, a modification of Mdm2 that will be reviewed in the following section. Refer to figure 3.1 
for a schematic depicting the dynamic interactions between Mdm2 and its downstream targets. 
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Figure 3.1 Mdm2 can affect both sides of the angio-adaptive balance by interactions with its 
downstream targets FoxO1, p53, and HIF-1α, leading to altered expression of the anti-angiogenic 
thrombospondin-1 (TSP-1) and the pro-angiogenic vascular endothelial growth factor-A (VEGF-
A). (+) indicates stimulatory and (-) indicates inhibitory effects. The letter “P” in a green circle 
represents a phosphorylated protein. Ser166, serine166 phosphorylation of Mdm2 
 
3.4 Murine Double Minute-2: multisite phosphorylation  
 The Mdm2 protein can be subjected to multi-site phosphorylation which affects Mdm2 
stabilization, activation, and localization (Figure 3.2) [153]. Phosphorylation of Mdm2 on its 
serine 166 (p-Ser166-Mdm2) is a signal for nuclear translocation [154], as this phosphorylation 
site lies in the Mdm2 nuclear localization sequence (NLS). In addition, it has been shown that p-
Ser166-Mdm2 overexpression significantly increases VEGF-A expression to a greater extent than 
Mdm2 overexpression alone [155]. Another study demonstrated that p-Ser166-Mdm2 contributes 
to the ability of Mdm2 to influence HIF-1α protein levels [156], which would result in increased 
transcriptional activity towards VEGF-A. p-Ser166-Mdm2 has also been shown to be important 
for Mdm2 interaction with p53 [157] since phosphorylation at this site promotes Mdm2 nuclear 
translocation where it can promote p53 nuclear export, ubiquitination, and proteasomal 
degradation [140,154]. In addition, our group has contributed to show that skeletal muscles of rats 
subjected to hind-limb ischemia by iliac artery ligation led to reduced p-Ser166-Mdm2 and a 
decreased interaction between Mdm2 and FoxO1 proteins [151]. 
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 Figure 3.2 Mdm2 undergoes post-translational modifications by multisite phosphorylation, 
stimulated by growth factor mediated signaling or DNA damage causing phosphorylation or hypo-
phosphorylation. Functional domains on Mdm2 are depicted and include p53 binding domain, 
nuclear localization sequence (NLS), nuclear export sequence (NES), acidic domain and the zinc 
and RING finger domains. Specific phosphorylation sites are listed. In response to growth factor 
mediated signaling, Mdm2 can be phosphorylated on its serine166 (shown in red) which lies in the 
nuclear localization sequence, thus favoring Mdm2 shuttling from the cytoplasm into the nucleus 
where it can interact with its key downstream targets p53, FoxO1 and HIF-1α (adapted from[153]).  
 
Interestingly, existing literature suggests there may be a link between VEGF-A signaling 
and Mdm2 phosphorylation on its serine 166. VEGF-A acts on VEGFR2 present on the surface of 
endothelial cells, subsequently activating downstream kinase signaling pathways including 
mitogen-activated protein kinases (MAPKs). MAPKs are expressed in all eukaryotic cells and 
include the following kinases: extracellular signal regulated kinase 1/2 (ERK1/2), extracellular 
signal-regulated kinase 5 (ERK5), c-Jun NH2-terminal Kinase (JNK), and p38 [158]. Figure 3.3 
depicts the activation pathway responsible for the onset of MAPK signaling. The initial step is the 
activation of a MAP kinase kinase kinase (MAPKKK), which are regulated by membrane 
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recruitment, oligomerization, or phosphorylation leading to the activation of a MAP kinase kinase 
(MAPKK) and sequentially a MAP kinase [158]. These signaling cascades can respond to a variety 
of factors including environmental stressors and growth factors and can control various cellular 
processes including gene expression, cell proliferation, differentiation, inflammation, and 
apoptosis (Figure 3.3). 
 
 
Figure 3.3 Mitogen activated protein kinase (MAPK) activation cascade. In response to stimuli 
such as environmental stresses and growth factors, a MAP kinase kinase kinase (MAPKKK) 
becomes active and leads to the activation of a MAP kinase kinase (MAPKK), ultimately inducing 
the phosphorylation of MAP kinase (MAPK). This MAPK activation stimulates the 
phosphorylation of downstream substrates such as cytosolic proteins and transcription factors that 
have various biological effects in gene expression, cell proliferation, differentiation, and apoptosis. 
(+) indicates stimulatory and (-) indicates inhibitory effects. The letter “P” in a green circle 
represents phosphorylation of a protein.  
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The activation of ERK1/2 is highly dependent on Raf, a MAPKKK for ERK1/2 [159]. Raf can 
phosphorylate and activate MEK1 and MEK2, which are MAPKKs that stimulate the 
phosphorylation of ERK1/2. This occurs predominantly in response to growth factors such as 
insulin [160] epidermal growth factor [161], nerve growth factors [162] or other factors involved 
in cell growth and differentiation. ERK1/2 can then assert effects on downstream kinases either in 
the cytoplasm, such as the p90 ribosomal S6 kinase (p90RSK), or translocate to the cell nucleus 
to phosphorylate transcription factors, such as c-Myc, c-Jun, c-Fos or ELK-1 [163]. ERK1/2 are 
known as downstream targets of the VEGF-A/VEGFR2 signaling pathway [164]. While Akt has 
been demonstrated to play a main role in phosphorylating Mdm2 [154,165], it has been suggested 
that ERK1/2 may be involved as well [166,167]. Since there is no evidence for a direct interaction 
of ERK1/2 and Mdm2, p90RSK may be the link for this ERK1/2 effect on Mdm2. p90RSK can 
be phosphorylated by ERK1/2 [168], and has been shown to phosphorylate Mdm2 in vitro [169]. 
Interestingly, a paper from Seko and colleagues [170] has shown that VEGF-A stimulation induced 
the activation of MAP kinases and p90RSK in cultured rat cardiac myocytes and fibroblasts. 
Furthermore, it has been shown that ERK1/2 can be phosphorylated by acute bouts of exercise 
which in combination with elevated VEGF-A protein (see previous section on VEGF-A in 
exercise-induced angiogenesis) further suggests a potential relationship between VEGF-A and 
ERK1/2 activation. Both mouse and rat models of exercise show an increase in ERK1/2 
phosphorylation in the skeletal muscle [165,171,172]. These results are paralleled in the skeletal 
muscle of both trained and untrained human subjects in response to cycling exercise [173-175], 
and both endurance and resistance exercise were found to be sufficient to induce ERK1/2 
activation [164,176,177]. Furthermore, isolated rat and mouse skeletal muscles that were 
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stimulated to contract in vitro underwent significant elevations in ERK1/2 phosphorylation 
[168,169,178,179]. 
4. Type 1 diabetes and skeletal muscle microvasculature 
 While Mdm2 is predominantly studied in the context of cancer due to its negative 
regulation of the tumor suppressor p53, Mdm2 could also play a significant role in other 
pathologies affecting the skeletal muscle capillary network, since it is now clear that Mdm2 
possesses p53-independent functions. Hyperglycemia has numerous deleterious effects on 
endothelial cells and can lead to microvascular complications and co-morbidities. Specifically, 
type 1 diabetes (T1D) is highly understudied in the context of skeletal muscle capillarization, with 
very few studies available investigating angio-adaptation of the skeletal muscle in response to 
diabetic hyperglycemia. Indeed, skeletal muscle capillaries could also susceptible to detrimental 
adaptations as a result of type 1 diabetic hyperglycemia. 
4.1 Murine Double Minute-2 in diabetes 
Previous results from our laboratory suggest that altered Mdm2 function may play an 
important role in the pathological adaptation to diabetes. It was shown that in Zucker diabetic fatty 
(ZDF) rats, a common model of type-2 diabetes, Mdm2 protein levels are significantly lower than 
in lean controls [75]. In addition, FoxO1 protein levels were elevated in the ZDF rats compared to 
controls. This decrease in Mdm2 and elevated FoxO1 proteins occurred concomitantly with 
significant loss of skeletal muscle capillaries. Interestingly, voluntary exercise training in ZDF rats 
rescued the loss of capillaries and restored Mdm2 protein levels to that of healthy control animals. 
Moving from type-2 to type 1 diabetes, I have contributed to show for the first time that Mdm2 
protein is significantly supressed in the skeletal muscle of streptozotocin-induced type 1 diabetic 
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rats  compared to non-diabetic controls, coinciding with a significant loss in skeletal muscle 
capillaries (see appendix for academic research paper 5 [180]). Taken together, it is evident that 
Mdm2 is affected by the diabetic state and observed alterations in Mdm2 protein are associated 
with decreased skeletal muscle capillarization in diabetic animal models. 
4.2 Endothelial dysfunction in type 1 diabetes 
 A serious cause of endothelial cell dysfunction is persistent and uncontrolled high blood 
glucose levels, or hyperglycemia, as a result of diabetes. Type 1 diabetes, also known as insulin-
dependent diabetes, is a disease that occurs in response to both genetic and environmental factors 
[181]. T1D triggers an autoimmune response that destroys pancreatic β-cells within the islets of 
Langerhans resulting in loss of insulin production and secretion, leading to high blood glucose 
levels (hyperglycemia) and reliance on exogenous insulin administration [182]. Although T1D 
only accounts for roughly 5-10% of all diabetes cases, it can contribute to as much as 40% of 
healthcare costs associated with diabetes due to the early age of onset [181,182]. Therefore, 
understanding the alterations in physiological vascular functioning that occurs in T1D is of great 
importance for both the treatment and prevention of diabetes-associated vascular pathology. 
Diabetes is associated with both macro- and micro-vascular complications, which represent 
the main causes of mortality in individuals with T1D, especially in patients living with the disease 
for 5 or more years [183]. Within these patients, retinopathy (eye disease), neuropathy (neural 
damage), and nephropathy (kidney disease) are the major micro-vascular diseases, evident in small 
blood vessels (i.e. capillaries). The causes of vascular complications are complex and varied, and 
typically include a combination of prolonged hyperglycemia leading to endothelial degeneration 
or (paradoxically) hyper-vascularization, alterations in vascular permeability, and changes in 
blood pressure [182]. Diabetic retinopathy, for instance, can be separated into two stages of 
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development (non-proliferative and proliferative) and is the leading cause of blindness in adults 
aged 20-74 years [184]. The non-proliferative phase entails the thickening of the retinal basement 
membrane, altering vascular permeability and therefore the blood-retinal barrier [185]. The 
proliferative phase is defined by the degeneration or occlusion of retinal capillaries, leading to 
hypoxia and the subsequent release of pro-angiogenic factors that induce neovascularization and 
the accumulation of fluid within the retina contributing to visual impairment [182]. Another 
prevalent disease in T1D is diabetic neuropathy, and is associated with microvascular dysfunction 
such as basement membrane thickening and endothelial hyperplasia leading to a hypoxic 
environment for neuronal cells [182]. However, recent research suggests that the observed vascular 
abnormalities are secondary to neural and glial disorders, and that diabetic neuropathy selectively 
targets sensory and autonomic neurons over motor neurons with minimal involvement of the 
vascular system [182]. Finally, diabetic nephropathy is characterized by a decrease in glomerular 
filtration rate and the development of proteinuria [182]. Nephropathy is associated with the onset 
of hypertension, and is a major risk factor for the development of macro-vascular complications 
such as heart attacks and strokes in T1D individuals [186].  
4.3 Skeletal muscle angio-adaptation in type 1 diabetes 
 To date, the majority of the literature available on the microvascular complications that 
arise in patients with TID focuses on the traditional ‘big three’ of diabetes-induced diseases; 
retinopathy, neuropathy and nephropathy. Far less research exists describing how T1D affects the 
skeletal muscle fibres and the skeletal muscle capillary network. However, the existing literature 
indeed suggests capillary rarefication and alterations in angio-adaptive molecules. Kivelä and 
colleagues [187] demonstrate that T1D induction by streptozotocin injection significantly 
decreased mRNA levels of VEGF-A, VEGF-A receptor-1 (Flt-1) and VEGF-A receptor-2 (Flk-1) 
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in samples of the mouse calf muscle complex (gastrocnemius, soleus and plantaris). In addition to 
the T1D-induced down-regulation of pro-angiogenic factor expression, mRNA levels of TSP-1 
were significantly higher in diabetic mice compared to healthy controls. Interestingly, a 5-week 
exercise program partially restored the diabetes-induced reduction in VEGF-A mRNA, however 
was unable to reverse the increase in TSP-1 expression seen in sedentary diabetic mice. In 
accordance with VEGF-A mRNA expression, VEGF-A protein levels were significantly lower at 
both 3 and 5 weeks following the onset of diabetes in sedentary mice. Exercise training served to 
delay the reduction in VEGF-A protein levels, however trained diabetic mice still displayed 
significantly lower VEGF-A protein levels after 5 weeks of training compared to healthy controls. 
Interestingly, there was no difference in the capillary-to-fiber ratio between trained diabetic and 
untrained diabetic mice, and both groups had a significant reduction in skeletal muscle 
capillarization compared to non-diabetic controls. Similarly, Wallberg-Henricksson et al [188] 
report that while healthy male subjects increased the capillary-to-fiber ratio and capillary density 
in the gastrocnemius muscle in response to an 8 week endurance exercise training, these effects 
were lost in subjects with T1D. While it has been demonstrated that individuals with type 1 
diabetes can benefit from exercise training as seen by increased oxygen uptake and improved 
muscle strength, muscle tissue perfusion suffered in diabetics, as capillary growth did not match 
exercise-induced muscle hypertrophy [189]. Other studies indeed have shown supressed muscle 
perfusion in type 1 diabetics [190,191], which may be a result of an enlargement of the capillary 
basement membrane [190]. The skeletal muscle may not be the only striated muscle in which the 
capillary network is detrimentally affected by diabetes, as it has been shown that coronary 
collateral vessel development is impaired diabetics compared to healthy individuals [192]. 
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 Taken together, very little research exists examining the impact of type 1 diabetes on the 
skeletal muscle microvasculature. However, an intriguing research area emerges as our laboratory 
has clearly identified Mdm2 as an essential regulator of skeletal muscle angiogenesis and capillary 
maintenance, and have demonstrated that Mdm2 protein levels are sensitive to the diabetic state 
corresponding with the loss of skeletal muscle capillaries. Therefore, Mdm2 appears to be an 
attractive target to study in the pathological context of type 1 diabetes. 
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5. OBJECTIVES & HYPOTHESES 
The global objective of my research is to elucidate the complex pro-angiogenic role of 
Mdm2 in both physiological (in response to exercise) and pathological (in response to disease 
states such as diabetes) contexts. Through the implementation of various experimental models 
including the investigation of Mdm2 in rodent and human skeletal muscle as well as in primary 
endothelial cell culture, my research aims to deepen our understanding of skeletal muscle capillary 
angio-adaptation. Specific research aims and hypotheses are presented below: 
1) Mdm2 has historically been studied in the context of cancer due to its negative regulation of 
p53. However, previous research from our laboratory has suggested an important physiological 
role of Mdm2 in healthy tissue such as the skeletal muscle. It was demonstrated that Mdm2 is 
essential for both capillary maintenance and for exercise-induced angiogenesis to occur in the 
skeletal muscle. Furthermore, it was shown in rodents that total Mdm2 protein in muscle is 
elevated following a prolonged exercise training period [75]. My first research objective was to 
determine whether this specific finding that Mdm2 protein levels are increased in response to 
training could be translated to human subjects. I hypothesized that similarly to what was observed 
in rodents, prolonged exercise training will also increase total Hdm2 (the human analogue of 
Mdm2) protein expression in human skeletal muscle.  
2) It has been well documented that Mdm2 can undergo post-translational modification by 
multisite phosphorylations. Specifically, phosphorylating Mdm2 on its serine 166 (p-Ser166-
Mdm2), which lies in the Mdm2 nuclear localization sequence, promotes Mdm2 translocation 
from the cytoplasm into the nucleus where it can interact with its key downstream targets p53, 
FoxO1 and HIF-1α. I hypothesize that Mdm2 will undergo phosphorylation (i.e. activation) in 
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response to an acute bout of exercise in rodent and human skeletal muscle tissue. Second, I aim to 
determine whether Mdm2 activation could lead to altered binding interactions between Mdm2 and 
its downstream targets in primary human endothelial cells. Finally, I hypothesized that this 
activation of Mdm2 by phosphorylation will have direct effects on the pro-angiogenic activity of 
those endothelial cells (i.e. migration). 
3) Previous results from our laboratory indicate that Mdm2 protein level is associated with 
capillary loss in a rodent model of type-2 diabetes [75]. It has been widely reported that type 1 
diabetes (T1D) leads to microvascular pathology, while only few studies have shown skeletal 
muscle capillary regression in rodent models. Those studies that have investigated the effect of 
type 1 diabetes on the skeletal muscle microvasculature in animal models have exclusively utilized 
the easy and cost-effective approach of chemically-inducing diabetes by systemic streptozotocin 
(STZ) injection. However, the onset of overt hyperglycemia in STZ-treated animals is rapid (as 
little as 48-72 hours following injection) with many potential systemic adverse effects from STZ 
itself on various cell types and tissues including skeletal muscle [193-196]. However, BioBreeding 
(BB) diabetic rats spontaneously develop T1D between 50-90 days of age, around the time of 
puberty, and present characteristics that closely resemble those of human patients with T1D [197-
201]. I therefore hypothesized that, similar to the observed effects in a rodent model of type 2 
diabetes, T1D will lead to downregulation of Mdm2 protein levels in BB diabetic rats. As Mdm2 
signaling is highly complex with Mdm2 able to interact with several downstream targets to affect 
both sides of angio-adaptive balance, I hypothesized that the downregulation of Mdm2 in the 
diabetic state could result in altered expression levels of VEGF-A, FoxO1, and TSP-1. Any 
alterations in these key angio-adaptive molecules could contribute to capillary regression in the 
muscle of type 1 diabetic BB rats.  
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Scientific context: 
 Our laboratory has demonstrated in a rodent model of Mdm2 deficiency that Mdm2 
is essential for skeletal muscle capillary maintenance, exercise-induced 
angiogenesis, and the pro-angiogenic response to an acute bout of exercise [75]  
 Mdm2 is considered to be highly oncogenic due to its interaction with p53, however 
the loss of capillaries in Mdm2 deficient mice was found to be independent of p53 
background 
 Among several other novel findings, it was shown that Mdm2 protein levels are 
elevated following prolonged exercise training in the skeletal muscle of wild-type 
rats 
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 These findings suggest a physiological role of Mdm2 in the skeletal muscle 
Research aims:  
 Determine whether the previous findings that Mdm2 protein is elevated following 
exercise in rodents could be translated to human skeletal muscle following an 
exercise training program 
Summary of main findings: 
 In agreeance with rodent models, Hdm2 (the human analogue of Mdm2) protein is 
elevated in human skeletal muscle in response to a 6-week exercise training 
program 
 The increase in Hdm2 was found to be consistent across young and senior subjects, 
men and women, and those with varying fitness levels 
 Despite Hdm2 being predominantly studied in the context of cancer, we show that 
Mdm2 is sensitive to the physiological stimulus of exercise training, and may play 
an important role in human skeletal muscle as a key regulator of angiogenesis  
 
 
 
 
 
 
43
Novel perspective: exercise training stimulus triggers the expression of the oncoprotein 
human double minute-2 in human skeletal muscle 
Physiol Rep. 2013 Jul;1(2):e00028. doi: 10.1002/phy2.28. 
 
Emilie Roudier1, Julian Aiken1, Dara Slopack1, Fares Gouzi2, Jacques Mercier2, Tara L. Haas1, 
Thomas Gustafsson3,*, Maurice Hayot2,* & Olivier Birot1 
 
1 Faculty of Health, Angiogenesis Research Group, York University, Toronto, Canada 2 
INSERM U1046, Department of Clinical Physiology, CHRU Montpellier, University of 
Montpellier 1, University of Montpellier 2, Montpellier, France 3 Department of Laboratory 
Medicine, Section of Clinical Physiology, Karolinska Institutet, Karolinska University Hospital, 
Stockholm, Sweden 
 
Correspondence: Olivier Birot, York University – Faculty of Health, Angiogenesis Research 
Group, Norman Bethune College - Room 353, 4700 Keele Street, Toronto, Ontario, M3J 1P3, 
Canada. Tel: +1-416-736-2100 ext. 44819; Fax: +1-416-736-5774; E-mail: birot@yorku.ca  
Running head: Hdm2 Expression in Exercised Human Skeletal Muscle 
 
 
 
44
Abstract 
High expression levels of human double minute-2 (Hdm2) are often associated with increased risk 
of cancer. Hdm2 is well established as an oncoprotein exerting various tumorigenic effects. 
Conversely, the physiological functions of Hdm2 in nontumor cells and healthy tissues remain 
largely unknown. We previously demonstrated that exercise training stimulates expression of 
murine double minute-2 (Mdm2), the murine analog of Hdm2, in rodent skeletal muscle and 
Mdm2 was required for exercise-induced muscle angiogenesis. Here we showed that exercise 
training stimulated the expression of Hdm2 protein in human skeletal muscle from +38% to +81%. 
This robust physiological response was observed in 60–70% of the subjects tested, in both young 
and senior populations. Similarly, exercise training stimulated the expression of platelet 
endothelial cell adhesion molecule-1, an indicator of the level of muscle capillarization. 
Interestingly, a concomitant decrease in the tumor suppressor forkhead box O-1 (FoxO1) 
transcription factor levels did not occur with training although Mdm2/Hdm2 is known to inhibit 
FoxO1 expression in diseased skeletal muscle. This could suggest that Hdm2 has different targets 
when stimulated in a physiological context and that exercise training could be considered 
therapeutically in the context of cancer in combination with anti-Hdm2 drug therapies in order to 
preserve Hdm2 physiological functions in healthy tissues. 
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Introduction 
Expression or function of the tumor suppressor p53 protein is statistically altered in about 
50–60% of human cancers (Soussi and Wiman 2007). The E3 ubiquitin ligase murine double 
minute-2 (Mdm2) is an oncoprotein mostly known for its negative regulatory role on p53 function, 
inhibiting p53 transcriptional activity, promoting its nuclear export, and targeting it for 
proteosomal degradation (Marine and Lozano 2010; Li and Lozano 2013). Interestingly, Mdm2 is 
often overexpressed in human cancers and can also exert some tumorigenic activity independently 
of p53 (Marine and Lozano 2010). For example, Mdm2 activity contributes to enhance cell 
proliferation and to suppress the cell cycle arrest and apoptosis by regulating various molecules 
such as the retinoblastoma protein, E2F transcription factors, p21, or XIAP. Also, Mdm2 
involvement in promoting tumor angiogenesis and inflammation has recently emerged through its 
implication in vascular endothelial growth factor-A (VEGF-A) proangiogenic and NF-jB 
proinflammatory signaling (Nieminen et al. 2005; Carroll and Ashcroft 2008; Busuttil et al. 2010; 
Thomasova et al. 2012). With such broad and complex tumorigenic effects, it is not surprising that 
a search in the Pubmed database indicates that 90% of Mdm2-related publications refer to a tumor 
context.  
Among current anti-cancer strategies, some aim to inhibit Mdm2 function including 
downregulating its expression level, inhibiting its ubiquitin ligase activity, and blocking its 
interaction with p53 (Vassilev 2007; Li and Lozano 2013). Clinical trials are even already in place 
(http://www.clinicaltrials.gov). Of importance, the administration of anti-Mdm2 drugs in animal 
models and even in clinical trials is usually performed with systemic delivery (Secchiero et al. 
2011), raising the unanswered question of non-negligible risks of deleterious side effects for 
healthy tissues.  
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Transgenic models have clearly established that full deletion of Mdm2 is lethal (Toledo 
and Wahl 2006). Mendysa et al. (2006) generated Mdm2Puro/Δ7-9 transgenic mice harboring 
knockout and hypomorphic alleles for Mdm2. As a consequence these animals express only 40% 
of Mdm2 compared with the wild-type littermates. Mdm2Puro/Δ7-9 mice show no embryonic 
lethality and are protected against tumorigenesis.  
We have recently explored further the vascular phenotype of the Mdm2Puro/Δ7-9 mice and 
demonstrated that Mdm2 plays a key physiological role in regulating rodent skeletal muscle 
capillarization. In sedentary Mdm2Puro/Δ7-9 mice, the level of muscle capillarization was decreased 
by 20% (Roudier et al. 2012). Interestingly, whereas prolonged endurance training stimulated 
Mdm2 protein expression and promoted angiogenesis in wild-type muscles, the growth of new 
capillaries was blunted in Mdm2Puro/Δ7-9 mice.  
To our knowledge, this is one of very few characterizations of a physiological role for 
Mdm2 in an adult and healthy tissue. Skeletal muscles account for about 40% of our body weight, 
ensuring key functions from locomotion to metabolic regulation of glycemia. By matching the 
blood supply to the metabolic demand of active myofibers, the capillary network is a crucial 
determinant of muscle function (Egginton 2009). Thus, if inhibiting Mdm2 expression or function 
in tumor cells is an appealing anti-cancer strategy, we can, however, question what could be the 
consequence of systemic targeting for striated muscles, including respiratory muscles, diaphragm, 
skeletal muscles, and cardiac muscle, with an impact on vital functions such as locomotion, blood 
circulation, respiration, and metabolic homeostasis.   
Exercise training has been established as an efficient, practical, and costless approach to 
minimize side effects of anti-cancer therapies in healthy tissues (Mishra et al. 2012). In the context 
of Mdm2, the use of rehabilitating exercise training could therefore be considered in combination 
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with anti-Mdm2 drugs to preserve its physiological (and required) level of expression in healthy 
tissues.  
Here, we hypothesize that the stimulatory effect of exercise training on Mdm2 muscle 
expression observed in rodent models will translate into human double minute-2 (Hdm2) protein, 
the human analog of the murine Mdm2, in human skeletal muscle. 
Methods 
Ethical approval. All research protocols conformed to the standards of the latest revision of the 
Declaration of Helsinki and were approved by local institutions, respectively, the ethics committee 
at the Karolinska Institutet (Stockholm, Sweden) for the training of young male subjects, and the 
ethics committee from Montpellier University Hospitals for the training of the senior population. 
Informed written consent was obtained from all subjects. 
Participants. Two populations of subjects were studied. Sixteen sedentary young male subjects, 
all healthy and without any medications, were recruited. The subjects did not undertake any regular 
sporting activities in the 6 months prior to the 6-week training program. These subjects were part 
of a larger study involving a total of 24 subjects (Keller et al. 2011). Fourteen senior subjects 
(seven men and seven women) aged from 50 to 75 years with no disease and less than 150 min of 
moderate-to-vigorous physical activity per week were recruited (Gouzi et al. 2013). The clinical 
characteristics of all subjects including age, body weight, height, body mass index, and peak 
oxygen consumption (VO2) are summarized in Table 1. 
Exercise training protocols. Young male subjects performed an incremental cycloergometric test 
until exhaustion on an electrically braked cycloergometer (RE 990, Rodby innovation, Vange, 
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Sweden), following the individualized protocol and according to the international standards (Ross 
2003). During the exercise test, heart rate, ECG, blood pressure, and transcutaneous oxygen 
saturation were monitored. Oxygen consumption (VO2) and carbon dioxide production (VCO2) 
were measured and calculated by breath-by-breath analysis (Sensormedics, Vmax 229, Autobox, 
Yorba Linda, CA). Maximal power output was the maximal workload sustainable, and peak 
oxygen consumption (peak VO2) was the mean value during the last 20 sec of the test. At peak 
VO2, the respiratory exchange ratio exceeded 1.10 on all occasions. The training protocol 
consisted of 24 sessions of 45-min cycling endurance exercise, condensed in 6 weeks, four times 
per week at an intensity corresponding to 70% of the pretraining peak VO2 (100% compliance). 
Senior subjects performed an incremental cycloergometric test until exhaustion on an electrically 
braked cycloergometer (Ergoselect 200P, Ergolyne, Bitz, Germany), following the individualized 
protocol and according to the international standards (Ross 2003). During the exercise test, heart 
rate, ECG, blood pressure, and transcutaneous oxygen saturation were monitored. Oxygen 
consumption (VO2) and carbon dioxide production (VCO2) were measured and calculated by 
breathby-breath analysis (Sensormedics, Vmax 229, Autobox, Yorba Linda, CA). The ventilatory 
threshold was blindly and independently assessed for each subject by two experienced 
practitioners on the basis of noninvasive methods (ventilator equivalent and V-slope methods), as 
recommended (Ross 2003). The training protocol consisted of 20 sessions of 45-min cycling 
endurance exercise, condensed in 6 weeks, three times per week at an intensity corresponding to 
the subject’s ventilatory threshold, and corresponding to 60 ± 5% of the pretraining peak VO2 
(Nici et al. 2006). This intensity was continuously monitored with a cardiofrequency meter. Each 
session was completed by 30 min of strength building exercise (8–10 exercises, with sets of 10–
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15 repetitions). All training sessions were supervised by an experienced clinician to ensure the 
compliance of subjects. 
Muscle biopsies. Vastus lateralis muscle biopsies were performed pretraining and 24 h after the 
last training session as previously described (Hayot et al. 2005; Keller et al. 2011). Muscle samples 
were dissected free of visible connective tissue and fat and the muscle tissue was immediately 
frozen in isopentane cooled to freezing point with liquid nitrogen, and stored at -80°C until 
analysis. 
Western blotting. Immunoblotting was carried out on protein extracts from muscle tissue as 
previously described (Milkiewicz et al. 2011; Roudier et al. 2012). Proteins were extracted from 
muscle tissue using a protein lysis buffer containing 1 mg/mL phenylmethylsulfonyl fluoride, 1 
mmol/L Na3VO4, 1 mmol/L NaF (Sigma, Montreal, Canada), and 19 protease inhibitors 
(Complete Mini and PhosStop tablets from Roche Diagnostics, Laval, Canada). Twenty to 40 mg 
of frozen muscle was mixed at 4°C with lysis buffer (15 volumes of RIPA per mg of muscle). For 
each sample, protein extracts were prepared using two stainless carbide beads (Retsch, Fisher 
Scientific, Montreal, Canada) in the Retsch MM400 tissue lyser (2 x 30 pulses/sec, Retsch GmbH, 
Haan, Germany). Denatured samples (20–30 µg/well) were subjected to SDS-PAGE (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis) and blotted onto nitrocellulose (Whatman, 
BA95, Sigma-Aldrich, Oakville, Ontario, Canada) membranes. Quality of the transfer was 
confirmed by Ponceau S red staining. After blocking with 5% fat-free milk at room temperature 
for 45 min, the blots were probed overnight at 4°C with primary antibodies against the following 
proteins: endothelial marker platelet endothelial cell adhesion molecule-1 (PECAM-1) (clone 
JC70A, cat. M0823, Dako, Burlington, Ontario, Canada), Mdm2/Hdm2 (clone 2A10, supernatant 
from the hybridoma previously described in Chen et al. [1993]), forkhead box O-1 (FoxO1) 
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transcription factor (clone C29H4, cat. #2880; Cell Signaling Technology, Danvers, MA), and β-
actin (clone C4, cat. Sc-47778; Santa Cruz Biotechnologies, CA). β-actin was detected as a loading 
control. Proteins were visualized using an enhanced chemiluminescence procedure (SuperSignal 
West Pico, #34080; Thermo Scientific, Nepean, Ontario, Canada, or Millipore Immobilon 
#WBKLS0100; Thermo Scientific) and a Kodak Imaging station 4000MM Pro. Western blot 
images were analyzed with Carestream Molecular Imaging software. For each population of 
subjects, samples were randomly loaded on gels including a calibrator (i.e., loading of a protein 
extract sample composed of a pool of all samples) in order to conduct inter-gel comparisons. 
Statistical analysis. Analyses were performed using Prism5 software (GraphPad). Data are 
represented as means ± SEM. Two populations were considered: young men (n = 16) and senior 
subjects (n = 14). The effect of age and exercise training on the levels of expression of Hdm2, 
PECAM-1, and FoxO1 proteins as well as the peak VO2 was analyzed using a two-way analysis 
of variance (ANOVA) followed by Bonferroni posttests. Results were considered statistically 
significant when P ≤ 0.05. 
Results 
Exercise training improves fitness level and increases muscle endothelial content. The 
maximal oxygen consumption (peak VO2) is a good indicator of the cardiovascular fitness level. 
Young subjects presented higher pretraining and posttraining levels of peak VO2 than the seniors 
(Table 6.1, pretraining: 49.7 ± 1.3 vs. 25.7 ± 1.6 mL kg -1 min -1 [+93%], posttraining: 56.7 ± 1.8 
vs. 28.6 ± 1.6 mL kg -1 min -1 [+98%], P < 0.001). Exercise training increased the peak VO2 
similarly in young and senior subjects (respectively, +14% and +11%, P < 0.01). The level of 
muscle vascularization is considered to be an important determinant of exercise capacity (Wagner 
2010) and we have previously shown that the level of expression of the PECAM-1 protein reflects 
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the level of rodent skeletal muscle vascularization (Roudier et al. 2009, 2012). Representative 
immunoblots for PECAM-1 pre- and posttraining expression levels in skeletal muscles from young 
and senior subjects are shown on Figure 6.1A and B. Following exercise training, PECAM-1 
protein expression in skeletal muscle was increased in both populations, respectively, by 129% in 
young men and 72% in the senior subjects (Fig. 6.1C, 1.00 ± 0.15 vs. 2.30 ± 0.34 arbitrary units 
in young men [n = 16]; 1.00 ± 0.14 vs. 1.72 ± 0.20 arbitrary units in senior subjects [n = 14], P < 
0.0001). Although the group of young subjects was only comprised of men, stratified analyses did 
not show any evidence of differences between senior men and women so results are pooled across 
gender for the senior group. No effect of age was observed between young and senior populations. 
Hdm2 protein expression in skeletal muscle increases with exercise training independently 
of age. Representative immunoblots for Hdm2 pre- and posttraining expression levels in skeletal 
muscles from young and senior subjects are shown on Figure 6.2A and B. Hdm2 protein expression 
was significantly increased by 38% in response to exercise training in young male subjects and by 
81% in the senior population (Fig. 6.2C, 1.00 ± 0.07 vs. 1.38 ± 0.16 arbitrary units in young men 
[n = 16]; 1.00 ± 0.11 vs. 1.81 ± 0.29 in senior subjects [n = 14], P = 0.0011). No effect of age or 
gender was detected, respectively, between young and senior populations or between senior men 
and senior women. Analysis of individual Hdm2 variations in response to exercise training 
revealed similar proportions of Hdm2 responders (i.e., Hdm2 increase posttraining) between 
young and senior subjects (respectively, 63% and 71%, Fig. 6.2D and E). 
Exercise training had no effect on protein expression level of Hdm2 target FoxO1. In either 
young or senior subjects, exercise training had no significant effect on FoxO1 protein expression 
(Fig. 6.3, young men: 1.00 ± 0.10 pretraining vs. 1.06 ± 0.16 posttraining; senior subjects: 1.00 ± 
0.16 pretraining vs. 0.98 ± 0.16 posttraining). 
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Discussion 
Our study identified exercise training as a stimulator of Hdm2 expression in human skeletal 
muscle. This is a robust physiological response that occurs in 60–70% of the population 
independently of age and gender. It also illustrates that our previous finding of a stimulatory effect 
of exercise training on Mdm2 levels in rodent muscle translate to humans.  
Concomitantly with the increase in Hdm2, exercise training also stimulated the expression 
of PECAM-1, a good indicator of the level of endothelial material (Roudier et al. 2009, 2012). 
This finding is in line with our previous study identifying Mdm2 as an important regulator of 
skeletal muscle capillarization in Mdm2Puro/Δ7-9 mice and showing that the reduction in Mdm2 
expression restrained the proliferative and migratory response of skeletal muscle endothelial cells 
to the exercise stimulus (Roudier et al. 2012).  
Demonstrating that exercise stimulus increases Hdm2 protein levels in human skeletal 
muscle might have important clinical consequences. Hdm2 is considered as an oncoprotein based 
on its various tumorigenic functions, and particularly its role as the main negative regulator of the 
tumor suppressor p53 (Li and Lozano 2013). The development of Mdm2/Hdm2 inhibitors is a very 
attractive approach to restore p53 function in cancer cells and to inhibit Mdm2-mediated tumor 
angiogenesis (Vassilev 2007; Millard et al. 2011 Li and Lozano 2013). In fact, clinical trials are 
already under development (Vassilev 2007; Millard et al. 2011).  
The ability to stimulate Hdm2 muscle expression using rehabilitating exercise training 
might thus represent an easy and practical approach to preserve Hdm2 function in skeletal muscles 
from cancer patients undergoing anti-Hdm2 therapy. In particular, Hdm2 response to exercise 
training was as strong in the senior population, equally composed of men and women and trained 
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at a very moderate intensity, as in young male subjects. The ability of the exercise training stimulus 
to increase Hdm2 muscle expression is therefore independent of the age, the gender, and the level 
of activity of the subjects, which makes the concept of combining anti-Hdm2 cancer therapies with 
rehabilitating exercise training very realistic. In line with this idea, physical activity is known to 
improve the overall quality of life and to decrease fatigue in cancer patients (Mishra et al. 2012), 
whereas most current anti-cancer therapies can unfortunately induced damages in non-cancer cells 
(Ballard-Barbash et al. 2012). Therefore, triggering Hdm2 expression by exercise training in 
healthy tissues might have strong antiapoptotic and survival effects in non-cancer cells, protecting 
them from anti-cancer therapy side effects.  
Aside from the context of cancer, Hdm2 could also represent a new therapeutic target to 
stimulate skeletal muscle angiogenesis in chronic metabolic diseases associated with capillary 
regression such as obesity, diabetes, and limb ischemia. This is consistent with our previous works 
showing some alterations of Mdm2 expression or activation in rodent models of type-2 diabetes 
and limb ischemia (Milkiewicz et al. 2011; Roudier et al. 2012).  
A balance between pro- and antiangiogenic factors tightly controls muscle 
angioadaptation, that is, the process regulating capillary maintenance, regression, or growth (Olfert 
and Birot 2011). Interestingly, Hdm2/Mdm2 could potentially affect both sides of the 
angioadaptive balance. Mdm2 was suggested to enhance the expression of the proangiogenic 
VEGF-A (Nieminen et al. 2005; Carroll and Ashcroft 2008). We recently showed in skeletal 
muscles from Mdm2Puro/D7-9 mice that Mdm2 was indispensable for the increase expression of 
VEGF-A in response to acute exercise (Roudier et al. 2012). Mdm2 could also contribute to 
restrain p53-mediated antiangiogenic effects. For example, p53 stimulates the expression of 
thrombospondin-1 (TSP-1) (Dameron et al. 1994), a key antiangiogenic regulator of muscle 
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angioadaptation (Olfert and Birot 2011). Interestingly, Mdm2 could also regulate TSP-1 
independently of p53. We have shown that Mdm2Puro/Δ7-9 mice express higher muscle levels of a 
disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS-1) expression 
(Roudier et al. 2012), a protein enhancing TSP-1 cleavage and promoting its antiangiogenic 
activity (Lee et al. 2006).  
Several other angioadaptive molecules might be under the control of Mdm2 such as the 
FoxO1 transcription factor that is known to exert antiangiogenic effects (Milkiewicz et al. 2011; 
Roudier et al. in press) and to be negatively regulated by Mdm2 (Fu et al. 2009). FoxO1 is also 
considered a tumor suppressor (Arden 2007). Interestingly, in this study, the increase in Hdm2 
expression in trained human skeletal muscle was not accompanied by a decrease in FoxO1. This 
suggests that an increase in Hdm2 in a healthy tissue in response to a physiological stress might 
not be associated with an increase in its oncogenic function.  
In summary, our results showed that Hdm2 expression in human skeletal muscle was 
increased in response to exercise training concomitantly with higher levels of capillarization. This 
observation provides new insight into the mechanisms by which physical activity might improve 
muscle function. Further studies are required to investigate the underlying mechanisms by which 
exercise training modulates Hdm2 and its targets. A better understanding of the molecular events 
that regulate Hdm2 in non-pathological versus oncogenic contexts might contribute to the 
development of new anti-Hdm2 drugs that are more efficient and less deleterious to healthy tissues, 
and thus limiting potential side effects of these promising anti-cancer therapies. 
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Figure legends 
Figure 6.1 Exercise training increases expression of the endothelial marker platelet endothelial cell 
adhesion molecule-1 (PECAM-1) in human skeletal muscle. (A and B) Representative 
immunoblots of PECAM-1 protein expression in the vastus lateralis muscle from young men (A, 
n = 16) or senior subjects (B, n = 14) before and after endurance training. C, Densitometric analysis 
of PECAM-1 protein expression is represented and β-actin was used as a loading control. Data are 
presented as means ± SEM. The effect of exercise training or age was considered statistically 
significant when P ≤ 0.05 after two-way ANOVA analysis and Bonferroni posttest. 
Figure 6.2 Exercise training increases expression of human double minute-2 (Hdm2) protein in 
human skeletal muscle. (A and B) Representative immunoblots of Hdm2 protein expression in the 
vastus lateralis muscle from young men (A, n = 16) or senior subjects (B, n = 14) before and after 
endurance training. C, Densitometric analysis of Hdm2 protein expression is represented and β-
actin was used as a loading control. Data are presented as means ± SEM. The effect of exercise 
training or age was considered statistically significant when P ≤ 0.05 after two-way ANOVA 
analysis and Bonferroni posttest. (D and E) Representation of individual responses to training for 
Hdm2 protein expression in muscles from young (D, n = 16) and senior subjects (E, n = 14). 
Individual responses are expressed as raw values (Hdm2 normalized to β-actin, top graph) and in 
percentage of change from pretraining (bottom graph). For each population, the percentages of 
Hdm2 responders (i.e., subjects having an increased expression of Hdm2 in response to training) 
and nonresponders are indicated. 
Figure 6.3 Forkhead box O-1 (FoxO1) transcription factor expression is not affected by exercise 
training in human skeletal muscle. (A and B) Representative immunoblots of FoxO1 protein 
expression in the vastus lateralis muscle of young men (A, n = 16) or senior subjects (B, n = 7 men 
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and n = 7 women) before and after endurance training. Densitometric analysis of FoxO1 protein 
expression is represented and β-actin was used as a loading control. No significant difference was 
observed in response to exercise training (two-way ANOVA and Bonferroni posttests). 
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Figure 6.3 
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Scientific context: 
 We have shown that Mdm2 is essential for skeletal muscle capillary maintenance 
and for exercise-induced angiogenesis to occur 
 Mdm2 protein is significantly elevated by exercise training in both rodent and 
human skeletal muscle 
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 In addition to understanding Mdm2 regulation in response to prolonged training, it 
is also important to study the role of Mdm2 during the ‘dynamic phase’ of the 
angiogenic process; acute bouts of exercise 
 Mdm2 can undergo multi-site phosphorylation, and phosphorylation of Mdm2 on 
its serine 166 residue can lead to nuclear localization and an increased interaction 
with its downstream targets p53, FoxO1, and HIF-1α [100,151,153,155,156]. 
Research aims: 
 Investigate how an acute bout of exercise, representing the dynamic phase of 
angiogenesis, affects Mdm2 activity (i.e. phosphorylation) 
 Investigate the impact of Mdm2 phosphorylation on endothelial cell pro-angiogenic 
activity 
 Determine Mdm2-dependent molecular signaling that could regulate endothelial 
cell functionality 
Summary of main findings: 
 An acute bout of exercise strongly induces both VEGF-A and p-Ser166-Mdm2 
protein 
 VEGF-A has been identified as a potent stimulator of p-Ser166-Mdm2 in the 
muscle tissue and in endothelial cells 
 VEGF-A-driven endothelial cell migration is dependent on Mdm2 activity  
 Mdm2 phosphorylation on serine 166 leads to an increased interaction between 
Mdm2 and FoxO1 with subsequent down-regulation of FoxO1 target genes, 
namely, TSP-1 in primary human endothelial cells 
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 Our results show for the first time that Mdm2 is essential for the pro-angiogenic 
effect of VEGF-A, highlighting the complex and reciprocal relationship existing 
between the two molecules 
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Abstract 
We demonstrated in a previous study that murine double minute (Mdm)-2 is essential for exercise-
induced skeletal muscle angiogenesis. In the current study, we investigated the mechanisms that 
regulate Mdm2 activity in response to acute exercise and identified VEGF-A as a key stimulator 
of Mdm2 phosphorylation on Ser166 (p-Ser166-Mdm2). VEGF-A and p-Ser166-Mdm2 protein 
levels were measured in human and rodent muscle biopsy specimens after 1 bout of exercise. 
VEGF-A-dependent Mdm2 phosphorylation was demonstrated in vivo in mice harboring 
myofiber-specific deletion of VEGF-A (mVEGF-/-) and in vitro in primary human and rodent 
endothelial cells (ECs). Exercise increased VEGF-A and p-Ser166-Mdm2 protein levels 
respectively by 157 and 68% in human muscle vs. pre-exercise levels. Similar results were 
observed in exercised rodent muscles compared to sedentary controls; however, exercise-induced 
Mdm2 phosphorylation was significantly attenuated in mVEGF-/- mice. Recombinant VEGF-A 
elevated p-Ser166-Mdm2 by 50–125% and stimulated migration by 33% in ECs when compared 
to untreated cells, whereas the Mdm2 antagonist Nutlin-3a abrogated VEGF-driven EC migration. 
Finally, overexpression of a Ser166-Mdm2 phosphorylation mimetic increased EC migration, 
increased Mdm2 to FoxO1 binding (+55%), and decreased FoxO1-dependent gene expression 
compared with ECs overexpressing WT-Mdm2. Our results suggest that VEGF-mediated Mdm2 
phosphorylation on Ser166 is a novel proangiogenic pathway within the skeletal muscle. 
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Introduction 
Angiogenesis is the formation of new capillaries from pre-existing ones, a process that can be 
observed under various physiologic and pathologic circumstances (1). Endurance training is a 
well-established illustration of physiologic angiogenesis in adult skeletal muscle tissue (2). A 
single bout of exercise represents a strong physiologic stress for the skeletal muscle, modulating 
the expression of pro- and antiangiogenic molecules and inducing significant changes in gene 
expression. If this exercise stimulus is repeated persistently [i.e., during daily exercise training, the 
balance between pro- and antiangiogenic factors is shifted toward a proangiogenic profile (3)], 
ultimately, endothelial cells will migrate and assemble into new capillaries. This expansion of the 
microvascular bed ensures that oxygen and nutrient supply is well matched with the metabolic 
needs of active myofibers (2). Several key factors have been identified as important regulators of 
angiogenesis in the adult skeletal muscle, particularly the proangiogenic VEGF-A and the 
antiangiogenic thrombospondin (TSP)-1 (3). 
 In this context, we recently demonstrated that the E3 ubiquitin ligase murine double minute 
(Mdm)-2 is a critical regulator of capillary maintenance and exercise-induced angiogenesis in 
skeletal muscles (4). Using transgenic mice with reduced Mdm2 expression, we demonstrated that 
Mdm2 is essential for exercise-induced VEGF-A expression, endothelial cell migration, and 
training-induced muscle angiogenesis (4). 
 Mdm2 was studied primarily for its role as a negative regulator of the tumor suppressor 
p53, and it may affect angiogenesis by inhibiting p53-dependent antiangiogenic activities, such as 
induction of TSP-1 expression. It also may exert proangiogenic activity independently of p53 (5). 
Mice that overexpress Mdm2 have a higher incidence of angiosarcoma, a type of tumor 
characterized by an excessive proliferation of endothelial cells (ECs), independent of their p53 
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status (6). In line with this knowledge, we have shown that reduced Mdm2 expression in skeletal 
muscle results in lower levels of capillarization independent of p53 expression (4), whereas p53 
knockout without concomitant alteration of Mdm2 expression has no effect on muscle 
capillarization (7). Aside from p53, Mdm2 interacts with other transcription factors that are 
essential for skeletal muscle angiogenesis, such as hypoxia inducible factor (HIF)-1α and forkhead 
box O1 (FoxO1). Recent in vitro studies indicated that Mdm2, when phosphorylated on Ser166, 
stimulates VEGF-A expression through HIF-1α stabilization (8, 9). Most of these studies were 
performed on tumor cells where Mdm2 is amplified or overexpressed, and the physiologic 
relevance of such regulatory effects of Mdm2 on VEGF-A expression remains uncertain. Mdm2 
can sense endogenous and exogenous stresses through posttranslational modifications, such as 
site-specific phosphorylation, that in turn control Mdm2 activity and recruitment of downstream 
targets (5, 10). For example, phosphorylation on Ser166 in response to insulin-like growth factor-
1 promotes degradation of p53 and HIF-1 α stabilization in tumor cells (11). Mdm2 also binds to 
FoxO proteins (12). In recent studies, we demonstrated that endothelial FoxO transcription factors 
promote an antiangiogenic microenvironment in skeletal muscle in both pathologic and 
physiologic contexts (13, 14). We have shown that mice harboring an EC-directed deletion of 
FoxO exhibit an earlier onset of exercise-induced angiogenesis than do their wild-type (WT) 
littermates (14). In another study, we showed that phosphorylated Mdm2 on Ser166 interacts with 
FoxO1 in the skeletal muscle and in endothelial cells (12), suggesting that Mdm2 negatively 
regulates FoxO activity. 
 In the present study, we investigated further how one bout of exercise regulates Mdm2 
activity in skeletal muscle. In our work, in the physiologic context of exercise, VEGF-A was an 
upstream regulator of Mdm2 phosphorylation on Ser166 (p-Ser166-Mdm2). Taking into 
72
consideration that other studies have positioned Mdm2 as an upstream regulator of VEGF-A 
expression, we now bring evidence of a more complex relationship between the 2 molecules. We 
found that Mdm2 activity was necessary for EC migration in response to exercise and VEGF-A 
stimulation. Overexpression of a phosphomimetic form of p-Ser166-Mdm2 (S166D-Mdm2) 
promoted EC migration, increased the binding between Mdm2 and FoxO1, and decreased gene 
expression of hallmark FoxO targets in primary ECs. Altogether, our results suggested that Mdm2 
activation by phosphorylation on Ser166 and its subsequent impact on FoxO1 targets represent a 
novel proangiogenic signaling pathway downstream of VEGF-A in exercised human and rodent 
skeletal muscle. 
Materials and methods 
Exercise protocol and muscle biopsies from human subjects. Experiments were performed after 
informed consent was obtained from the subjects and after ethics approval (Karolinska Institutet 
2006/1232-31/1). Five healthy male subjects were included in the study. Their mean (range) age, 
height, and weight were 27 (22–34) yr, 180 (173–187) cm, and 75 (69–83) kg, respectively. They 
were moderately active, which corresponded to a mean (range) maximum oxygen consumption 
(VO2max) of 48 (41–57) ml/kg/min. The subjects had no history of chronic disease. They performed 
60 min of cycle exercise on an electrodynamically loaded cycle ergometer. During the first 20min, 
they cycled at 60 rpm at a median (range) work rate of 125 (105–145) W, chosen to correspond to 
50% of VO2max, after which the work rate was increased to 170 (140–190) W, corresponding to 
65% of VO2max for a further 40min. Blood pressure and heart rate were measured every 10min 
during exercise. Muscle biopsy samples were obtained by the percutaneous needle biopsy 
technique from the vastus lateralis muscle at rest, immediately after 60 min of exercise, and after 
120 min of recovery after exercise. All biopsy samples were frozen in liquid nitrogen until analysis. 
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Exercise protocols in rodents. Animal experiments were conducted according to the Canadian 
Council on Animal Care, and the animal care and use committees of York University and West 
Virginia University. Nine week-old female Sprague-Dawley rats (n = 24; 180–200 g) were 
purchased from Charles River Laboratories (Saint-Constant, QC, Canada). Engineering of 
myofiber-specific VEGF-A deficient mice (mVEGF-/-) was as described elsewhere (15). 
 After familiarization to treadmill running, the animals performed a single bout of running 
exercise on a rodent treadmill until exhaustion (4, 15). Plantaris or gastrocnemius muscles were 
collected immediately after exercise. The rats performed a running exercise at 25–30 m/min, at a 
10% incline, for 60–90 min (n =8 rats per group). WT and mVEGF-/- mice ran on the treadmill at 
10 m/min for 10 min with a 10% incline, followed by 15 m/min until exhaustion (18–20 min), as 
described previously (15). 
Three-dimensional muscle explant assay. The 3-dimensional (3D) muscle explant assay was 
performed according to a published method (4, 13). Muscle explants were embedded in type-1 
collagen. In some wells, the Mdm2 inhibitor Nutlin-3a was added to the gel and medium with 2% 
fetal calf serum (FCS; 1 mM; N6287; Sigma-Aldrich, Oakville, ON, Canada). After 6 d, the 3D 
muscle explants were fixed with 4% formalin, and endothelial outgrowth was detected with 
isolectin-B4 and tetramethylrhodamine isothiocyanate (TRITC)-conjugated streptavidin (cat. no. 
016-020-084; Jackson ImmunoResearch, West Grove, PA, USA). Images were acquired with an 
inverted microscope. The relative number of ECs was quantified by measuring the intensity of 
staining of the major migration front surrounding the muscle biopsy. The value attributed to an 
animal is the average of 4–6 analyzed biopsy specimens. Data are represented as staining intensity 
(arbitrary units) per pixel (n = 4 animals per group). 
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In vitro plantaris biopsy sample incubation. Forty milligrams of muscle were rinsed 3 times in 
PBS and DMEM before incubation in DMEM with 2% FCS and stimulation with increasing 
concentrations of recombinant VEGF165 (recVEGF165; 0–50 ng/ml; Peprotech, Rocky Hills, NJ, 
USA), or 10% muscle homogenates prepared from plantaris muscles of sedentary and exercised 
rats for 2 h. After muscle lysis with a MM400 tissue lyser (30 pulses/s at 4°C; Retsch GmbH, 
Haan, Germany), they were centrifuged at 4°C for 15 min at 15,000 g, and the supernatants were 
collected to serve as homogenates. Before muscle homogenate stimulation, biopsies specimens 
were preincubated or not with 200 nM of the VEGF-A receptor inhibitor KRN633 (sc-204379; 
Santa Cruz Biotechnology, Dallas, TX, USA). 
Cell culture. Rat or mouse skeletal muscle microvascular ECs (SMECs) were isolated from 
extensor digitorum longus and tibialis anterior muscles and cultured as has been described (12, 
13). The cells were starved overnight with DMEM containing 1% FCS before stimulation with 
recombinant rat or mouse VEGF165, as indicated in the figure legends (Peprotech). 
 Primary human dermal and human adipose microvascular ECs (HDMECs and HAMECs, 
respectively) were purchased from ScienCell Research Laboratories (cat. no. 2000 and 7200, 
respectively; Carlsbad, CA, USA). The cells were maintained in ECM (cat. no. 1001) 
supplemented with 5% FBS (cat. no. 0025), 1% EC growth supplement (ECGS; cat. no. 1052), 
and antibiotic solution containing 100 U/ml penicillin and 100 µg/ml streptomycin (cat. no. 0503; 
all from ScienCell). HAMECs and HDMECs were starved with ECM containing 1% FBS before 
stimulation with recombinant human VEGF165 (Peprotech). 
Generation of WT-Mdm2 and S166D-Mdm2 mutant cell lines. Lentiviruses encoding WT-Mdm2 
(cat. no. 16233; Addgene) or mutant S166D-Mdm2 (cat. no. 16234; Addgene) plasmids were 
generated by subcloning into lentiviral vector with puromycin selection, pLenti CMV/TO Puro 
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DEST (cat. no. 17293; Addgene) (16), and viral particles were produced by transfecting 293T cells 
with the packaging vectors (pLP1, pLP2, and pLP/VSVG) (ViraPower; Thermo Scientific-
Invitrogen) and pLenti Mdm2 or pLenti S116DMdm2. Subconfluent HDMECs in culture were 
infected with one of the lentiviruses. Transduced cells were selected with 2 µg/ml puromycin and 
subcultured in endothelial cell medium (ECM) with 1 µg/ml puromycin until use in experiments, 
generating WT-Mdm2 and mutant S166-Mdm2 (S166D-Mdm2)–overexpressing HDMECs. 
Immunoblot analysis. Immunoblot analysis was conducted on protein extracts from rodent 
plantaris or gastrocnemius muscles, human vastus lateralis biopsies, or primary ECs (4, 13). Blots 
were probed with the following primary antibodies: αβ-tubulin (cat.no. 2148; Cell Signaling 
Technology, Beverly, MA, USA), Mdm2 clone SMP14 (sc-965; Santa Cruz Biotechnology), 
Mdm2 clone 2A10 (4), Mdm2 4B11 (Ab-3; Calbiochem, Etobicoke, ON, Canada), p-Ser166-
Mdm2 (cat.no. 3521; Cell Signaling Technology), β-actin (sc-47778; Santa Cruz Biotechnology), 
VEGF-A (VG-1; Millipore, Etobicoke, ON, Canada), p53 (sc-6243; Santa Cruz Biotechnology), 
HIF-1α (NB100-105; Novus Biologicals, Littleton, CO, USA), and FoxO1 (C29H4, catno. 2880; 
Cell Signaling Technology). After incubation with secondary antibody (horseradish peroxidase 
[HRP]-linked anti-rabbit antibody, cat. no. 7074, Cell Signaling Technology; or HRP-linked anti-
mouse; cat. no. P0260; Dako, Carpinteria, CA, USA), proteins were visualized with enhanced 
chemiluminescence (Santa Cruz Biotechnology) on Imaging Station 4000MM Pro (Carestream 
Health, Rochester, NY, USA). Blots were analyzed with Image 1.62 (National Institutes of Health, 
Bethesda, MD, USA) or Carestream software. 
Immunoprecipitation. HDMECs overexpressing WT or S166D-Mdm2 were treated with 20 µM 
MG132 (I-130; Boston Biochem, Cambridge, MA, USA) for 5 h before cell lysis, to block 
proteasomal degradation. FoxO1, Mdm2, or p53 were immunoprecipitated by overnight 
76
incubation with the respective primary antibodies (cat. no. 2880; Cell Signaling Technology, and 
sc-965 and sc-126; Santa Cruz Biotechnology) and Immunocruz Optima F IP matrix (sc-45043; 
Santa Cruz Biotechnology). Normal rabbit (sc-2027) or mouse (sc-2025; both from Santa Cruz 
Biotechnology) IgG was used as a species-specific control primary antibody. Cell lysates were 
precleared (Immunocruz Optima F preclearing matrix; sc-45060; Santa Cruz Biotechnology) and 
incubated overnight with the IP antibody–matrix complex. Supernatants were analyzed by Western 
blot for FoxO1 (Cell Signaling Technology), Mdm2 (clone 4B11, OP143 or non-commercial 
2A10; Calbiochem), p53 (sc-6243; Santa Cruz Biotechnology), or HIF-1α (cat. no. 100-105; 
Novus Biologicals). 
Boyden chamber migration assay. Assessment of EC migration was performed with HDMECs in 
the Boyden chamber assay (17). HDMECs were pretreated with the Mdm2 inhibitor Nutlin-3a (10 
µM) or vehicle for 1 h before trypsinization and resuspension in ECM with 1% FBS at a 
concentration of 400 cells/ml. Cell migration was stimulated by recVEGF165 (100 ng/ml). Cells 
migrated through an 8-µm polycarbonate membrane filter (cat. no. PFB8; Neuro Probe, Inc., 
Gaithersburg, MD, USA) coated with 50µg/ml collagen (cat. no. A10438-01; Thermo Scientific-
Gibco, Grand Island, NY, USA) in 0.02 M acetic acid (cat. no. 320099; Sigma-Aldrich, St. Louis, 
MO, USA). After 4.5 h of migration time, the membrane filter was fixed in cold methanol, stained 
with 10% Giemsa stain diluted in water (cat. no. GS500; Sigma-Aldrich), and mounted on a 
microscope slide. Three independent experiments were performed with 4–6 wells per condition 
(with or without recVEGF165 and with or without Nutlin-3a). 
 To assess the role of p-Ser166-Mdm2 phosphorylation on HDMECs migration, we 
performed the Boyden chamber assay on HDMECs infected with lentiviruses encoding for either 
WT-Mdm2 or S166D-Mdm2. The bottom chambers were loaded with 28 µl of either ECM with 
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1% FBS and no ECGS (no-stimulation condition) or ECM supplemented with 10% FBS and 5% 
ECGS (stimulation condition). Two separate experiments were performed with 4–6 wells per 
condition per experiment. 
For each experiment, 4 individual fields of view per well were counted under X40 
magnification. Results are presented as the average of all fields of view. 
Statistical analysis. Statistical analyses were performed with Student’s t test and 1- and 2-way 
ANOVAs with Prism5 (GraphPad, San Diego, CA, USA). For 1- and 2-way ANOVAs, Newman-
Keuls multiple comparison and Bonferroni post hoc tests were used, respectively. Correlation 
analyses between variables were performed with nonparametric 2-tailed Pearson correlation with 
determination of Pearson r and r2. P ≤ 0.05 was considered to be statistically significant. 
Results 
Exercise stimulates VEGF-A expression in human and rodent skeletal muscles. Whereas a 
single bout of exercise had no effect on the Mdm2 protein level in human (Fig. 7.1A), rat (Fig. 
7.1C), and mouse skeletal muscles (Fig. 7.2E, G), it strongly stimulated p-Ser166-Mdm2 (Figs. 
7.1A–D and 7.2E, F). The p-Ser166-Mdm2 level increased significantly (68%) in human 
(postexercise vs. pre-exercise, 0.61 ± 0.07 vs. 0.27 ± 0.18; P ≤ 0.05) and by 128% in rat skeletal 
muscles (postexercise vs. pre-exercise, 0.57 ± 0.09 vs. 0.25 ± 0.05; P ≤ 0.05). This phosphorylation 
was transient, however, as no significant increase was detected at 2 and 4 h after exercise in human 
or rat muscles, respectively (Fig. 7.1A–D). VEGF-A protein in response to 1 bout of exercise 
followed a pattern similar to that of p-Ser166-Mdm2 levels. VEGF-A protein levels were increased 
by 157% in exercised human biopsy samples (postexercise vs. pre-exercise, 0.90 ± 0.18 vs. 0.35 
± 0.11; P ≤ 0.05) and by 45% in rat muscles (postexercise vs. preexercise, 0.46 ± 0.03 vs. 0.30 ± 
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0.02; P ≤ 0.05). At 2 h after exercise, no significant increase in VEGF-A was observed in human 
muscles and the increase in rat samples, although still significant, was considerably attenuated. 
The transient increase in p-Ser166-Mdm2 correlated positively with the increase in VEGF-A 
protein levels in human skeletal muscle (Fig. 7.1E; r2 = 0.621; P ≤ 0.0005). Similar data were 
recorded in rat skeletal muscle (data not shown; correlation slope = 0.062 ± 0.01; r2 = 0.879; P ≤ 
0.001). 
 Muscle VEGF-A expression is essential for Mdm2 phosphorylation in response to exercise. 
In transgenic mice harboring a muscle-specific deletion of VEGF-A (mVEGF-/-), we investigated 
whether Mdm2 phosphorylation on Ser166 is dependent on exercise-induced expression of VEGF-
A. As has been described (15), mVEGF-/- mice expressed less VEGF-A protein in their skeletal 
muscle at rest (Fig. 7.2A) and presented a severe reduction (257%) in their level of muscle 
capillarization (Fig. 7.2B). In contrast to their WT littermates, no significant increase in VEGF-A 
was observed in the mVEGF-/- mice after one bout of running exercise (Fig. 7.2C, D; WT, 0.28 ± 
0.09 at rest vs. 0.57 ± 0.03 after exercise; P ≤ 0.05; mVEGF-/-, 0.18 ± 0.03 at rest vs. 0.30 ± 0.05 
after exercise; P > 0.05). Whereas mVEGF-/- mice expressed slightly more Mdm2 protein than did 
WT animals at basal levels (Fig. 7.2E, F; 2-way ANOVA, overall effect of genotype, P = 0.0092), 
no change in Mdm2 protein level was observed after one bout of running exercise in both WT and 
mVEGF-/- mice (Fig. 7.2E, F). p-Ser166-Mdm2 protein levels were strongly increased by exercise 
in WT animals (Fig. 7.2E, G; +71%; 0.14 ± 0.03 at rest vs. 0.24 ± 0.02 after exercise; P ≤ 0.05) 
but no significant increase was observed in mVEGF-/- mice (Fig. 7.2E, G; 0.10 ± 0.02 at rest vs. 
0.18 ± 0.03 after exercise; P > 0.05). Given the effect of the genotype on total Mdm2 expression, 
we analyzed the p-Ser166-Mdm2:Mdm2 ratio (Fig. 7.2H). Whereas this ratio increased in WT 
mice with exercise (+77%; 0.49 ± 0.05 at rest vs. 0.87 ± 0.07 after exercise; P ≤ 0.05), no 
79
significant change was detected in mVEGF-/- mice (+24%; 0.33 ± 0.05 at rest vs. 0.41 ± 0.08 after 
exercise; P > 0.05). VEGF-A deletion in muscle cells therefore strongly reduced the exercise-
induced increase in p-Ser166-Mdm2. This finding suggests that VEGF-A is an upstream regulator 
of Mdm2 phosphorylation on Ser166 in exercised skeletal muscle. 
 VEGF-A stimulation promotes the phosphorylation of Mdm2 on Ser166 in ex vivo skeletal 
muscle biopsies. To confirm that VEGF-A could act as an upstream regulator of Mdm2 
phosphorylation, plantaris biopsy samples from sedentary rats were incubated in vitro in the 
presence of increasing concentrations of recVEGF165 (0–50 ng/ml) for 2 h (Fig. 7.3A, B). VEGF-
A stimulated an increase in p-Ser166-Mdm2 protein levels (1-way ANOVA; P < 0.0001). Next, 
some samples from sedentary rats were incubated in vitro in the presence of 10% muscle 
homogenate obtained from sedentary or exercised rats. Whereas the stimulation with the exercise 
homogenate significantly induced p-Ser166-Mdm2 levels in the plantaris specimen (Fig. 7.3C; 
0.22 ± 0.02 sedentary homogenate vs. 0.30 ± 0.02 exercise homogenate; 2-way ANOVA; P ≤ 
0.05), this effect was abolished in the presence of the VEGF receptor inhibitor KRN933 (Fig. 7.3D; 
0.25 ± 0.02 sedentary homogenate with KRN633 vs. 0.26 ± 0.04 exercise homogenate with 
KRN633). 
 VEGF-A stimulates Mdm2 phosphorylation on Ser166 in primary ECs. Both exercise and 
VEGF-A stimulated the phosphorylation of Mdm2 on Ser166 in skeletal muscle. Therefore, we 
sought to determine whether Ser166 phosphorylation occurs more specifically in the endothelium 
of the skeletal muscle. 
 We incubated primary microvascular ECs isolated from rat skeletal muscles (rSMECs) 
with increasing doses of rat recVEGF165 (0–100 ng/ml) for 1 h. VEGF-A increased p-Ser166-
Mdm2 in rSMECs (Fig. 7.4A). We further studied the effect of VEGF-A stimulation on primary 
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microvascular ECs from mSMECs, as well as HAMECs and HDMECs (Fig. 7.4B). One hour of 
stimulation with recVEGF165 increased the levels of p-Ser166-Mdm2 by 50, 108, and 125% in 
mSMECs, HAMECs, and HDMECs, respectively (recVEGF165 vs. control: mSMECs, 1.51 ± 
0.13 vs. 1.00 ± 0.05; P = 0.0234; HAMECs, 2.08 ± 0.28 vs. 1.00 ± 0.04; P = 0.0178; and HDMECs, 
2.25 ± 0.5 vs. 1.00 ± 0.09; P = 0.0286). No significant change in the level of Mdm2 protein 
expression was observed in response to recVEGF165 stimulation. 
Mdm2 inhibitor Nutlin-3a inhibits exercise-induced endothelial outgrowth from skeletal 
muscle explants. To test the hypothesis that Mdm2 activity is necessary for SMEC migration in 
the context of exercise, we performed an ex vivo skeletal muscle explant assay by embedding 
plantaris biopsy specimens from sedentary and exercised rats in a 3D collagen gel in the presence 
of Nutlin-3a (Fig. 7.5A). Biopsy samples were obtained from the plantaris muscles as presented in 
Fig. 7.1, where postexercise levels of VEGF-A and p-Ser166-Mdm2 protein are both shown to 
have increased. A single bout of running exercise strongly increased endothelial outgrowth 
compared with the sedentary condition (Fig. 7.5B, C) (+118%; 34.8 ± 2.4 at rest vs. 76.00 ± 7.6 
after exercise; 2-way ANOVA; P ≤ 0.0001). However, this stimulatory effect was abolished in the 
presence of Nutlin-3a (24.4 ± 1.6 at rest vs. 22.8 ± 3.3 after exercise) (Fig. 7.5C, D). No significant 
effect of Nutlin-3a was observed under resting conditions. These results suggest that Mdm2 
activity is necessary for exercise-induced EC migration in skeletal muscle. 
Mdm2 inhibitor Nutlin-3a inhibits VEGF-A-induced migration of primary microvascular 
ECs. Next, we wanted to know whether Mdm2 activity is specifically essential for VEGF-A-
induced EC migration (Fig. 7.6). Incubation with human recVEGF165 of HDMECs used in the 
Boyden chamber migration assay efficiently stimulated the phosphorylation of Mdm2 on Ser166 
(Fig. 7.6A; no VEGF-A, 1.00 ± 0.12 vs. VEGF-A treated, 1.83 ± 0.13; P ≤ 0.01), whereas total 
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Mdm2 protein levels were unaltered (no VEGF-A, 1.00 ± 0.11 vs. VEGF-A treated, 1.03 ± 0.07). 
These data served as a control to confirm that the ECs subsequently placed into the migration 
chamber exhibited an elevated level of p-Ser166-Mdm2 after recVEGF165 incubation. Endothelial 
cell migration was significantly enhanced (+33%) with VEGF-A stimulation (Fig. 7.6B; untreated, 
100.0 ± 1.4% vs. VEGF-A stimulation, 133.0 ± 2.1%; P ≤ 0.001). However, Nutlin-3a fully 
abolished VEGF-A’s stimulatory effects (untreated, 100.0 ± 1.4% vs. VEGF-A + Nutlin-3a, 102.0 
± 2.0%; P > 0.05). Nutlin-3a treatment had no significant effect on basal EC migration (untreated, 
100 ± 1.4% vs. Nutlin-3a, 96.4 ± 1.3%; P > 0.05). 
In addition, stimulation of HDMECs with 10% FBS and 5% ECGS was used as a standard 
positive control for the Boyden chamber assay, showing an 80% increase in EC migration (Fig. 
7.6C; untreated, 100.0 ± 0.1% vs. FBS +ECGS, 181.0 ± 2.5%; P ≤ 0.001). Nutlin-3a partially 
inhibited (~14%) the FBS/ECGS-induced migration of ECs (FBS/ECGS, 181.0 ± 2.5% vs. 
FBS/ECGS + Nutlin-3a, 155.0 ± 2.0%). 
Mdm2 phosphorylation on Ser166 regulates EC migration. To specifically assess the 
functional impact of p-Ser166-Mdm2, we generated HDMECs that overexpressed WT-Mdm2 or 
S166D-Mdm2. BothWT-Mdm2 and S166D-Mdm2 showed increased protein expression levels of 
Mdm2 vs. levels in noninfected HDMECs (Fig. 7.7A, B; noninfected, 6.32 ± 0.36 vs. WT-Mdm2, 
24.09 ± 1.90; +281%; P ≤ 0.001 and vs. S166D-Mdm2, 18.41 ± 1.24; +191%; P ≤ 0.001). As 
expected, the S166D-Mdm2 showed a loss of reactivity to the anti-p-Ser-166-Mdm2 antibody 
detection (Fig. 7.7C). The migratory activity of infected HDMECs was evaluated in the Boyden 
chamber assay (Fig. 7.7D, E). Overexpression of WT-Mdm2 did not affect basal HDMEC 
migration (noninfected HDMECs 100.0 ± 2.3% vs. WT-Mdm2 95.0 ± 3.4%; P > 0.05). In contrast, 
overexpression of S166D-Mdm2 significantly enhanced (+38%) the basal migration level (without 
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any source of stimulation) (noninfected HDMECs 100.0 ± 2.3% vs. S166D-Mdm2 138.0 ± 8.4%; 
P ≤ 0.001). Stimulation with 10% FBS + 5% ECGS enhanced migration in all cell lines by 95 ± 
8.76% for non-infected HDMECs, 116 ± 4.7638% for WT-Mdm2, and 275 ± 4.17% for S166D-
Mdm2, compared with each corresponding nonstimulated condition (P ≤ 0.001). The percentage 
of HDMECs migrating under FBS + ECGS stimulation was significantly higher in the S166D-
Mdm2 cells when compared with the percentages of both the stimulated noninfected and WT-
Mdm2 cells (P ≤ 0.001). This result suggests that Mdm2 phosphorylation on Ser166 is essential 
for basal and stimulated primary microvascular EC migration. 
Ser166 phosphorylation enhances Mdm2 binding to FoxO1 and leads to the down-
regulation of FoxO target genes. We have shown that the level of p-Ser166-Mdm2 correlates 
negatively with FoxO1 levels (12). In the current study, we investigated whether Mdm2 
phosphorylation on Ser166 changes the ability of Mdm2 to bind FoxO1 in WT-Mdm2 and S166D-
Mdm2 cells. The anti-FoxO1 antibody pulled down more Mdm2 in S166D-Mdm2 cells (Fig. 
7.8A). The ratio between the levels of Mdm2 and FoxO1 that were coimmunoprecipitated was 
higher in S166D-Mdm2 than in WT-Mdm2 HDMECs (0.31 ± 0.02 vs. 0.16 ± 0.02, respectively). 
This finding suggests ~91% more binding between Mdm2 and FoxO1 in ECs overexpressing the 
S166D-Mdm2. No differences were observed in Mdm2-p53 or Mdm2-HIF-1α binding, 
respectively, between WT-Mdm2- and S166D-Mdm2-overexpressing cells (Supplemental Fig. 
7.1). 
Next, we measured the level of expression of p27, Sprouty-2, and TSP-1mRNAs, all 
regulated by FoxO in ECs (13, 18). mRNA levels of all FoxO target genes decreased significantly 
in S166D-Mdm2 vs. WT-Mdm2 cells (Fig. 7.8B–D): p27 mRNA, -34%; 0.92 ± 0.07 in WT-Mdm2 
vs. 0.64 ± 0.03 in S166D-Mdm2; P = 0.037; TSP-1 mRNA, -46%; 1.20 ± 0.05 in WT-Mdm2 vs. 
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0.65 ± 0.07 in S166D-Mdm2; P ≤ 0.0001; and Sprouty-2 mRNA, -26%; 1.18 ± 0.02 in WT-Mdm2 
vs. 0.87 ± 0.08 in S166D-Mdm2; P = 0.047. 
We also assessed the effect of S166D-Mdm2 overexpression on VEGF-A mRNA levels. 
VEGF-A is a strong regulator of angiogenesis that can be regulated by Mdm2 (10) and FoxO1 (19, 
20). S166D-Mdm2 cells expressed reduced levels of VEGF-A mRNA compared with WT-Mdm2 
HDMECs (Fig. 7.8E; -20%; WT-Mdm2, 1.17 ± 0.02 vs. S166D-Mdm2, 0.94 ± 0.06; P ≤ 0.006). 
We have described the VEGF-A:TSP-1 ratio to be a good indicator of the angiogenic 
balance in skeletal muscle (3, 4). This ratio increased by 56% in S166D-Mdm2 vs. WT-Mdm2 
cells (Fig. 7.8F; S166-Mdm2, 1.53 ± 0.130 vs. WT-Mdm2, 0.98 ± 0.04; P ≤ 0.028) suggesting a 
shift of the angioadaptive balance toward a more proangiogenic profile in S166D-Mdm2 ECs. 
VEGF-A stimulation affects FoxO target genes and the VEGF-A/TSP-1 ratio in primary 
human ECs. The time-course stimulation of primary HDMECs with recVEGF165 (100 ng/ml) led 
to decreased mRNA expression of the FoxO target genes p27 and TSP-1 (Fig. 7.9A, B). p27mRNA 
expression was affected rapidly (effect of time, P = 0.0039) with a significant decrease at all of the 
time points (Fig. 7.9A; no stimulation (0 h), 1.39 ± 0.18 vs. 1 h, 0.99 ± 0.05; P ≤ 0.05; 3 h, 0.68 ± 
0.05; P ≤ 0.01; and 6 h, 0.63 ± 0.07; P ≤ 0.01). A decrease in TSP-1 mRNA expression was also 
observed (effect of time, P = 0.0099), becoming significant at 6 h (Fig. 7.9B; -48%; no stimulation 
(0 h), 1.14 ± 0.07 vs. 6 h, 0.55 ± 0.04; P ≤ 0.01). 
The VEGF-A mRNA level was significantly up-regulated with recVEGF165 stimulation at 
all time-points (Fig. 7.9C; 1-way ANOVA overall effect, P = 0.0109; no stimulation (0h), 0.71 ± 
0.13 vs. 1 h (+110%), 1.49 ± 0.13, 3 h (+94%), 1.40 ± 0.01, and 6 h (+62%), 1.15 ± 0.05; 
significantly different from (0 h), P ≤ 0.05). Combined, the increase in VEGF-A and the decrease 
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in TSP-1 resulted in an increased VEGF-A:TSP-1 ratio that became significant at 6h (Fig. 7.9D; 
+200%; no stimulation (0 h), 0.64 ± 0.09 vs. 6h, 1.93 ± 0.11; P = 0.006). 
Discussion 
In our study, Mdm2 activation by phosphorylation on Ser166 occurred as a robust response 
of the skeletal muscle to acute physical exercise, observable both in rodent and human skeletal 
muscle. Mdm2 phosphorylation was regulated by VEGF-A and had a strong functional impact on 
EC migration. The evidence showed that Mdm2 phosphorylation on Ser166 modulated the 
angioadaptive balance, in particular the ratio between VEGF-A and TSP-1, by interacting directly 
with the transcription factor FoxO1. Altogether, our results identified Mdm2 as a novel 
downstream effector of VEGF-A in the physiologic context of exercise-induced muscle 
angiogenesis. 
A single bout of exercise increases muscle expression and secretion of VEGF-A, as we and 
others have reported (4,21). This effect should increase VEGFR-2 activation on ECs and its 
downstream signaling, including several kinases (22), which in turn are known to regulate Mdm2 
Ser166 phosphorylation and its enzymatic activity (10). In our study, muscle-derived VEGF-A 
was a key regulator of Mdm2 Ser166 phosphorylation. Not only did the exercise-induced increase 
in Ser166 phosphorylation of Mdm2 closely match the pattern of change in VEGF-A protein in 
both human and rodent muscles, but this effect was also absent in mice deficient in myocyte-
VEGF-A. Direct stimulation of cultured ECs with recombinant VEGF-A provided additional 
evidence that Ser166 phosphorylation of Mdm2 is a downstream consequence of VEGF receptor 
activation. 
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Prior work has identified Mdm2 as an upstream regulator of VEGF-A expression in various 
cell lines (23). We recently identified Mdm2 as a critical regulator of skeletal muscle 
angioadaptation, both at rest and during exercise. Exercise-induced VEGF-A expression in skeletal 
muscle was strongly attenuated in mice harboring a reduced expression of Mdm2, compared to 
their exercised littermate controls (4). This effect occurred independent of the animals’ p53 status, 
supporting the concept that Mdm2 could contribute to microvascular homeostasis in a p53-
independent manner and through the regulation of other transcription factors. 
Mdm2 can indeed regulate the activity of other transcription factors, such as HIF-1α and 
FoxO (11, 12). VEGF-A is a well-established target of HIF-1α (21). Inhibition of Mdm2 activity 
by Nutlin-3a or Mdm2-knockdown can reduce HIF-1α stabilization and VEGF-A gene expression 
(9,24). Phosphorylation of Mdm2 at Ser166 has been demonstrated to enhance HIF-1α stability 
and activation under hypoxic conditions (25). Similarly, a phosphomimetic form of Mdm2 
promotes HIF-1α-dependent transcription of VEGF-A in response to growth factor stimulation 
(26). 
A few recent studies have suggested that FoxO proteins down-regulate VEGF-A mRNA 
(19, 20). The effect of the phosphomimetic Mdm2 on VEGF-A expression is prevented by 
overexpression of FoxO1 (26). Our group reported that Mdm2 phosphorylation on Ser166 in ECs 
stimulated with growth factors or shear stress increases Mdm2-FoxO1 interaction and reduces 
FoxO1 protein levels (12). We also have observed that overexpression of FoxO1 causes a reduction 
in VEGF-A mRNA (20). In the current study, we measured no change in the binding between 
Mdm2 and p53 or HIF-1α when comparing human primary microvascular ECs overexpressing 
WT-Mdm2 or S166D-Mdm2. However, more Mdm2 protein was pulled down with a FoxO1 
antibody in S166D-Mdm2 cells than in WT-Mdm2 cells, suggesting an increased interaction 
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between these 2 proteins. Thus, our data suggest that FoxO1 is a more relevant target of Mdm2 in 
non-hypoxic ECs. 
Although other studies have supported the idea that Mdm2 is an upstream regulator of 
VEGF-A, in our present work VEGF-A-dependent phosphorylation of Mdm2 at Ser166 was an 
important mediator of a broad pattern of proangiogenic signaling within ECs. We have shown 
clear evidence that VEGF-A-induced phosphorylation of Mdm2 on Ser166 is associated with 
increased binding to FoxO1 and a reduced transcription of the FoxO target genes Sprouty-2, p27, 
and TSP-1 in primary ECs (13, 18). Sprouty-2 is an inhibitor of MAPK signaling, whereas p27 
mediates cell cycle arrest (18). TSP-1 is a potent antiangiogenic factor associated with inhibition 
of EC migration and proliferation (13).The expression levels of FoxO1 targets TSP-1, p27, and 
Sprouty-2 all were decreased in S166D-Mdm2 cells. We observed that ECs overexpressing 
S166D-Mdm2 exhibited a down-regulation of VEGF-A mRNA compared with WT-Mdm2 cells, 
which was counter to the expected effect. Because Mdm2 activity has been shown to both down-
regulate FoxO and stabilize HIF-1α, we hypothesized that constitutive activation of Mdm2 would 
result in enhanced VEGF-A expression. However, Mdm2 also exerts posttranscriptional control 
of VEGF-A by interacting with the 3’-UTR region of VEGF-A mRNA in the cytoplasm, which 
increases transcript stability and leads to increased protein production. However, this influence is 
enhanced by expression of the nonphosphorylated form of Mdm2, which remains cytoplasmic 
(27). Thus, prolonged overexpression of S166D-Mdm2, which localizes to the nucleus, could have 
the effect of reducing VEGF-A mRNA stability, which underlies the significant reduction of 
VEGF-A mRNA observed in these cells when compared to WT-Mdm2 cells. Further investigation 
would be needed to determine whether this mechanism occurs in response to exercise-induced 
phosphorylation. Overall, stimulation of primary human microvascular ECs with recombinant 
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VEGF-A or expression of S166D-Mdm2 increased the angioadaptive VEGF-A:TSP-1 ratio, 
suggesting the promotion of a proangiogenic phenotype in these cells. 
We examined the role of Ser166 phosphorylation on cell migratory activity because it is a 
key step of the angiogenic process. Past work indicated that the major effect of Nutlin-3a on ECs 
was inhibition of cell migration rather than cell proliferation or cell survival (28). In the current 
study, we used a 3D ex vivo muscle explant model to demonstrate that exercise-driven skeletal 
muscle EC migration was impaired by Nutlin-3a. This finding suggests that Mdm2 activity is 
necessary for exercise-induced endothelial outgrowth and was confirmed in vitro by using human 
primary microvascular ECs. Nutlin-3a treatment fully abolished the stimulatory effect of VEGF-
A, but only partially abolished the response induced by serum and ECGS. This result leads to the 
proposal that Mdm2 is a critical downstream effector of VEGF-A in human primary ECs. 
Migratory activity was enhanced in cells transduced with S166D-Mdm2, even in the absence of a 
growth factor stimulus, indicating a specific role of Ser166 phosphorylation in the modulation of 
EC migration. We have provided evidence that stimulation of ECs with VEGF-A promotes 
numerous proangiogenic alterations in gene expression that could influence cell migration. 
Phosphorylation of Mdm2 at Ser166 also could initiate rapid changes in migratory phenotype by 
directly influencing cell migratory signal pathways, but to date, potential mechanisms through 
which this might occur remain to be established. 
In conclusion, our findings represent a major advance in our understanding of the 
physiologic regulation of Mdm2 activity during exercise by identifying VEGF-A as an upstream 
regulator of Ser166 phosphorylation. Our work revealed a novel exercise-induced VEGF-A-
Mdm2-FoxO pathway that has the potential to control the angiogenic process in skeletal muscle. 
This finding revisits the previously established relationship between Mdm2 and VEGFA, 
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suggesting that these 2 molecules interact with each other in a complex and reciprocal manner in 
the physiologic milieu. This study provides a foundation for future research to explore potential 
clinical and therapeutic advantages of modulating Mdm2 angiogenic function in chronic diseases 
where skeletal muscle capillarity limits exercise capacity and affects disease prognosis. 
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Figure legends 
Figure 7.1 Physical exercise stimulates VEGF-A expression and Mdm2 phosphorylation in 
skeletal muscle. A–D) Immunoblots (A,C) and densitometry analyses (B, D) for the p-Ser166-
Mdm2, Mdm2, and VEGF-A in vastus lateralis muscle biopsy specimens from healthy human 
subjects (A, B; n = 5 subjects) and in plantaris muscles from Sprague-Dawley rats (C, D; n = 12 
animals per group). β-Actin was used as a loading control. Human biopsy specimens were 
collected at rest, pre-exercise (pre), immediately after exercise (post), and 2 h after exercise. Rat 
muscles were collected from sedentary animals, immediately after exercise, or 4 h after exercise. 
Data are means ± SEM. *P ≤ 0.05; ***P ≤ 0.001 vs. pre-exercise group, by 1-way ANOVA. E) 
Correlation between VEGF-A and p-Ser166-Mdm2 protein levels in rat plantaris muscle (n = 8 
animals). 
Figure 7.2 VEGF-A stimulates in vivo Mdm2 phosphorylation on Ser166 in response to 1 bout of 
exercise. A) Immunoblots of VEGF-A in gastrocnemius muscles from WT mice and mice deficient 
in VEGF-A expression in skeletal myofibers (mVEGF-/-). β-Actin was used as a loading control. 
B) The capillary:fiber ratio was determined after isolectin staining in gastrocnemius cross sections 
from WT and mVEGF-/- mice. Data are means ± SEM (n = 7 WT and n = 9 mVEGF-/- mice). ***P 
≤ 0.001 WT vs. mVEGF-/- mice. C, E) Immunoblots for VEGF-A (C) and p-Ser166-Mdm2 and 
Mdm2 (E) in gastrocnemius muscles from sedentary (Sed.) and exercised (Ex.) WT and mVEGF-
/- mice. D, F, G) Densitometry analyses for VEGF-A (D), p-Ser166-Mdm2 (F), and Mdm2 (G) 
from (C, E). β-Actin was used as a loading control. H) Ratio of p-Ser166-Mdm2 to Mdm2 
quantifications obtained in (F, G). Data are means ± SEM (n = 3–5mice/group); 2-way ANOVA 
shows an overall effect of VEGF-A deletion on the protein expression of VEGF-A, # P ≤ 0.05; p-
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Ser166-Mdm2, # P ≤ 0.05; and the p-Ser166-Mdm2:Mdm2 ratio, ### P ≤ 0.001. * P ≤ 0.05 and 
** P ≤ 0.01, sedentary vs. exercise WT mice in each genotype. 
Figure 7.3 VEGF-A stimulates Mdm2 phosphorylation on Ser166 in ex vivo incubated muscle 
specimens. A, B) Immunoblot (A) and densitometry analysis (B) of the p-Ser166-Mdm2 in 
response to recombinant VEGF-A stimulation (recVEGF165; 0–50 ng/ml) (n = 4 specimens per 
condition). P ≤ 0.001; *P ≤ 0.01; **P ≤ 0.001; ***P ≤ 0.0001 vs. no rVEGF-A; P ≤ 0.01 vs. 50 
ng/ml VEGF-A, by 1-way ANOVA. C, D) Immunoblot (C) and densitometry analysis (D) of p-
Ser166-Mdm2 after stimulation with 10% sedentary or exercised muscle homogenate in the 
presence of KRN633 inhibitor (200 nM) β-Actin was used as a loading control. Results are means 
± SEM (n = 6 specimens per condition). *P ≤ 0.05 vs. sedentary homogenate stimulation, by 2-
way ANOVA. 
Figure 7.4 VEGF-A stimulates Mdm2 phosphorylation on Ser166 in primary microvascular ECs. 
A) Immunoblot and densitometry analysis of p-Ser166-Mdm2 in rat SMECs stimulated in vitro 
with increasing doses of recVEGF165 (0–100 ng/ml). Means ± SEM are represented. β-Actin was 
used as a loading control. B) Immunoblots and densitometry analyses of p-Ser166-Mdm2 and 
Mdm2 in primary mouse SMECs and in human primary HAMECs and HDMECs stimulated with 
recVEGF165 (100 ng/ml). β-Actin was used as a loading control. Data are means ± SEM, 
normalized to untreated condition within each group (n = 3 per group). *P ≤ 0.05 vs. untreated, by 
unpaired Student’s t test. 
Figure 7.5 Nutlin-3a inhibits exercised-induced EC outgrowth in skeletal muscle. A) Illustration 
of the 3D muscle explant assay. B) Representative muscle explant. The intensity of EC staining 
was measured between the red line (edge of the muscle biopsy) and the yellow line (the edge of 
the migration front) represented by (b); (a) indicates the muscle biopsy (not included in the 
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quantification). The intensity of fluorescence estimates the quantity of migrated ECs. C) 
Representative pictures of EC outgrowth from sedentary and exercised rat plantaris specimens 
embedded in collagen gel in the presence or absence of Nutlin-3a (1 µM). Endothelial cells were 
detected by staining with TRITC-conjugated isolectin-B4. D) Quantification of EC outgrowth. 
Data are means ± SEM (2 experiments, each with n = 4 specimens treated with nutlin-3a and n = 
6 untreated). P = 0.0008; 2-way ANOVA indicates an interaction between the effects of Nutlin-3a 
and exercise stimulation. ***P ≤ 0.001 vs. specimens from sedentary rats without Nutlin-3a, by 
Newman-Keuls multiple-comparisons test. 
Figure 7.6 Nutlin-3a inhibits VEGF-A-induced EC migration in vitro. A) Representative 
immunoblots and densitometry analyses of protein levels for Mdm2, p-Ser166-Mdm2, and β-actin 
in HDMECs in response to stimulation with recVEGF165 (100 ng/ml). β-Actin was used as a 
loading control. Data are means ± SEM, normalized to untreated group (n = 3 for untreated and n 
= 4 for recVEGF165 treated). **P ≤ 0.01 vs. untreated. B) Representative pictures and data analysis 
of the Boyden chamber migration assay with HDMECs in response to recVEGF165 (100 ng/ml) 
stimulation, with or without the Mdm2 functional inhibitor Nutlin-3a (10 µM). Data are means ± 
SEM from 3 independent experiments, each of them with 6 migration wells/condition, 4 cell 
counts/well. Data for each condition are normalized to the no-recVEGF165, no-Nutlin-3a condition. 
Both VEGF (P ≤ 0.0001) and Nutlin-3a treatment (P ≤ 0.0001) had an overall effect, by 2-way 
ANOVA and post hoc comparison. ***P ≤ 0.001 vs. all other conditions. C) Same as in (B) by 
replacing recVEGF165 by a stimulation with 10% FBS and 5% ECGS. Both VEGF (P ≤ 0.0001) 
and Nutlin-3a treatment (P ≤ 0.0001) had an overall effect, 2-way ANOVA and post hoc 
comparison. ***P ≤ 0.001 vs. nonstimulation in each respective condition; †P ≤ 0.001, no nutlin-
3a stimulation vs. nutlin-3a stimulation. 
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Figure 7.7 Mdm2 phosphorylation on Ser166 stimulates EC migration. A, B) Representative 
immunoblots (A) and densitometry analyses (B) for the protein expression level of Mdm2 in 
HDMECs overexpressing WT-Mdm2. Noninfected cells served as controls. β-Actin was used as 
a loading control. Data are means ± SEM vs. noninfected (n = 5 experiments/cell line). ***P ≤ 
0.001; # P ≤ 0.05 vs. S166D-Mdm2, by 1-way ANOVA. C) Representative immunoblots for the 
protein level of p-Ser166-Mdm2 in HDMECs overexpressing p-Ser166D-Mdm2. Noninfected 
cells served as controls. β-Actin was used as a loading control. D) Representative micrographs of 
cells described in (A), after migration in the Boyden chamber assay in response to stimulation with 
10% FBS + 5% ECGS. E) Quantification of the migration shown in (B). Data are means ± SEM 
from 2 independent experiments (n = 4–6 wells per condition). Noninfected, WT-Mdm2, and 
S166D-Mdm2; 4 cell counts/well. One-way ANOVA, significantly different from the no-
stimulation condition in each cell type. *** P ≤ 0.001, vs. other cell types under similar stimulation 
conditions. # P ≤ 0.05, ### P ≤ 0.001, 1% FBS vs. 10% FBS / 5% EGGS. 
Figure 7.8 Phosphorylation on Ser166-enhanced Mdm2 binding to FoxO1 leading to the down-
regulation of FoxO target genes. A) After immunoprecipitation (IP) of FoxO1 in WT-Mdm2 and 
S166D-Mdm2 HDMECs treated with MG132, levels of FoxO1 and Mdm2 were measured by 
immunoblot analysis in whole-cell lysate (input) and in the IP products. Normal rabbit IgG was 
used as a control. The Mdm2;FoxO1 ratio expressed in raw values and as fold change in Mdm2 
protein intensity between WT-Mdm2 and S166D-Mdm2 HDMECs is indicated. Data are means ± 
SEM (n = 2 per group). * P ≤ 0.05, WT-Mdm2 vs. S166D-Mdm2, by unpaired Student’s t test. B–
E) mRNA levels for p27 (B), TSP-1 (C), sprouty-2 (D), and VEGF-A (E) in WT-Mdm2 and 
S166DMdm2 cells, relative to the HPRT housekeeping gene. F) VEGF-A:TSP-1 ratio mRNA in 
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WT-Mdm2 and S166D-Mdm2 cells. B–F) Data are means ± SEM (n = 6 per group). ** P ≤ 0.01; 
*** P ≤ 0.001 WT-Mdm2 vs. S166D-Mdm2, by unpaired Student’s t test. 
Figure 7.9 VEGF-A stimulation affects FoxO target genes and the VEGF-A:TSP-1 ratio in primary 
human ECs. HDMECs were stimulated with recVEGF165 (100 ng/ml) for 1, 3, and 6 h. mRNA 
levels were measured for p27 (A), TSP-1 (B), VEGF-A (C), and VEGF-A:TSP-1 ratio (D) relative 
to HPRT housekeeping gene expression. Data are means ± SEM (n = 3). One-way ANOVA shows 
an overall effect of VEGF-A stimulation on the mRNA expression of p27 (P = 0.0039), TSP-1 (P 
= 0.0099), VEGF-A (P = 0.0109), and VEGF-A/TSP-1 ratio (P = 0.0063). * P ≤ 0.05 and ** P ≤ 
0.01 vs. nonstimulated (0). 
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Scientific context: 
 We have identified VEGF-A as an important stimulator of Mdm2 phosphorylation 
on its serine 166 
 This activation of Mdm2 enhances endothelial cell migration and increased 
interaction between Mdm2 and FoxO1, resulting in the down-regulation of TSP-1 
 It is unclear which molecular signaling pathway(s) could be regulating VEGF-A-
driven Mdm2 phosphorylation 
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 On the surface of endothelial cells, VEGF-A acts on its receptor VEGF-A receptor 
2 (VEGFR2) [202], initiating a series of intracellular signaling cascades leading to 
several pro-survival and pro-angiogenic outcomes [203] 
 Conveying this VEGF-A-dependent signaling are intracellular kinases that have 
been shown to be activated (i.e. phosphorylated) by both VEGF-A and exercise 
 Previous research suggests that Akt, extracellular signal related kinases 1/2 
(ERK1/2) and p90 ribosomal s6 kinase (p90RSK) can directly or indirectly induce 
Mdm2 phosphorylation on its serine 166, and that these kinases have been shown 
to be responsive to VEGF-A signaling and exercise 
Research aims: 
 Determine which kinase(s) are involved in VEGF-A-driven Mdm2 phosphorylation 
in primary human endothelial cells 
 Utilize a time-course stimulation of recombinant VEGF-A (recVEGF-A) protein in 
primary human endothelial cells with and without kinase-specific pharmacological 
inhibitors 
Summary of main findings: 
 Time-course stimulation of primary human endothelial cells with recVEGF-A led 
to increased VEGFR2, Mdm2, Akt, ERK1/2, and p90RSK phosphorylation 
 Following treatment with VEGF-A protein, inhibition of Akt phosphorylation by 
wortmannin treatment resulted in further Mdm2 phosphorylation 
 Pharmacological inhibition of ERK1/2 and p90RSK led to significant attenuation 
of Mdm2 phosphorylation in response to VEGF-A stimulation 
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 VEGF-A-driven Mdm2 phosphorylation on its serine 166 is dependent on the 
ERK1/2-p90RSK signaling pathway in human endothelial cells 
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Abstract 
Murine Double Minute-2 (Mdm2) has been identified as an essential regulator of skeletal muscle 
angiogenesis and the pro-angiogenic activity of endothelial cells. We have recently demonstrated 
that the pro-angiogenic Vascular Endothelial Growth Factor-A (VEGF-A) is a potent upstream 
regulator of Mdm2 phosphorylation on its Serine 166 (p-Ser166-Mdm2), a protein modification 
leading to an increase in endothelial cell migration. Here, we investigated the kinase signaling 
pathways that could be responsible for mediating VEGF-A-dependent Mdm2 phosphorylation. 
Incubation of primary human dermal microvascular endothelial cells with recombinant VEGF-A 
for 15 min led to increased phosphorylation levels of VEGF-receptor-2, Mdm2, Akt, Extracellular 
Signal-Regulated Kinase 1/2 (ERK1/2), and p90 Ribosomal S6 Kinase (p90RSK) proteins. In 
addition to being linked to VEGF-A signaling, Akt, ERK1/2 and p90RSK have been shown to 
potentially lead to Mdm2 phosphorylation. We therefore next analyzed which of these kinases 
could be responsible for VEGF-A-dependent Mdm2 phosphorylation on Serine 166 by using 
kinase-specific pharmacological inhibitors. Inhibition of ERK1/2 phosphorylation by UO126 
entirely abrogated the response of p-Ser166-Mdm2 to VEGF-A treatment, while Akt 
phosphorylation inhibition by wortmannin led to further elevations in p-Ser166-Mdm2. p90RSK 
has been identified as a potential candidate downstream of ERK1/2 that could induce Mdm2 
Ser166 phosphorylation. Two independent p90RSK inhibitors, FMK and BI-D1870, each led to 
an entire loss of p-Ser166-Mdm2 responsiveness to VEGF-A. Taken together, our results 
demonstrate that VEGF-A driven Mdm2 phosphorylation on Ser166 is dependent on the 
ERK1/2/p90RSK signaling pathway in primary human endothelial cells, furthering our 
understanding of the complex relationship between Mdm2 and VEGF-A in a physiological 
context. 
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Introduction 
The E3 ubiquitin ligase Murine Double Minute-2 (Mdm2) is mainly known for its role as 
a negative regulator of the tumor suppressor p53. Interestingly, recent studies have shown that 
Mdm2 could also be considered as a crucial regulator of angiogenesis, i.e. the growth of blood 
capillaries, under pathological (cancer) [1-3] or physiological (exercise) [4-6] situations. We have 
recently demonstrated in vivo that Mdm2 expression level in rodent skeletal muscle was indeed 
indispensable both for the maintenance of established capillaries as well as for exercise-induced 
angiogenesis [4]. The level of Mdm2 activity has also significant implications within the 
endothelial cell, regulating cell proliferation [7], migration [6,7] and tube formation [7], three 
major cell activities required during the angiogenic process. 
The Vascular Endothelial Growth Factor-A (VEGF-A) is a potent pro-angiogenic molecule 
that similarly to Mdm2 has been demonstrated to be required in the skeletal muscle for capillary 
maintenance as well as exercise-induced angiogenesis [8]. Mdm2 has been identified as an 
upstream regulator of VEGF-A expression through interactions with its downstream target hypoxia 
inducible factor-1α (HIF-1α), a well-established transcription factor for VEGF-A [9-11]. We have 
recently revisited this Mdm2-VEGF-A relationship, providing novel evidence that in addition to 
Mdm2 being an upstream regulator of VEGF-A expression, VEGF-A also acts as an upstream 
regulator of Mdm2 phosphorylation on its Serine 166 (p-Ser166-Mdm2) [6]. This site of Mdm2 
phosphorylation lies in the nuclear localization sequence of Mdm2, and promotes the translocation 
of Mdm2 from the cytoplasm to the nucleus where it can interact with its downstream targets 
[12].We have shown that one single bout of exercise leads to a significant increase in the protein 
expression levels of VEGF-A and p-Ser166-Mdm2 in both rodent and human skeletal muscle, 
however this response was impaired in myofibre-specific VEGF-A knockout mice [6]. Using an 
115
in vitro approach to explore this relationship specifically in endothelial cells, we demonstrated that 
recombinant VEGF-A (recVEGF-A) protein indeed stimulates Mdm2 phosphorylation on Ser166, 
a modification that enhances the migratory activity of primary human endothelial cells [6]. The 
importance of this phosphorylation site in stimulating endothelial cell migration was confirmed by 
generating an endothelial cell line expressing a phospho-mimetic form of p-Ser166-Mdm2 [6]. 
Interestingly, the stimulatory effect of recVEGF-A on cell migration was lost when treating the 
cells with the Mdm2 antagonist Nutlin-3a, indicating that Mdm2 activity is required for the pro-
angiogenic activity of human endothelial cells in response to VEGF-A. 
Here, we aimed to identify the kinase(s) involved in VEGF-A mediated phosphorylation 
of Mdm2 on Ser166 in primary human microvascular endothelial cells. We focused on the main 
kinases previously shown in the literature to be activated by VEGF-A signaling and exercise that 
have also been identified as upstream regulators of Mdm2 phosphorylation on Ser166. 
Materials and methods 
Cell culture. Primary human dermal microvascular endothelial cells (HDMECs) were purchased 
from ScienCell Research Laboratories (cat. no. 2000; Carlsbad, CA, USA). The cells were 
maintained, as previously described [6], in ECM (cat. no. 1001) supplemented with 5% FBS (cat. 
no. 0025), 1% endothelial cell growth supplement (ECGS; cat. no. 1052), and antibiotic solution 
containing 100 U/ml penicillin and 100 mg/ml streptomycin (cat. no. 0503; all from ScienCell). 
For VEGF-A stimulation time-course experiments, HDMECs were starved overnight with ECM 
containing 1% FBS before stimulation with recombinant human VEGF-A (#100-20; Peprotech, 
Rocky Hill, NJ, USA) for the indicated lengths of time. For pharmacological kinase inhibitor 
experiments, cells were starved overnight then pre-treated for 1 h with wortmannin (#9951; Cell 
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Signaling Technology), UO126 (#9903; Cell Signaling Technology), BI-D1870 (BML-EI407-
0001; Enzo Life Sciences, Farmingdale, NY, USA), or FMK (#1848; Axon MedChem, Reston, 
VA, USA), respectively, before stimulation with recombinant human VEGF-A for 5 min. 
Western blotting. Immunoblotting was carried out on protein extracts from primary human dermal 
microvascular endothelial cells as previously described [6]. Denatured samples (20 mg/well) were 
subjected to SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and blotted 
onto nitrocellulose (Whatman, BA95, Sigma-Aldrich, Oakville, Ontario, Canada) membranes. 
Quality of the transfer was confirmed by Ponceau S red staining. After blocking with 5% fat-free 
milk at room temperature for 45 min, the blots were probed overnight at 4°C with primary 
antibodies against the following proteins: p-Ser166-Mdm2 (#3521), Akt (#9272), pser473-Akt 
(#4058), ERK1/2 (#4695), p-Thr202/Tyr204-ERK1/2 (#4370), RSK1/2/3 (#9355), p-Ser380-
p90RSK (#9335), p-Tyr1175-VEGFR2 (#3770) and α/β-tubulin (#2148) were from Cell Signaling 
Technology (Beverly,MA, USA); Mdm2 clone SMP14 (sc-965) and β-actin (sc-47778) were from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). After incubation with the secondary antibodies 
HRP-linked anti-mouse antibody (cat. no. P0260; Dako, Carpinteria, CA, USA) or HRP-linked 
anti-rabbit antibody (#7074; Cell Signaling) proteins were visualized with enhanced 
chemiluminescence (Millipore) on Imaging Station 4000 MM Pro (Carestream Health, Rochester, 
NY, USA) or on X-ray film (CL-XPosure Film; prod. no. 34090; Thermo Scientific, Rockford, IL, 
USA). Blots were analyzed with Carestream software. 
Statistical analysis. Statistical analyses were performed with 1- and 2-way ANOVAs with Prism5 
(GraphPad, San Diego, CA, USA). For 1- and 2-way ANOVAs, Newman-Keuls multiple 
comparison and Bonferroni post hoc tests were used, respectively. P ≤ 0.05 was considered to be 
statistically significant. 
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Results and discussion 
The VEGF-receptor 2 (VEGFR2) is key to initiate VEGF-A-dependent intracellular 
signaling pathways [13]. Tyr1175 is a major VEGF-A-dependent autophosphorylation site present 
on VEGFR2 that initiates a variety of cellular processes including vascular permeability, cell 
survival and proliferation [14]. Therefore, in order to identify the kinase(s) that could link VEGF-
A to p-Ser166-Mdm2, we first ensured in our culture of primary human dermal microvascular 
endothelial cells (HDMECs) that time-course stimulation with human recombinant VEGF-A 
(recVEGF-A) led to increased VEGFR2 phosphorylation at Tyr1175 (Fig. 8.1A and B, 0.05 ± 0.02 
at 0 min vs. 1.99 ± 0.13 at 5 min (+3968% increase); 1.77 ± 0.24 at 10 min (+3514%); and 1.45 ± 
0.03 at 15 min (+2866%); 1-way ANOVA; P ≤ 0.0001). 
As expected, recVEGF-A concomitantly stimulated Mdm2 phosphorylation at Ser166 
throughout the 15 min time-course with increases of respectively +122% at 5 min, +112% at 10 
min, and +135% at 15 min in VEGF-A-stimulated cells versus the untreated ones (Fig. 8.1C and 
D; 0.64 ± 0.07 at 0 min vs. 1.42 ± 0.11 at 5 min; 1.35 ± 0.05 at 10 min; and 1.50 ± 0.05 at 15 min; 
1-way ANOVA; P ≤ 0.0001), while total Mdm2 protein levels remained unaltered (Fig. 8.1C). 
Phosphatidylinositol 3-kinase (PI3K) activation is well established as part of VEGF-A 
signaling [15], and the PI3K downstream target Akt has been widely reported, predominantly in a 
cancer context, to induce Mdm2 phosphorylation on Ser166 [16-18]. Thus, we investigated 
whether VEGF-A treatment of HDMECs could induce Akt phosphorylation on Ser473, as it is this 
residue on Akt that has shown to induce Mdm2-Akt association and promote Mdm2 nuclear 
localization [19]. Here, VEGF-A led to a significant time-course increase in Akt phosphorylation 
(Fig. 8.1E and F; 0.12 ± 0.05 at 0 min vs. 0.93 ± 0.12 at 5 min (+708%); 0.81 ± 0.09 at 10 min 
(+600%); and 0.78 ± 0.07 at 15 min (+577%); 1-way ANOVA; P ≤ 0.001). The extracellular 
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signal-regulated kinase 1/2 (ERK1/2) are also known as downstream targets of the VEGF-
A/VEGFR2 signaling pathway [14]. Others have suggested that ERK1/2 could play an important 
role in the induction of p-Ser166-Mdm2 in response to various environmental and growth factors 
[20]. Previous studies have shown that VEGF-A stimulates the phosphorylation of ERK1/2 at 
Thr202/Tyr204 [21e23], and that this site of ERK1/2 activation could play a role in Mdm2 
phosphorylation on Ser166 [20]. Here, we show that ERK1/2 phosphorylation at Thr202/Tyr204 
is strongly induced by VEGF-A treatment in HDMECs (Fig. 8.1G and H; 0.62 ± 0.07 at 0 min vs. 
1.55 ± 0.09 at 5 min (+152%); 1.49 ± 0.02 at 10 min (+142%); and 1.41 ± 0.11 at 15 min (+128%); 
1-way ANOVA; P ≤ 0.0001). While ERK1/2 is phosphorylated by VEGF-A, and has been 
suggested to induce p-Ser166-Mdm2, there is no available evidence for a direct interaction of 
ERK1/2 and Mdm2. Therefore, the p90 ribosomal S6 kinase (p90RSK) could be an intriguing 
candidate for mediating VEGF-A directed Mdm2 phosphorylation. p90RSK lies downstream of 
ERK1/2 signaling [24], has been shown to be activated by VEGF-A in cultured rat cardiac 
myocytes and fibroblasts [25] and has been suggested to induce p-Ser166-Mdm2 in vitro [26,27]. 
Several phosphorylation sites have been identified on p90RSK and among them, phosphorylation 
of serine 380 plays a key role in mediating p90RSK activation [24]. In the present study, we found 
that p90RSK phosphorylated on Ser380 is significantly elevated throughout the VEGF-A 
treatment period (Fig. 8.1I and J; 0.08 ± 0.01 at 0 min vs. 1.64 ± 0.06 at 5 min (+2084%); 1.30 ± 
0.01 at 10 min (+1635%); and 0.79 ± 0.09 at 15 min (+950%); 1-way ANOVA; P ≤ 0.0001). 
To determine which of these kinases identified to respond to VEGF-A treatment in our 
human endothelial cells could be involved in VEGF-A-dependent Mdm2 phosphorylation on its 
Ser166, we incubated HDMECs with or without recVEGF-A in the presence or absence of kinase-
specific pharmacological inhibitors. As an irreversible PI3K inhibitor, wortmannin is well 
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established as an inhibitor of Akt phosphorylation [28]. In our study, we observed a complete loss 
of Akt phosphorylation in response to wortmannin treatment independently of recVEGF-A 
stimulation (Fig. 8.2A and B; 1 ± 0.09, untreated vs. 6.98 ± 0.54, with recVEGF-A; 0 ± 0 with 
wortmannin; and 0 ± 0 with wortmannin and recVEGF-A). Interestingly, such inhibition of Akt 
activity led to a further induction of p-Ser166-Mdm2, both with and without the addition of 
recVEGF-A (Fig. 8.2A and C; 1 ± 0.07, untreated vs. 2.66 ± 0.15, with recVEGF-A; 1.92 ± 0.09, 
with wortmannin; and 3.18 ± 0.12, with wortmannin and recVEGF-A). One hypothesis for such 
an unexpected result could be that the increased Mdm2 phosphorylation observed in response to 
wortmannin treatment could be a result of further ERK1/2 signaling activation due to the inhibition 
of a parallel Akt pathway. Although not significant, we indeed observed a 46% increase in ERK1/2 
phosphorylation on Thr202/Tyr204 in wortmannin treated HDMECs independent of VEGF-A, 
while VEGF-A treatment led to a similar level of ERK1/2 phosphorylation with and without the 
presence of wortmannin (1 ± 0.06, untreated vs. 2.16 ± 0.33, with recVEGF-A; 1.46 ± 0.20, with 
wortmannin; and 2.04 ± 0.36, with wortmannin and recVEGF-A). In line with our observation, 
Malmlof et al. [20] have shown that the PI3K inhibitor LY294002 significantly induces p-Ser166-
Mdm2 while concomitantly increasing the level of ERK1/2 phosphorylation on Tyr204 in hepatic 
cancer cells. Next, we investigated whether ERK1/2 could be responsible for Mdm2 
phosphorylation in response to recVEGFA in HDMECs. The pharmacological inhibitor UO126 is 
a highly selective inhibitor of both MEK 1 and 2, therefore disrupting MEK1/2-dependent ERK1/2 
phosphorylation [29]. UO126 at the concentration of 20 µM led to a partial but significant 
inhibition of ERK1/2 phosphorylation on Thr202/Tyr204 in response to recVEGF-A treatment in 
HDMECs (Fig. 8.2D and E; 1 ± 0.05, untreated vs. 1.98 ± 0.22, with recVEGF-A; 0.14 ± 0.06, 
with UO126; and 0.87 ± 0.23, with UO126 and recVEGF-A). This partial inhibition of p-
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Thr202/Tyr204-ERK1/2 entirely abrogated the response of p-Ser166-Mdm2 to recVEGF-A (Fig. 
8.2D and F; 1 ± 0.04, untreated vs. 2.34 ± 0.32, with recVEGF-A; 0.72 ± 0.19, with UO126; and 
0.96 ± 0.26, with UO126 and recVEGF-A). These results identify ERK1/2 activation as essential 
for VEGF-A-induced Mdm2 phosphorylation on its Ser166. As the use of a PI3K inhibitor showed 
a further elevation in p-Ser166-Mdm2, and that the MEK1/2 inhibitor significantly attenuated 
Mdm2 phosphorylation in response to recVEGF-A, we narrowed our investigation downstream of 
ERK1/2 signaling. p90RSK represents a strong candidate for this ERK1/2 effect on Mdm2. 
p90RSK is phosphorylated by ERK1/2 at its C-terminal kinase domain, thus activating the N-
terminal kinase domain and allowing p90RSK to subsequently phosphorylate its downstream 
targets [30]. We therefore hypothesized that p90RSK is the main direct kinase involved in the 
VEGF-A/ERK1/2 signaling pathway responsible for Mdm2 phosphorylation on Ser166. In order 
to provide robust evidence of the role of p90RSK in phosphorylating Mdm2 in response to VEGF-
A, we used two separate pharmacological inhibitors that bind to mutually exclusive domains on 
the p90RSK protein. FMK has been shown to be an irreversible p90RSK inhibitor that binds to 
the C-terminal kinase domain of the protein [30]. As previously demonstrated, p-Ser166-Mdm2 is 
elevated following recVEGF-A stimulation, however this effect is entirely lost in the presence of 
FMK (Fig. 8.3A and B; 1 ± 0.05, untreated vs. 1.64 ± 0.09, with recVEGF-A; 0.65 ± 0.13, with 
FMK; and 0.64 ± 0.12, with FMK and recVEGF-A). Conversely to FMK, BID1870 is a p90RSK 
inhibitor that instead binds to the N-terminal kinase domain of p90RSK [30]. As with FMK 
treatment, BI-D1870 was found to prevent VEGF-A-driven Mdm2 phosphorylation in the 
HDMECs (Fig. 8.3C and D; 1 ± 0.11, untreated vs. 2.3 ± 0.41, with recVEGF-A; 0.99 ± 0.16, with 
BI-D1870; and 0.84 ± 0.13, with BID1870 and recVEGF-A). 
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It is well documented that VEGF-A mRNA and protein expression are increased in 
response to one single and intense bout of exercise in human skeletal muscle [31] and that 
interstitial VEGF-A protein levels remain significantly elevated during and following exercise 
[32]. Alongside the well-described increase in VEGF-A, we have recently shown that a similar 
exercise regimen also strongly increased p-Ser166-Mdm2 protein levels in both rodent and human 
skeletal muscle tissue, and that increases in these two proteins were significantly and positively 
correlated [6]. Furthermore, numerous studies have shown increases in ERK1/2 and p90RSK 
phosphorylation in rodent and human skeletal muscle tissue in response to a variety of acute 
resistance and endurance exercise protocols [33-37]. Although these findings were obtained at the 
whole muscle level, VEGF-A is a potent myokine that when released from the muscle fibre in 
response to an acute bout of exercise can interact with VEGFR2 present on endothelial cells. As 
our current findings strongly suggest, this initiation of VEGF-A signaling in the endothelial cell 
can lead to the phosphorylation of ERK1/2 and p90RSK, subsequently triggering an elevation in 
p-Ser166-Mdm2 levels. These results identify an intracellular signaling pathway that is activated 
by VEGF-A signaling and regulates Mdm2 phosphorylation in primary human endothelial cells. 
Taken together with previous work from our laboratory that demonstrated VEGF-A as a potent 
upstream regulator of Mdm2 phosphorylation in endothelial cells [6], these findings unveil an in-
depth understanding of the intracellular mechanisms regulating the complex pro-angiogenic 
VEGF-A/Mdm2 relationship. 
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Figure legends 
Figure 8.1 Recombinant VEGF-A treatment stimulates phosphorylation of VEGF-receptor-2, 
Mdm2, Akt, ERK, and p90RSK proteins in primary human endothelial cells. Immunoblotting and 
densitometry analysis were performed on cell lysates of primary human dermal microvascular 
endothelial cells (HDMECs) collected after 0 (untreated), 5, 10 or 15 min of incubation with 
recombinant human VEGF-A (recVEGF-A) (100 ng/ml). (A,B) Representative immunoblots and 
densitometry analysis for p-VEGFR2 (Tyr1175). (C,D) Representative immunoblots and 
densitometry analysis for p-Ser166-Mdm2 and Mdm2 protein expression. (E,F) Representative 
immunoblots and densitometry analysis for p-Akt (Ser473) and Akt protein expression. (G,H) 
Representative immunoblots and densitometry analysis for p-ERK1/2 (Thr202/Tyr204) and 
ERK1/2. (I,J) Representative immunoblots and densitometry analysis for p-p90RSK (Ser380) and 
RSK1/2/3 protein expression. In A-J, β-actin or α/β-tubulin were used as loading controls. Data 
are means ± SEM (n = 3 samples per condition). 1-way ANOVA and Newman-Keuls multiple 
comparison post hoc test indicate *** P ≤ 0.001 vs. 0 min; † P ≤ 0.01 for 5 min vs. 10 min, 5 min 
vs. 15 min, 10 min vs. 15 min. 
Figure 8.2 The MEK1/2 inhibitor UO126 attenuates VEGF-A-induced Mdm2 phosphorylation on 
Ser166 in primary human endothelial cells. Immunoblotting and densitometry analysis were 
performed on cell lysates of HDMECs collected after treatment with or without recVEGF-A (100 
ng/ml) in the presence or absence of the PI3K inhibitor wortmannin (1 µM) or the MEK1/2 
inhibitor UO126 (20 µM), respectively. (A-C) Representative immunoblots and densitometry 
analysis for p-Akt (Ser473), Akt, p-Ser166-Mdm2 and Mdm2 in response to recVEGF-A and 
wortmannin treatment. (D-F) Representative immunoblots and densitometry analysis for p-
ERK1/2 (Thr202/Tyr204), ERK1/2, p-Ser166-Mdm2 and Mdm2 in response to recVEGF-A and 
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UO126 treatment. In A-F, β-actin or α/β-tubulin was used as loading controls. Data are means ± 
SEM (n = 2 samples per condition, repeated in 3 independent experiments). 2-way ANOVA and 
Bonferroni post hoc tests indicate; in B, *** P ≤ 0.001 vs. all other conditions; in C, *** P ≤ 0.001 
vs. untreated within each respective condition, † P ≤ 0.01 vs. no inhibitor conditions; in E, ***P ≤ 
0.001 and * P ≤ 0.05 vs. each respective untreated group, † P ≤ 0.01 vs. no inhibitor conditions; in 
F, *** P ≤ 0.001 vs. untreated, † P ≤ 0.001 vs. VEGF-A treated in the no inhibitor condition. 
Figure 8.3 The p90RSK inhibitors FMK and BI-D1870 ablate the response of p-Ser166-Mdm2 to 
VEGF-A stimulation in primary human endothelial cells. Immunoblotting and densitometry 
analysis were performed on cell lysates of HDMECs collected after treatment with or without 
recVEGF-A (100 ng/ml) in the presence or absence of the p90RSK inhibitors FMK (25 µM) or 
BI-D1870 (10 µM), respectively. (A,B) Representative immunoblots and densitometry analysis 
for p-Ser166-Mdm2 and Mdm2 in response to recVEGF-A and FMK treatment. (C,D) 
Representative immunoblots and densitometry analysis for p-Ser166-Mdm2 and Mdm2 in 
response to recVEGF-A and BI-D1870 treatment. In A-D, β-actin or α/β-tubulin were used as 
loading controls. Data are means ± SEM (n = 2 samples per condition, repeated in 3 independent 
experiments). 2-way ANOVA and Bonferroni post hoc tests indicate *** P ≤ 0.001 vs. untreated; 
** P ≤ 0.01 vs. untreated; † P ≤ 0.01 vs. VEGF-A treated in the no inhibitor condition. 
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9. ACADEMIC RESEARCH PAPER 4 
Hyperglycemia strongly correlates with skeletal muscle capillary regression and is 
associated with alterations in the murine double minute-2/foxO1/thrombospondin-1 
pathway in type 1 diabetic BioBreeding rats. 
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Scientific context: 
 Our laboratory has previously shown that Mdm2 protein is significantly reduced in 
Zucker diabetic fatty (ZDF) rats, a model of type-2 diabetes 
 Other studies suggest that type 1 diabetes (T1D) leads to capillary regression and 
the alteration of key angio-adaptive molecules in the skeletal muscle [180,187] 
 I have demonstrated that Mdm2 levels are decreased in streptozotocin-induced T1D 
in rats, corresponding with skeletal muscle capillary regression (see appendix for 
academic research paper 5 [180]) 
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 It is yet to be determined how T1D-induced alterations in Mdm2 could potentially 
lead to shifts in the angiogenic balance as explained by changes in key Mdm2-
dependent targets, FoxO1, TSP-1 and VEGF-A 
 Previous studies investigating muscle capillaries in type 1 diabetes have exclusively 
utilized rodent models in which T1D is induced through systemic streptozotocin 
injection 
Research aims: 
 Determine whether hyperglycemia resulting from spontaneous T1D development 
in BioBreeding (BB) diabetic rats leads to skeletal muscle capillary regression 
 Investigate whether T1D leads to maladaptive expression of Mdm2 and its key 
targets VEGF-A, FoxO1, and TSP-1 in the skeletal muscle of diabetic animals 
 Compare between soleus and plantaris, two metabolically distinct skeletal muscles 
Summary of main findings: 
 TID resulted in significant capillary regression in both the soleus and plantaris 
muscles 
 This capillary impairment was significantly correlated with the level of glycemic 
control in diabetic animals 
 Mdm2 protein was found to be decreased in the diabetic muscle, corresponding 
with increased FoxO1 and TSP-1 protein levels 
 Despite no change or even elevated VEGF-A protein, the VEGF-A/TSP-1 ratio and 
VEGFR2 protein levels were significantly less in the diabetic animals 
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 Significant correlations were observed between changes in blood glucose and 
Mdm2, TSP-1, VEGFR2 and the capillary-to-fiber ratio  
 Alterations in Mdm2 and TSP-1 were inversely and significantly correlated 
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Abstract 
Type 1 diabetes (T1D) is an autoimmune disease that causes a loss in insulin production that can 
have deleterious effects on skeletal muscle and its microvasculature. Studies that have investigated 
alterations in skeletal muscle capillarization in T1D are limited and mainly based on the toxin 
model of streptozotocin-injection in rodents. Our laboratory has recently identified Murine Double 
Minute-2 (Mdm2) as a master regulator of skeletal muscle capillarization by controlling expression 
levels of two key molecular actors of the angio-adaptive process: the pro-angiogenic Vascular 
Endothelial Growth Factor-A (VEGF-A) and the anti-angiogenic Thrombospondin-1 (TSP-1). The 
effect of T1D on these key regulators of muscle capillarization are unclear. Here, we show for the 
first time that the diabetic-prone BioBreeding (DPBB) rat, a rodent model of autoimmune T1D, 
undergoes capillary regression and altered protein expression of key angio-adaptive regulators in 
both plantaris and soleus skeletal muscles. We demonstrate that Mdm2 protein levels are 
significantly decreased in the skeletal muscles of DPBB rats, coinciding with elevated protein 
levels of TSP-1 and its transcription factor Forkhead Box O1 (FoxO1). Significant capillary 
regression was observed in T1D rats to similar extents in the soleus and plantaris muscles. 
Interestingly, manipulating blood glucose control in these animals, by using insulin implants, was 
significantly and positively correlated with the loss of capillaries, the reduction in Mdm2 
expression, and with the elevations in TSP-1. VEGF-A protein levels were unaltered or even 
increased in diabetic animals, however we observed significantly less VEGF receptor-2 
abundance. Furthermore, the VEGF-A / TSP-1 ratio, a good indicator of the skeletal muscle angio-
adaptive environment, was significantly decreased in T1D muscle. Altogether, our results suggest 
that the Mdm2-FoxO1-TSP-1 signaling pathway plays an important role in angio-regulation of the 
skeletal muscle in the pathophysiological context of T1D. 
138
Introduction 
Type 1 diabetes (T1D) is an autoimmune disease that results in the destruction of pancreatic 
β-cells and the loss of endogenous insulin production, leading to hyperglycemia and reliance on 
exogenous insulin administration [1]. Even with exogenous insulin therapy, control is often 
imperfect in T1D, with extensive lifetime exposure to hyperglycemia. Control is particularly poor 
in youth and young adults and there appears to be a legacy effect of poor control on clinical 
complications later in life [2]. Hyperglycemia is a major risk-factor for endothelial cell 
dysfunction, both directly and indirectly [1]. Consequently, T1D is associated with a number of 
microvascular complications affecting our smallest blood vessels, the capillaries. We and others 
have previously observed in rodent models of T1D a loss of capillaries in skeletal muscle [3,4]. 
The skeletal muscle tissue is paramount for a variety of functions ranging from locomotion to the 
metabolic regulation of glycemia. Indeed, skeletal muscle is the major site of glucose uptake in 
the postprandial state in healthy humans, accounting for ~80% of the body’s insulin-mediated 
glucose disposal [5]. With muscular exercise, the rate of glucose uptake into muscle increases up 
to 50-fold [6,7]. Since capillaries are responsible for the delivery of oxygen and nutrients to 
skeletal myofibers, the capillary network appears as a key determinant of overall muscle 
functionality and it is crucial that the equipment in capillaries perfectly matches the metabolic 
needs of active myofibers. For endogenous (i.e. pancreatic) or exogenous (i.e. via needle or pump) 
insulin to promote glucose uptake into muscle, it must first distribute among the muscle capillaries, 
pass the endothelial barrier and diffuse though the interstitial space and bind with its receptor on 
the myocyte. A failure to deliver insulin to the target location (i.e. muscle) is now regarded as 
another reason for reduced insulin sensitivity [8], but the role of the capillaries in this process in 
T1D is not completely understood.  
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With a remarkable plasticity, the capillary network can grow, regress, or simply keep 
maintained in order to adapt to the myofibers' needs. Such skeletal muscle angio-adaptation is 
tightly regulated by a dynamic balance between pro- and anti-angiogenic molecules [9]. We have 
previously identified the E3 ubiquitin ligase Murine Double Minute-2 (Mdm2) as indispensable 
for skeletal muscle capillary maintenance, physiological capillary growth (i.e. angiogenesis) and 
the pro-angiogenic activity of endothelial cells (i.e. cell migration) [10-12]. We have also shown 
that Mdm2 could be considered a master regulator of skeletal muscle angio-adaptation as it can 
modulate both sides of the angio-adaptive balance, most notably, through the regulation of the pro-
angiogenic Vascular Endothelial Growth Factor-A (VEGF-A) and the anti-angiogenic 
Thrombospondin-1 (TSP-1) [10,12]. In the context of diabetes, our laboratory has recently shown 
that Mdm2 protein levels were significantly lowered in skeletal muscles of type 1 and 2 diabetic 
animals, coinciding with muscle capillary regression [4,10].  
Several studies suggest altered muscle capillarization and microvascular function in 
humans living with T1D. It has been observed, using human and animal models, that T1D prevents 
exercise training-induced angiogenesis [13], unmatched capillary perfusion alongside myofiber 
hypertrophy in response to exercise training [14], an enlargement of the capillary basement 
membrane hindering perfusion and vascular elasticity [15], and reduced peripheral skeletal muscle 
perfusion both at rest and after ischemia [16]. Furthermore, diabetes has been shown to impair the 
development of coronary collateral vessels [17]. Although very limited in number, previous studies 
that have investigated the impact of TID on skeletal muscle molecular angio-adaptation have 
exclusively utilized chemically-induced diabetes through streptozotocin (STZ) injection in 
rodents. STZ is a highly toxic alkylating agent that leads to hyperglycemia by accumulating in 
pancreatic β-cells through the glucose transporter-2 (GLUT-2) causing DNA alkylation and β-cell 
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death [18,19]. The onset of overt hyperglycemia is rapid, occurring in as little as 48-72 hours 
following STZ injection [18,20]. The systemic administration of STZ therefore represents an easy 
and cost-effective diabetes-inducing approach that is similar to the severe insulinopenia that occurs 
in untreated T1D. However, it raises questions regarding the toxicity of the substance in other 
tissues [21]. Indeed, the uptake of STZ by GLUT-2 is not specific to pancreatic β-cells, therefore 
being potentially toxic to other tissues and organs, such as the kidney and liver, potentially leading 
to confounding experimental results [18,21,22]. In cell culture and in vivo, STZ directly causes 
muscle protein ubiquitination, cell cycle arrest and reduced cell proliferation rates, independent of 
its impact on glycemia [23]. Alternatively, BioBreeding (BB) diabetic rats spontaneously develop 
T1D between 50-90 days of age, around the time of puberty, and present characteristics that closely 
resemble those of human patients with T1D, including exogenous insulin dependency, 
hyperglycemia, polydipsia, polyuria, and ketoacidosis [24-28]. As is the case with human T1D 
patients, the onset of diabetes in the BB rat is characterized by the infiltration of immune cells in 
the islets of Langerhans (insulitis) [28], preceding overt diabetes by two to three weeks. 
Subsequently, β-cells of the pancreas are selectively destroyed resulting in a severe type 1 diabetic 
phenotype. BB diabetic rats are classified as either diabetic-prone (DPBB) or diabetic-resistant 
(DRBB), the latter serving as a control group that have the same diabetes-susceptible genes but do 
not spontaneously develop T1D in viral-free conditions. In comparing the timeline of diabetes 
onset between BB rats and STZ-induction, the BB rat represents a chronic pathological state 
compared to the rapid development of diabetes induced by STZ. The selection of the BB rat model 
for our investigation is relevant since the skeletal muscle and its associated microvasculature 
undergo considerable growth and development during the age of onset in the BB rat, and are likely 
impacted by the level of glycemic control achieved [29].  
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To date, it is still unclear how, and to which extent, T1D could affect the microcirculation 
in skeletal muscle, especially in terms of capillarization. Here, we sought to determine whether 
capillary regression occurs in skeletal muscles from diabetic prone BB rats in order to more closely 
mimic the installation of type 1 diabetes seen in humans. We aimed to identify potential diabetes-
induced alterations in key angio-regulatory molecules such as Mdm2, VEGF-A and TSP-1. To our 
knowledge, this is the first study to investigate skeletal muscle angio-regulation in the BB diabetic 
rat. Understanding deleterious adaptations that occur in skeletal muscle as a result of T1D is of 
great importance for both the treatment and prevention of diabetes-associated vascular pathology.  
Materials and methods 
Animal model. This study was approved by the York University Animal Care Committee and was 
conducted in accordance with the Canadian Council for Animal Care Guidelines. Animals were 
bred at Sunnybrook Research Institute, Toronto, Canada, courtesy of Dr. Philippe Poussier 
(protocol #520). BioBreeding diabetes-prone (DPBB) rats and age-matched diabetes-resistant 
(DRBB) rats (n = 20 & 22 respectively) were housed under temperature-controlled conditions in 
a 12-hour light-dark cycle with ad libitum access to a standard rodent chow diet and water. DPBB 
animals typically become diabetic (blood glucose [BG] > 15mM) at a young age (i.e. between 50 
& 90 days post birth) and require insulin treatment to survive. Our blood glucose threshold for the 
determination of diabetes is in line with standard guidelines [30]. After diabetes was established, 
the animals' blood sugar was maintained between 12-20 mM to simulate the fair to poor glycemic 
control that is generally observed in youth living with the disease [31] by using subcutaneous 
insulin pellets (Linchen Canada) for a period of two weeks. Briefly, under inhaled isoflurane 
anesthetic a 0.5cm subcutaneous incision, just below the neck, was made and half to a full insulin 
pellet was implanted (LinShin, Canada Inc., Toronto, Ontario, Canada), with a full pellet releasing 
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about 2U of insulin/24hours for up to 40 days. The incision wound was closed and treated with 
topical antibiotics and pain cream (Flamazine, Smith & Nephew Canada) prior to being placed 
back in their cage.  
Glucose measurement. Whole blood glucose levels were measured daily using an AlphaTRAK2 
glucose meter (Abbott Diabetes Care Inc., Alameda CA) from a sterile saphenous vein bleed. 
Blood glucose values reported here were recorded just prior to skeletal muscle harvest.  
Skeletal muscle tissue isolation. Two weeks after insulin pellet implantation, animals were 
anaesthetized with inhaled isoflurane. Soleus and plantaris muscles were removed, weighted and 
immediately flash frozen in liquid nitrogen (protein measurements) or frozen in liquid nitrogen-
cooled isopentane for histology. All samples were stored at (-80˚C) until analysis.  
Muscle capillarization analysis. Transverse 10µm cryosections were obtained from the mid-belly 
of plantaris and soleus muscles from DRBB and DPBB rats using a cryostat set to -18°C (Leica 
CM1860) as previously described [10]. Capillaries were visualized after a brief fixation of 
cryosections in cold acetone followed by incubation with 5-bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium (FAST BCIP/NBT; cat. no. B5655-25TAB; Sigma-Aldrich, 
Oakville, ON, Canada) for 45 minutes at 37°C to stain for alkaline phosphatase activity. 
Microscope slides were mounted with VectaMount (cat. no. H-5501; Vector Laboratories Inc., 
Burlingame, CA, USA). Images were acquired on an Arcturus PixCell II inverted microsope (serial 
no. 0573; Arcturus Engineering, Mountain View, CA, USA) at x10 magnification and captured 
using QCapture software. For each muscle, the capillary-to-fiber ratio was determined after 
counting capillaries and myofibers in 6 independent images of a muscle cross section. Because the 
plantaris muscle is not homogeneous in its fiber-type composition, counting areas were chosen so 
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they cover all the muscle cross section. Capillary-to-fiber ratio is calculated by dividing the number 
of capillaries in each image by the number of myofibers. 
Western blotting. Immunoblotting was carried out on protein extracts from the plantaris and soleus 
muscles obtained from DRBB and DPBB rats, respectively, as previously described [10,11]. 
Protein concentrations for each sample were determined by the bicinchoninic acid (BCA) assay, 
and denatured samples (30 µg/sample) were subjected to SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) and blotted onto nitrocellulose membranes (Whatman, BA95, 
Sigma-Aldrich, Oakville, Ontario, Canada). Quality of the transfer was confirmed by Ponceau S 
red staining. After blocking with 5% fat-free milk at room temperature for 45 min, the blots were 
probed overnight at 4°C with the following primary antibodies: antibody against Mdm2 was a non-
commercial supernatant from the hybridoma (clone 2A10, previously described in [32]); antibody 
against FoxO1 was from Cell Signaling Technology (clone C29H4, #2880, Beverly,MA, USA); 
antibody against TSP-1 was from Invitrogen (clone A6.1, #MA5-13398, Burlington, ON, Canada); 
antibody against VEGF-A was from Millipore (clone VG1, #05-1117, Etobicoke, ON, Canada); 
antibodies against β-actin (#sc-47778) and VEGFR2 (clone D-8, #sc-393163) was from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). After incubation with secondary antibodies HRP-linked 
anti-mouse (#P0260; Dako, Carpinteria, CA, USA) or HRP-linked anti-rabbit antibody (#7074; 
Cell Signaling), proteins were visualized with enhanced chemiluminescence (Millipore) on X-ray 
film (CL-XPosure Film, #34090, Thermo Scientific, Rockford, IL, USA). Blots were analyzed 
with Carestream software. 
Statistical analysis. Statistical analyses were performed using Prism5 software (GraphPad, San 
Diego, CA, USA). Unpaired, two-tailed t-tests were performed for blood glucose, capillary-to-
fiber ratio, and all western blot analyses. Correlation analyses between variables were performed 
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with nonparametric 2-tailed Pearson correlation with determination of Pearson r and r2. P ≤ 0.05 
was considered to be statistically significant. 
Results 
Type 1 diabetes leads to hyperglycemia and skeletal muscle capillary regression. As 
expected, DPBB rats spontaneously develop type 1 diabetes (T1D), reflected by significantly 
higher blood glucose levels (+259%) measured at the time of muscle collection compared to 
DRBB animals (Fig 9.1A; BD-R, 6.58 ± 0.17 vs. DPBB rats, 23.64 ± 1.39 mmol/L; P ≤ 0.001). 
T1D leads to capillary regression in both plantaris (-15%) and soleus (-21%) muscles of DPBB 
rats as evidenced by measuring the capillary-to-fiber ratio (Fig 9.1B; DRBB, 1.68 ± 0.039 vs. 
DPBB, 1.43 ± 0.049 in plantaris; DRBB, 1.90 ± 0.045 vs. DPBB, 1.52 ± 0.063 in soleus; P ≤ 
0.001). The level of skeletal muscle capillarization had a significant inverse correlation with blood 
glucose levels in both muscles analyzed (Fig 9.1C; r = -0.327, P < 0.05 in plantaris; r = -0.479, P 
< 0.01 in soleus), suggesting that hyperglycemia is a strong predictor of capillary regression.  
Type 1 diabetes results in lowered Mdm2 and increased anti-angiogenic FoxO1 and TSP-
1 protein levels in skeletal muscle. As DPBB rats displayed a significant reduction in the number 
of skeletal muscle capillaries, with the severity of impairment related at least in part to the level of 
glucose control, we next aimed to determine which key angio-regulatory factors could be involved 
in the observed regression of capillaries. Diabetic DPBB rats had a significantly reduced 
expression of Mdm2 protein in both the plantaris (-19%) and soleus (-15%) muscles (Fig 9.2A; 
DRBB, 0.77 ± 0.05 vs. DPBB, 0.62 ± 0.04 arbitrary units in plantaris; DRBB, 0.74 ± 0.04 vs. 
DPBB, 0.63 ± 0.02 arbitrary units in soleus; P < 0.05). Alongside decreased levels of Mdm2 
protein in diabetic muscles, DPBB rats had ~80% more FoxO1 protein in the plantaris muscle 
compared to controls (Fig 9.1B; DRBB, 1.07 ± 0.09 vs. DPBB, 1.92 ± 0.3 arbitrary units; P < 
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0.05). Although not statistically significant, diabetic animals also tended to express more (~20%) 
FoxO1 protein in the soleus then what was observed in the control rodents (Fig 9.1B; DRBB, 1.12 
± 0.06 vs. DPBB, 1.31 ± 0.09 arbitrary units; P = 0.075). Concomitant with the decrease in Mdm2 
and the increase in FoxO1 expression, TSP-1 protein expression was drastically higher in skeletal 
muscles from diabetic DPBB rats compared to control rats (+172% and +67% in plantaris and 
soleus muscle, respectively) (Fig 9.1C; DRBB, 0.32 ± 0.04 vs. DPBB, 0.88 ± 0.1 arbitrary units in 
plantaris, P < 0.01; DRBB, 0.91 ± 0.15 vs. DPBB, 1.51 ± 0.13 arbitrary units in soleus, P < 0.001). 
Hyperglycaemia is correlated with decreases in Mdm2 and elevations in TSP-1 protein 
expression. Correlation analyses were performed between blood glucose level, Mdm2, and TSP-1 
protein expression in plantaris and soleus muscles from DPBB and DRBB rats. Interestingly, in 
the plantaris muscle, blood glucose levels were inversely correlated with Mdm2 protein expression 
(Fig 9.3A; r = -0.312, P < 0.05). A similar finding was observed in the soleus muscle, although 
this relationship was on the boarder of statistical significance (Fig 9.3A; r = -0.303, P = 0.054). In 
both the soleus and plantaris muscle, blood glucose was found to be positively correlated with 
TSP-1 protein levels (Fig 9.3B; r = 0.557, P < 0.001 in plantaris; r = 0.481, P < 0.01 in soleus). 
Furthermore, in both muscles, Mdm2 and TSP-1 protein expression were significantly, and 
inversely, correlated (Fig 9.3C; r = -0.335, P < 0.05 in plantaris; r = -0.424, P < 0.01 in soleus).  
The VEGF-A/TSP-1 ratio is drastically reduced in skeletal muscles of type 1 diabetic 
animals. Interestingly, DPBB rats show no change (soleus) or even an increase (plantaris) in 
VEGF-A protein expression level compared to non-diabetic animals (Fig 9.4A; DRBB, 0.37 ± 
0.02 vs. DPBB, 0.48 ± 0.04 arbitrary units in plantaris, P < 0.05; DRBB, 1.14 ± 0.04 vs. DPBB, 
1.12 ± 0.04 arbitrary units in soleus, P = 0.68). We have previously described the VEGF-A/TSP-
1 ratio as a good indicator of the angio-adaptive balance in rodent and human skeletal muscles 
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[9,10,12,33]. Here, and despite either no alteration (soleus) or even an increase (plantaris) in 
VEGF-A protein expression, the VEGF-A/TSP-1 ratio was strongly reduced in the plantaris (-
52%) and soleus (-71%) muscles of type 1 diabetic rats compared to non-diabetic animals (Fig 
9.4B; DRBB, 1.52 ± 0.2 vs. DPBB, 0.74 ± 0.15 in plantaris, P < 0.01; DRBB, 2.92 ± 0.9 vs. DPBB, 
0.87 ± 0.09 in soleus, P < 0.05).  
VEGF receptor-2 protein levels are decreased in type 1 diabetic muscle. In the soleus, a 
significant decrease (-32%) in Vascular Endothelial Growth Factor receptor-2 (VEGFR2) protein 
level was observed in DPBB rats compared to DRBB controls (Fig 9.5A; DRBB, 0.35 ± 0.03 vs. 
DPBB, 0.24 ± 0.02 arbitrary units, P < 0.01). Although not statistically significant, VEGFR2 
protein expression was reduced by ~30% in the plantaris of (Fig 9.5A; DRBB, 0.16 ± 0.02 vs. 
DPBB, 0.11 ± 0.01 arbitrary units, P = 0.06). Interestingly, a significant and inverse correlation 
was found between VEGFR2 protein and blood glucose levels in the soleus (Fig 9.5B; r = -0.427, 
P < 0.01), while a near-significant correlation was also found in the plantaris (Fig 9.5B; r = -0.307, 
P = 0.051).  
Discussion 
We showed here for the first time using the BioBreeding rodent model of T1D that in 
skeletal muscles from T1D rats poor blood glucose control is associated with capillary regression 
and alterations in protein expression of key angio-regulatory molecules. We performed our 
investigation in two muscles with distinct contractile and metabolic phenotypes:  the fast-twitch 
and predominantly glycolytic plantaris and the slow-twitch oxidative soleus. As summarized in 
Figure 9.6, we propose that T1D led to similar levels of capillary regression in both muscle types 
likely as a result of decreased Mdm2 and VEGFR2 levels, and elevated FoxO1 and TSP-1 proteins. 
While the direction and general trend of alteration in angio-adaptive molecules was found to be 
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similar between the plantaris and soleus muscle, the magnitude of change differed, especially for 
FoxO1, TSP-1, and VEGFR2. This could be explained by phenotypic differences in contractile 
and metabolic properties of the respective muscles, potentially leading to muscle type-specific 
regulation of the measured proteins. Nonetheless, despite these differences, the appreciable end 
result of capillary loss was comparable between the soleus and plantaris. Remarkably, alterations 
in Mdm2 expression and the VEGF-A/TSP-1 ratio were also very similar between the two muscles 
with the ratio reflecting a shift of the angio-adaptive balance towards an anti-angiogenic 
environment in muscles from T1D animals. This is in line with our previous work demonstrating 
that Mdm2 is a central regulator of skeletal muscle angio-adaptation and that such a complex 
biological process must be studied with an integrative approach taking into consideration both pro- 
and anti-angiogenic signals [10,12,33].  
It is well documented that T1D leads to an array of microvascular-related pathologies 
including retinopathy, neuropathy and nephropathy [34]. These three most common diabetic 
comorbidities typically arise through poor glycemic regulation leading to endothelial degeneration 
or (paradoxically) hyper-vascularization, alterations in vascular permeability, and changes in 
blood pressure [1]. However, very little research exists examining the molecular actors regulating 
skeletal muscle microvasculature in type 1 diabetes. In addition, those limited existing studies were 
based on STZ injection as a means to induce diabetes in rodent models. STZ treatment leads to the 
rapid destruction of pancreatic β-cells and subsequent hyperglycemia, but also can promote direct 
damage to other organs and tissues including skeletal muscle [23]. Alternatively, BB rats represent 
a chronic condition with the onset of diabetes occurring pathophysiologically as a result of 
spontaneous autoimmune-mediated destruction of pancreatic β-cells, similar to the disease 
progression in humans. In consequence, STZ-induced diabetes may represent a reasonable but 
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somewhat flawed model for the investigation of new insulin formulations and transplantation 
experiments, while the use of BB rats could be more appropriate for understanding the underlying 
mechanisms of T1D-mediated alterations including those affecting skeletal muscle angio-
adaptation [21]. In our study, the onset of T1D in the BB rat model indeed led to significant 
capillary regression in the skeletal muscle tissue (within a one to two weeks period), characterized 
by a true loss of existing capillaries as evidenced by the decreased capillary-to-fiber ratio. 
Conversely to capillary density, which can be affected by capillary loss but also by any change in 
the size of myofibers, the capillary-to-fiber ratio represents the gold standard for assessing true 
muscle angiogenesis or capillary regression. Here, we observed that the level of dysglycaemia (~2-
3 fold higher values than normal despite exogenous insulin therapy) were significantly correlated 
with alterations in the capillary-to-fiber ratio. 
We next aimed to explore key angio-adaptive molecular pathways that could be involved 
in such T1D-induced capillary regression. Our laboratory has recently identified Mdm2 as 
essential for the maintenance and plasticity of skeletal muscle microvasculature. In a pioneering 
study using transgenic mice expressing about 60% less Mdm2 compared to their wild-type 
littermates, Mdm2 deficiency resulted in a 20% reduction in skeletal muscle capillarization and 
fully blunted the exercise-induced angiogenic response [10]. We also showed that Mdm2 and its 
human analog Hdm2 were strongly associated with the level of skeletal muscle capillarization and 
endothelial markers in both rodents and humans [10,11]. The mechanisms through which reduced 
Mdm2 levels can lead to capillary regression are complex, as Mdm2 can be considered a ‘master 
regulator’ of the angio-adaptive balance affecting both pro- and anti-angiogenic factors (i.e. 
VEGF-A and TSP-1). VEGF-A is the most widely studied pro-angiogenic factor, promoting 
endothelial cell survival, proliferation, and migration [12,35-37]. Through the use of transgenic 
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animal models where VEGF-A had been deleted specifically in myofibers, we and others have 
shown that VEGF-A deficiency leads to significant capillary regression in skeletal muscle tissue 
[12,38]. It has been suggested that Mdm2 could stabilize Hypoxia-Inducible Factor-1α (HIF-1α), 
a transcription factor for VEGF-A, thereby promoting VEGF-A expression [39-42]. Aside from 
the HIF-1α/VEGF-A pathway, we have also shown that Mdm2 can directly bind to and negatively 
regulate the activity of the transcription factor FoxO1 and thus the expression of its downstream 
target TSP-1, a potent anti-angiogenic factor in skeletal muscle [10,12,43,44]. Interestingly, it has 
also been demonstrated that overexpression of FoxO1 in endothelial cells led to a decrease in 
VEGF-A mRNA levels suggesting FoxO1 could regulate not only TSP-1, but rather both sides of 
angio-adaptive balance (i.e. VEGF-A and TSP-1) [45]. 
In the context of diabetes, we have previously reported that Mdm2 protein expression was 
altered in skeletal muscle from Zucker Diabetic Fatty (ZDF) rats, a common model of obesity and 
type 2 diabetes. In ZDF plantaris muscles, Mdm2 was significantly lowered and a concomitant 
increase in FoxO1 protein levels was observed [10]. More recently, we reported a significant 
decrease in Mdm2 protein levels in both the tibialis anterior and soleus muscles of STZ-treated 
type 1 diabetic rats [4]. In the present study, we observed a decreased Mdm2 protein level in both 
soleus and plantaris muscles of DPBB rats. Taken together, our laboratory has investigated three 
separate models of diabetes (including both type 1 and type 2) in which skeletal muscle capillary 
regression has occurred. In each model, a significant reduction in Mdm2 protein levels was 
detected. The observed reductions in Mdm2 could potentially explain the loss of capillaries in type 
1 diabetic animals through Mdm2-dependent regulation of VEGF-A, FoxO1 and TSP-1.  
It is of vital importance to take into account both sides of the angio-adaptive balance when 
attempting to appreciate the overall effect of physiological and pathological stimuli on the skeletal 
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muscle microvasculature. As an important pro-angiogenic myokine, VEGF-A binds to receptors, 
and VEGFR2 plays a key role in mediating at the intracellular level the VEGF-A pro-angiogenic 
signal [46]. A previous study from Kivelä and colleagues [3] demonstrated that T1D induction by 
STZ injection significantly decreased mRNA levels of VEGF-A and VEGFR2 in the mouse calf 
muscle complex (gastrocnemius, soleus and plantaris). In accordance with VEGF-A mRNA 
expression, VEGF-A protein levels were significantly lower at both 3 and 5 weeks following the 
onset of diabetes. Similar to their findings, we show here reductions in VEGFR2 protein 
expression in diabetic muscles. However, in our study VEGF-A protein levels remained either 
unchanged (soleus) or even elevated (plantaris) in DPBB rats. Kivelä et al. [3] also show that TSP-
1 mRNA was significantly higher in diabetic mice compared to healthy controls, yet did not 
measure TSP-1 at the protein level. Here, we show that T1D leads to significant elevations in both 
FoxO1 and TSP-1 protein expression, and that Mdm2 and TSP-1 protein expression (the respective 
start and end point of the Mdm2-FoxO1-TSP-1 signaling axis) were significantly and inversely 
correlated. We have recently established that the VEGF-A to TSP-1 ratio is a good indication of 
the overall angiogenic environment [9,10,12,33]. In both soleus and plantaris, this ratio was 
dramatically decreased regardless of VEGF-A protein levels, reflecting an anti-angiogenic 
microenvironment in the skeletal muscle tissue. In addition, previous studies demonstrated that 
TSP-1 can negatively regulate VEGFR2 through inhibition of VEGF-A-dependent VEGFR2 
phosphorylation and activation in microvascular endothelial cells [47,48]. Based on these findings, 
an intriguing hypothesis could be made that the observed elevations in TSP-1 might inhibit 
VEGFR2 sensitivity to VEGF-A in diabetic muscles, concomitantly with an already diminished 
VEGFR2 protein abundance. Further investigation would be needed to elucidate this potentially 
novel regulatory relationship in T1D.  
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Our findings that some capillary regression occurred in T1D rats despite unchanged or 
increased VEGF-A expression levels is not surprising. Using hindlimb unloading as a well-
established rodent model for muscle atrophy, we demonstrated that plantaris and soleus muscles, 
despite similar levels of myofiber atrophy, had entirely different angio-adaptive responses [33]. In 
the plantaris, where capillarization was maintained, VEGF-A levels were found to be increased. 
In contrast, capillary regression occurred in the soleus muscle despite no decrease in VEGF-A but 
concomitantly to a strong increase in TSP-1 and reduction in VEGFR2. Taken together, it appears 
that anti-angiogenic factors (i.e. TSP-1) are equally important, if not more influential, than their 
pro-angiogenic counterparts in regulating skeletal muscle angio-adaptation to physiological as 
well as pathological conditions such as type 1 and type 2 diabetes.  
Interestingly, when focusing only on diabetic DPBB rats, the correlation analyses 
performed between blood glucose, capillary-to-fiber ratio, Mdm2, TSP-1 and VEGFR2 indicate 
that the DPBB rats that had lower blood glucose (i.e. 20 mmol/L) had similar magnitudes of angio-
adaptive alterations as the DPBB rats with highest blood glucose levels. This suggests that even 
the lower-end of hyperglycemia level in our model could be sufficient to initiate a shift in the 
angio-adaptive balance leading to capillary loss in the muscle. The notion of such a hyperglycemic 
‘threshold’ for changes at the molecular level leading to capillary regression is intriguing, and 
definitely warrants future research.  
Here, we identified a novel relationship whereby the magnitude of capillary regression in 
skeletal muscle may be predicted by the level of glycemic control in type 1 diabetes. This 
relationship between muscle capillarization and blood glucose level is of importance since reduced 
capillarization may exacerbate poor glycemic regulation in patients with diabetes, as capillaries 
are essential for insulin delivery and provision of glucose for uptake by myofibers. The loss of 
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capillaries in response to diabetic dysglycemia may be preceded by pathological alterations in 
angio-regulatory factors that are sensitive to glucose control, in particular Mdm2 whose expression 
level is also directly correlated to blood glucose levels. We have previously demonstrated that 
Mdm2 is at the fork between pro-angiogenic VEGF-A and anti-angiogenic TSP-1 signals. Our 
present results suggest that Mdm2-FoxO1-TSP-1 signaling may represent a strong molecular 
determinant of this pathological adaptation of capillary regression in type 1 diabetic skeletal 
muscle. Our findings provide merit for future studies investigating the Mdm2 signaling axis as 
related to capillary regulation in the skeletal muscle of humans living with type 1 diabetes.  
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Figure legends 
Figure 9.1. Type 1 diabetes in BB diabetes-prone rats results in hyperglycemia and decreased 
skeletal muscle capillarization. A) Blood glucose levels (mmol/L) in diabetes-resistant (DRBB) 
and -prone (DPBB) rats (n = 20 animals per group). The dashed line corresponding to 15mM blood 
glucose depicts the threshold where animals were considered diabetic. B) Top: Capillary staining 
in skeletal muscle cross-sections from DRBB and DPBB rat plantaris and soleus muscles (Scale 
bar = 100µm; x10 view). Bottom: Determination of the capillary-to-fiber ratio. Data are means ± 
SEM (n = 20-22 animals per group). Unpaired two-tailed t-tests indicate ***P ≤ 0.001 vs. DRBB 
rats. C) Correlation analysis between blood glucose and capillary-to-fiber ratio in the animals used 
in A-B. Blue circles and red squares represent data points for DRBB and DPBB rats, respectively. 
Figure 9.2. Type 1 diabetes alters protein expression levels of Mdm2, FoxO1 and TSP-1 in rat 
skeletal muscles. Representative immunoblots and densitometry analyses of protein expression are 
shown for Murine Double Minute-2 (Mdm2) (A), Forkhead Box O1(FoxO1) (B), and 
Thrombospondin-1 (TSP-1) (C) in plantaris and soleus muscles from type 1 diabetic rats (DPBB) 
and their controls (DRBB). β-actin was used as a loading control. Data are means ± SEM (n = 20-
22 animals per group). Unpaired two-tailed t-tests indicate ***P ≤ 0.001, **P ≤ 0.01 and *P ≤ 
0.05 vs. DRBB rats. 
Figure 9.3. Blood glucose levels are strongly correlated with Mdm2 and TSP-1 protein expression 
in skeletal muscle. Correlation analysis between blood glucose and Mdm2 protein (A), blood 
glucose and TSP-1 protein (B), and between Mdm2 and TSP-1 skeletal muscle protein levels (C) 
in the plantaris and soleus muscles of BB rats, respectively (n = 41-42 animals). Blue circles and 
red squares represent data points for DRBB and DPBB rats, respectively. 
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Figure 9.4. The ratio between TSP-1 and VEGF-A protein levels, and not VEGF-A alone, is a 
strong reflection of capillary regression in skeletal muscles from diabetic animals. (A) 
Representative immunoblots and densitometry analyses of VEGF-A protein expression and (B) 
the ratio of VEGF-A/TSP-1 protein expression in plantaris and soleus muscles from DRBB and 
DPBB rats, respectively. β-actin was used as a loading control. Data are means ± SEM (n = 20-22 
animals per group). Unpaired two-tailed t-tests indicate **P ≤ 0.01 and *P ≤ 0.05 vs. resistant rats. 
Figure 9.5. VEGF receptor-2 protein expression is decreased in skeletal muscles of type 1 diabetic 
animals and is inversely correlated with blood glucose levels. (A) Representative immunoblots 
and densitometry analyses of VEGF receptor-2 (VEGFR2) protein expression in plantaris and 
soleus muscles from DRBB and DPBB rats. β-actin was used as a loading control. Data are means 
± SEM (n = 20-22 animals per group). Unpaired two-tailed t-tests indicate **P ≤ 0.01 vs. resistant 
rats. (B) Correlation analysis between blood glucose and VEGFR2 protein expression in the 
plantaris and soleus muscles of BB rats, respectively (n = 41 animals). Blue circles and red squares 
represent data points for DRBB and DPBB rats, respectively. 
Figure 9.6. The BB rat model of type 1 diabetes results in hyperglycemia, skeletal muscle capillary 
regression, and altered angio-adaptive signaling. Type 1 diabetes in BB diabetes-prone rats results 
in significant elevation of blood glucose levels. This chronic hyperglycemic state induces angio-
adaptive alterations observable at the tissue level such as capillary regression (capillary-to-fiber 
ratio, C/F) as well as at the molecular level with changes in the angio-adaptive signaling. Mdm2 
serves as a negative regulator of FoxO1, therefore in the diabetic state, a down-regulation of Mdm2 
could lead to elevated FoxO1 and its transcriptional target TSP-1, a critical anti-angiogenic factor 
in skeletal muscle tissue. VEGF-A however is not lowered in the skeletal muscle of diabetic 
animals, whereas the expression of its receptor-2 (VEGFR2) is significantly reduced. Interestingly, 
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several significant correlations were found between some of these parameters (blood glucose level, 
capillaries, molecular markers) measured individually.   
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Figure 9.3 
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Figure 9.5 
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Figure 9.6 
 
 
 
 
 
 
 
 
 
169
10. DISCUSSION 
The role of Mdm2 in the angiogenic process is very complex, suggesting that Mdm2 may 
represent a novel ‘master regulator’ of several transcription factors influencing the angio-adaptive 
balance (FoxO1, HIF-1α, p53). These interactions affect both pro- and anti-angiogenic factors 
(VEGF-A, TSP-1), and the interplay between Mdm2 targets further highlights the complexity of 
the Mdm2-dependent angiogenic process. Refer to figure 10.1 for a schematic representing the 
various identified interactions between Mdm2 and its downstream targets. 
 
 
 
Figure 10.1 Schematic diagram of the complex regulatory functions of Mdm2 in the skeletal 
muscle and endothelial cell angio-adaptive balance including the reciprocal relationship between 
Mdm2 and VEGF-A, (+) indicates stimulatory and (-) indicates inhibitory effects. The letter “P” 
in a green circle represents a phosphorylated protein. 
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It has been the scope of my dissertation research to ascertain the physiological role of 
Mdm2 in regulating the skeletal muscle microvasculature. Ongoing clinical trials investigating 
drugs that block the interaction between Mdm2 and p53 in order to restore p53 function in cancer 
cells is intriguing. Although Mdm2 is overexpressed in some disease states (i.e. cancer), its basal 
expression level appears to be important in other contexts (i.e. in order to prevent muscle capillary 
regression in type 1 diabetes) and is essential for other healthy and physiological processes (the 
growth of muscle capillaries in response to exercise). My research highlights the necessity of 
understanding the role of Mdm2 in healthy tissues such as the skeletal muscle, as Mdm2-centered 
anti-cancer treatments could have devastating effects to the microvasculature in this tissue. It is of 
great importance to understand both pathological and physiological functions of Mdm2 in order to 
optimize existing pharmaceutical interventions and prevent unwanted deleterious effects in non-
targeted tissues.  
My research took the unique approach of investigating the pro-angiogenic function of 
Mdm2 in skeletal muscle and in endothelial cells at 4 distinct levels; 1) identifying signalling 
pathways and mechanisms of Mdm2 activation upstream of Mdm2, 2) investigating what happens 
to Mdm2 itself (i.e. protein abundance and post-translational modifications) in response to exercise 
training and an acute bout of exercise, 3) elucidating the pro-angiogenic effect downstream of 
Mdm2 in regard to molecular targets and the functional implications in endothelial cells, and 4) 
investigating the clinical relevance of the Mdm2 protein in the context of type 1 diabetes. 
Upstream of Mdm2, we have identified VEGF-A as a potent regulator of p-Ser166-Mdm2, 
uncovering a key pro-angiogenic relationship between Mdm2 and VEGF-A in both primary human 
endothelial cells and in human skeletal muscle tissue as a whole. Mediating this VEGF-A 
dependent Mdm2 activation is the ERK1/2-p90RSK signalling cascade, which was found to be 
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indispensable for VEGF-A-driven Mdm2 phosphorylation in human endothelial cells. Both acute 
bouts and the accumulation of exercise bouts (training) led to alterations in the activity or 
abundance of Mdm2 in rodent and human skeletal muscle tissue. We have shown that concomitant 
with elevated VEGF-A protein expression, Mdm2 is phosphorylated on its serine 166 in response 
to an acute bout of exercise. In addition, Mdm2, which is predominantly studied as an oncoprotein, 
is significantly upregulated in response to the physiological stimulus of exercise training in human 
skeletal muscle, translating findings from our laboratory previously obtained in rodents. 
Downstream of Mdm2 activation, my research demonstrates that Ser166 phosphorylation on 
Mdm2 enhances endothelial cell migration and promotes Mdm2/FoxO1 binding and supressed 
TSP-1 expression, uncovering a novel pro-angiogenic signalling pathway in endothelial cells. 
Finally, we have identified Mdm2 as a potentially important regulator of the skeletal muscle 
microvasculature in the context of diabetes, as Mdm2 protein levels are lowered corresponding to 
elevations in FoxO1 and TSP-1 alongside significant capillary regression in type 1 diabetic 
animals. 
Throughout my research, I have consistently shown that Mdm2 may exert its pro-
angiogenic effects by modulating the Mdm2-FoxO1-TSP-1 signaling axis. While we and others 
have described Mdm2 as a key regulator of VEGF-A expression [75,147-149], taken together, my 
research strongly suggests that the anti-angiogenic side of the regulatory balance may be more 
influential in exerting Mdm2 downstream pro-angiogenic effects. In “academic research paper 2” 
I show that while VEGF-A strongly stimulated the phosphorylation of Mdm2, thereby promoting 
Mdm2 activity, it was an increased interaction with FoxO1 and subsequent downregulation of 
FoxO1 transcriptional activity toward hallmark target genes, namely TSP-1, that led to enhanced 
endothelial cell migration. Interestingly, in cells that overexpressed the phospho-mimetic form of 
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Mdm2 (S166D-Mdm2), TSP-1 mRNA levels were significantly reduced along with suppressed 
VEGF-A expression. Despite the reduction in VEGF-A, the VEGF-A/TSP-1 ratio was much 
greater in cells overexpressing S166D-Mdm2 due to the larger relative reductions in TSP-1. While 
VEGF-A appears to be an essential driving force behind Mdm2 activation, signaling downstream 
of Mdm2 appears to be the limiting functional step in the pathway, as the Mdm2 antagonist nutlin-
3a entirely prevented the VEGF-A induced cell migration. The Mdm2-FoxO1-TSP-1 axis appears 
to be this functional link. Similarly, results observed in “academic research paper 4” show that in 
the context of type 1 diabetes, TSP-1 protein levels are significantly elevated concomitant with 
decreased Mdm2 abundance and capillary regression in the muscle of diabetic rats. VEGF-A 
protein however were either unaltered (soleus) or significantly higher (plantaris) in diabetic muscle 
despite the observed loss in capillaries. In both the soleus and plantaris, the VEGF-A/TSP-1 ratio 
was a better reflection of capillary loss, as this ratio was dramatically reduced in diabetic animals, 
again due to the relative alterations in TSP-1. Overall, the available literature indeed suggests that 
skeletal muscle capillary regression is more correlated with increased TSP-1 levels as opposed to 
reductions in VEGF-A [64,72]. Taken together, my research contributes novel evidence supporting 
the important role of anti-angiogenic factors in the regulation of the skeletal muscle 
microvasculature. 
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11. FUTURE RESEARCH 
Given the complex nature of Mdm2 interaction with angio-adaptive molecules, it is very 
likely that other angiogenic regulators are controlled by Mdm2 in skeletal muscle tissue and in 
endothelial cells. Broadening the scope of potential Mdm2 dependent angiogenic factors could be 
achieved by performing a Taqman real-time qPCR arrays. These arrays measure the expression 
level of >40 genes involved in angiogenesis, measured in duplicate. Modulating Mdm2 abundance 
and activity would allow direct comparison of the expression level of several angiogenic regulators 
measurable by the array that could be affected by Mdm2 status and activation. To investigate 
Mdm2 regulation in whole skeletal muscle tissue, arrays could be performed on muscles from 
Mdm2Puro/Δ7-9 transgenic mice that are Mdm2 deficient [75]. In primary human endothelial cells, 
S166D-Mdm2 infected cells could be compared to control and WT-Mdm2 overexpressing cells 
(see academic research paper 2). Changes detected in the array can be confirmed by regular 
Taqman qPCR (and at the protein level by western blot). 
My research significantly contributed to the understanding of both the upstream 
mechanisms of Mdm2 phosphorylation, and how this activation affects the functionality of 
endothelial cells. Alternatively, the potentially pro-angiogenic role of Mdm2 in the myofiber has 
not yet been identified. It is understood that the skeletal muscle is an endocrine organ [204], and 
myofibers can be considered the ‘power plant’ behind the production and release of several 
angiogenic factors that are essential for the health of the capillary network, such as VEGF-A. 
Indeed, the impact of myofiber-derived VEGF-A for the maintenance of muscle capillaries and for 
exercise-induced angiogenesis to occur has been reviewed earlier in this dissertation [93-96]. 
Furthermore, preliminary data from our laboratory shows that cultured muscle cells express TSP-
1 mRNA, and secrete TSP-1 protein into culture media (data not shown), identifying the myofiber 
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as a source of TSP-1 production and release. We have already demonstrated that Mdm2 has the 
ability to regulate both VEGF-A and TSP-1 expression at the level of whole skeletal muscle tissue 
and in endothelial cells, yet have not elucidated this relationship specifically in myocytes. 
Therefore, an intriguing research project would be to investigate Mdm2 regulation of VEGF-A 
and TSP-1 production and release from skeletal myocytes by manipulating Mdm2 activity and 
expression with the Mdm2 antagonist nutlin-3a or transfecting cells with Mdm2 siRNA. In 
addition, we have identified VEGF-A as an upstream regulator of p-Ser166-Mdm2 in endothelial 
cells, however it is not yet known the upstream stimuli responsible for Mdm2 phosphorylation in 
skeletal muscle cells.  
As outlined in the literature review section, exercise represents a complex environmental 
stimulus, in which multiple factors could play a role in the observed increase in p-Ser166-Mdm2 
protein levels. Mechanical forces such as shear stress and tissue stretch along with localized 
hypoxia could all serve as pro-angiogenic signals leading to alterations in the angio-adaptive 
balance, and have the ability to stimulate signaling pathways involved in the promotion of p-
Ser166-Mdm2. Indeed, my research clearly shows that Mdm2 acutely senses exercise stimulus, as 
can be appreciated by the increased phosphorylation of Mdm2 in response to an acute bout of 
exercise in both rodent and human skeletal muscle tissue (academic research paper 2). By utilizing 
cell culture models, we can mimic and isolate the effect of each exercise-related stressor by 
exposing cultured endothelial cells and/or myocytes to hypoxic incubation, hydrogen peroxide 
(oxidative stress), static stretch (Flexcell strain unit), or shear stress (parallel plate flow chambers). 
Following each respective treatment, p-Ser166-Mdm2 levels could be measured to evaluate which 
specific exercise-induced stress could be most important for regulating Mdm2 activity. 
Furthermore, and in combination with potential future research outlined in the previous paragraph, 
175
VEGF-A and TSP-1 production and secretion from myocytes in response to the various stimuli 
could be measured. The role of Mdm2 in regulating VEGF-A and TSP-1 production could be 
appreciated by pre-treating cells with nutlin-3a or transfection of Mdm2 siRNA prior to exposure 
of the exercise-related stressor.  
The well-established Mdm2 downstream targets p53, HIF-1α, and FoxO1 have all been 
implicated in the regulation of mitochondrial content in various cell types (i.e. cancer cells, skeletal 
myocytes, and endothelial cells). Namely, it has been shown that p53 plays an important role in 
the exercise-induced activation of mitochondrial synthesis in skeletal muscle tissue [205], and that 
an acute bout of exercise significantly induces translocation of the p53 protein to the mitochondria 
[206]. HIF-1α, conversely, appears to suppress mitochondrial biogenesis, as prolonged exposure 
to hypoxia (an event which stabilizes HIF-1α) leads to decreased mitochondrial content in skeletal 
muscle fibres [207]. Furthermore, Mason and Johnson [208] found that while wild-type mice had 
an increased oxidative capacity, muscle-specific HIF-1α knockout mice had already developed 
this adaptation without undergoing an exercise training program. Finally, FoxO1 may also play an 
important role in the metabolic regulation of endothelial cells, as a recent study by Wilhelm et al. 
[209] shows that forced expression of FoxO1 in endothelial cells reduces glycolysis and 
mitochondrial respiration. Using an in vivo model of Mdm2 deficiency [75], our laboratory has 
shown that Mdm2Puro/Δ7-9 mice who express 60% less Mdm2 than wild-types have an elevated HIF-
1α protein level in their skeletal muscle. These mice display a 20% reduction in skeletal muscle 
vascularization at rest, potentially leading to a hypoxic environment and HIF-1α upregulation. 
Furthermore, the Mdm2 deficient mice had significantly elevated FoxO1 protein levels and 
expression of the FoxO1 transcriptional target TSP-1. These elevations in HIF-1α and FoxO1 
could be a direct result of Mdm2 deficiency, and may potentially be a contributing factor to 
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lowered mitochondrial content. To date, it is not known whether Mdm2 could regulate 
mitochondrial biogenesis and respiration through interactions with its downstream targets. As 
previously stated, results from our laboratory show that increasing activation of Mdm2 in 
endothelial cells leads to an elevated binding between Mdm2 and FoxO1, and not between Mdm2 
and p53 or HIF-1α (academic research paper 2). The role of Mdm2 in skeletal muscle 
mitochondrial content and respiration in vivo could be assessed in Mdm2Puro/Δ7-9 mice, while the 
role of Mdm2 in endothelial and myocyte mitochondrial regulation in vitro could be investigated 
by treating primary human endothelial cells and myotubes with increasing concentrations of 
nutlin-3a or by transfection with Mdm2 siRNA. Whether the Mdm2-FoxO1 relationship could 
lead to increases in mitochondrial respiration in endothelial cells would be a novel finding in the 
field of Mdm2 research. 
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12. CLOSING STATEMENT  
It is common knowledge that exercise leads to numerous health benefits, and that by 
exercising we can become more “in shape” or “fit”. One very important determinant of this end-
result is adaptation of the skeletal muscle tissue. However, the muscle tissue would simply not be 
able to function properly without tightly orchestrated alterations to its vasculature. It has been my 
passion as a researcher to elucidate the molecular mechanisms that govern this adaptation to 
exercise. Just prior to the beginning of my graduate studies, the pioneering study from our 
laboratory that identified Mdm2 as an essential regulator of skeletal muscle capillarization had 
been published [75]. This research article truly paved the way and plotted the course for my 
research endeavours. 
Our laboratory is one of the few investigating the physiological function of Mdm2. When 
I began graduate studies in 2012, very little research existed examining the role of Mdm2 outside 
the context of cancer therapy. While investigating Mdm2 function in cancer is a promising field 
of research, it has been a great experience being able to contribute to the accumulation of evidence 
for a physiological role of Mdm2 in healthy tissues such as the skeletal muscle. At the time of 
writing this dissertation, our laboratory has solidified Mdm2 as an essential regulator of the muscle 
microvasculature through several research publications and scientific collaborations. I have 
dissected the pro-angiogenic role of Mdm2 in response to exercise training, as well as in response 
to individual acute bouts of exercise. Our laboratory has implemented an integrative approach to 
the study of Mdm2 angio-regulation, and I have contributed to the identification of novel 
interactions and signalling pathways involving Mdm2 and other angio-adaptive molecules in 
rodent and human skeletal muscle and in primary human endothelial cells. Additionally, my 
research has generated findings that may contribute in the long term to improving the treatment of 
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diseases such as type 1 diabetes that affect the muscle vasculature. Taken together, my doctoral 
research provides an important contribution to the field of muscle biology and exercise physiology, 
and improves our understanding of the molecular mechanisms regulating microvascular 
adaptability of skeletal muscle to physical exercise. It has been a privilege to immerse myself in 
the detailed investigation of skeletal muscle capillary plasticity in health and disease. 
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Abstract 
Type-1 diabetes mellitus (T1D) causes impairments within the skeletal muscle microvasculature. 
Both regular exercise and prazosin have been shown to improve skeletal muscle capillarization 
and metabolism in healthy rats through distinct angiogenic mechanisms. The aim of this study was 
to evaluate the independent and additive effects of voluntary exercise and prazosin treatment on 
capillary-to-fiber ratio (C:F) in streptozotocin (STZ)-treated diabetic rats. STZ (65 mg/kg) was 
intraperitoneally administered to male Sprague-Dawley rats (n = 36) to induce diabetes, with 
healthy, nondiabetic, sedentary rats (n = 10) as controls. The STZ-treated rats were then divided 
into sedentary (SED) or exercising (EX; 24-h access to running wheels) groups and then further 
subdivided into prazosin (Praz) or water (H2O) treatment groups: nondiabetic-SED-H2O, STZ-
SED-H2O, STZ-EX-H2O, STZ-SED-Praz, and STZ-EX-Praz. After 3 wk, untreated diabetes 
significantly reduced the C:F in tibialis anterior (TA) and soleus muscles in the STZ-SED-H2O 
animals (both P < 0.05). Voluntary exercise and prazosin treatment independently resulted in a 
normalization of C:F within the TA (1.86 ± 0.12 and 2.04 ± 0.03 vs 1.71 ± 0.09, P < 0.05) and the 
soleus (2.36 ± 0.07 and 2.68 ± 0.14 vs 2.13 ± 0.12, P < 0.05). The combined STZ-EX-Praz group 
resulted in the highest C:F within the TA (2.26 ± 0.07, P < 0.05). Voluntary exercise volume was 
negatively correlated with fed blood glucose levels (r2 = -0.7015, P < 0.01) and, when combined 
with prazosin, caused further enhanced nonfasted glucose (P < 0.01). Exercise and prazosin 
reduced circulating nonesterified fatty acids more than either stimulus alone (P < 0.05). These 
results suggest that the distinct stimulation of angiogenesis, with both regular exercise and prazosin 
treatment, causes a cooperative improvement in the microvascular complications associated with 
T1D. 
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Introduction 
Type-1 diabetes mellitus (T1D) is a chronic autoimmune disease targeting the pancreatic 
β-cells resulting in little to no insulin production and hyperglycemia (8). Despite exogenous insulin 
therapy, individuals with diabetes have an increased risk for long-term microvascular and 
macrovascular complications, which can significantly impact their morbidity and mortality (7, 10). 
T1D is also associated with impaired angiogenesis in skeletal muscle (1, 38). It is generally held 
that hyperglycemia itself, or some metabolic byproduct of hyperglycemia, induces remodeling of 
capillaries within the skeletal muscle, resulting in a lower capillary-to-fiber ratio (C:F) and 
ultimately affecting regional hemodynamic regulation (26, 41). 
New capillary growth within the skeletal muscle occurs via existing capillaries through two 
morphologically different, and separately inducible, forms of physiological angiogenesis termed 
sprouting or nonsprouting angiogenesis (13). The growth of new capillaries in response to 
exercising muscle is a highly regulated process (16), which is stimulated by increased functional 
hyperemia and shear stress (19), mechanical stretch of the tissue in addition to increases in 
metabolic demand, or reduced oxygen delivery (12). These signals modulate the expression and 
activity of proangiogenic and angiostatic factors, which act together to regulate sprouting 
angiogenesis (13). 
In addition to insulin therapy, regular exercise is an established management strategy for 
T1D, improving glucose uptake and insulin sensitivity within skeletal muscle (15). Additional 
health benefits include increased cardiorespiratory fitness, improved endothelial function, 
increased vascular health, and quality of life (6, 15). Regular endurance exercise increases skeletal 
muscle capillarization in healthy individuals (22). However, the effects of endurance training on 
changes in capillarization in diabetic animals and patients are contradictory (20, 27, 29, 44). 
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Vascular function has been shown to improve with physical activity in both animal models of 
diabetes (27) and in patients with T1D (6), but these alterations were unable to fully restore the 
diabetes-induced defects (14, 33). 
Prazosin, an α1-adrenergic antagonist, increases skeletal muscle capillarization via a 
vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase-dependent 
pathway (eNOS) (5, 45). These two mechanisms of action for prazosin ultimately cause 
longitudinal splitting of existing capillaries (46), which is distinct from the angiogenic, or 
sprouting, mechanisms that are observed with exercise. Prazosin has been used in many rodent 
studies (3, 9, 47) to selectively increase skeletal muscle C:F, but it has yet to be used as an agent 
to stimulate angiogenesis in an animal model of T1D. Chronic treatment with prazosin in 
streptozotocin (STZ)-induced diabetic rats reduces elevations in blood pressure and cholesterol 
levels and improves cardiac function (18), but its effect in muscle is unknown in the STZ model. 
In humans with type 2 diabetes, prazosin enhances hepatic function (11, 34), improves insulin 
sensitivity, and lowers lipid levels (21, 32), in addition to decreasing blood pressure (11, 21, 32, 
34). 
The aim of this study was to evaluate the independent and combined effects of exercise 
and prazosin administration on skeletal muscle capillary content in the STZ-induced rodent model 
of T1D. 
Methods 
This study was carried out in accordance with the recommendations of the Canadian Council for 
Animal Care guidelines and was approved by the York University Animal Care Committee (2013–
5). The Guide for the Care and Use of Laboratory Animals (8th ed., 2011) was followed. 
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 Animals. Adult, male Sprague-Dawley rats (Charles River Laboratories; initial mass of 
225–250 g, n = 46) were individually housed (lights on 12-h cycle: lights off 12-h cycle) after 1 
wk of acclimatization to room temperature (22–23°C)- and humidity (50–60%)-controlled 
facilities. 
 Experimental design. A timeline of the experimental protocol is shown in Fig. 14.1. All 
animals had access to voluntary running wheels for 1 wk. Each exercising animal was placed into 
rodent cages with 24-h access to a running wheel (Harvard Apparatus), while sedentary animals 
were housed in standard cages. Running distance was assessed daily. Seven days after wheel 
assignment, a single injection of STZ (65 mg/kg) was administered to induce diabetes. Animals 
were also provided with sugar water (20% sucrose) to assist with diabetes development, and any 
exercising animals had their wheels removed overnight to further promote diabetes induction. Two 
days after diabetes inducement, animals were divided into one of five groups: nondiabetic-SED-
H2O (control), STZ-SED-H2O, and STZ-EX-H2O, all given regular drinking water; and STZ-
SED-Praz and STZ-EX-Praz, all given drinking water containing prazosin hydrochloride (5 
mg/kg; P7791; Sigma-Aldrich). Five days after diabetes induction, all animals had their food 
reduced to 30% of their total body weight to improve glycemia in the diabetic animals. Body mass, 
fed blood glucose, food intake, and fluid consumption were measured daily for each rodent and 
any changes in the rodents’ health were noted and monitored. 
 Blood glucose, nonesterified fatty acid, and corticosterone sampling. Blood glucose values 
were measured with a glucometer (Alpha-TRAK; Abbott Laboratories) and 5 µl of blood from the 
tip of the tail. Blood samples were collected from each animal via saphenous vein for nonesterified 
fatty acid (NEFA kit, HR Series NEFA-HR; Wako Chemicals) and corticosterone (MP 
Biomedical) concentration measurements on days 1 (basal) and 32. Glucose area under the curve 
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(AUC) was measured relative to each animal’s individual day 11 glucose value and the net area 
was used to account for the lowering in blood glucose observed in both exercising groups. 
 Capillary-to fiber analysis. Skeletal muscle, tibialis anterior (TA), and soleus, from 
euthanized animals, was embedded in tissue freezing medium, frozen in liquid nitrogen, and 
cryosectioned (10-µm thick). TA and soleus sections (10-µm thick) were fixed with 3.7% 
paraformaldehyde before being stained with fluorescein isothiocyanate-conjugated Griffonia 
simplicifolia isolectin B4 (1:100; Vector Laboratories). Sections were viewed using a Zeiss M200 
inverted microscope with a X20 objective and images were captured using Metamorph imaging 
software. Capillary-to-fiber counts were averaged from five to seven independent fields of view 
per animal by a blinded observer, and ~45 fibers/image were counted. 
 Western blotting. Immunoblotting was carried out on protein extracts from rat soleus or 
TA muscles as previously described (2). Frozen muscle (20-40 mg) was mixed at 4°C with RIPA 
buffer. For each sample, protein extracts were prepared using two stainless carbide beads (Retsch, 
Fisher Scientific, Montreal, Canada) in the Retsch MM400 tissue lyser (30 pulses/s; Retsch, Haan, 
Germany). Denatured samples (30 µg/well) were subjected to SDS-PAGE and blotted onto 
nitrocellulose membranes. After blocking with 5% fat free milk at room temperature for 45 min, 
the blots were probed overnight at 4°C with primary antibodies against the following proteins: β-
actin (sc-47778; Santa Cruz Biotechnology, Santa Cruz, CA), murine double minute-2 (Mdm2; 
noncommercial clone 2A10 (2, 39, 40), VEGF (clone VG-1; 05–1117; Millipore, Etobicoke, ON, 
Canada), or TSP-1 (clone A6.1; MS-421-P0; Invitrogen, Burlington, ON, Canada). After 
incubation with secondary antibody (cat. no. P0260; Dako, Carpinteria, CA), proteins were 
visualized with chemiluminescence (Millipore) on Imaging Station 4000MM Pro (Carestream 
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Health, Rochester, NY) or on X-ray film (CL-XPosure Film; prod. no. 34090; Thermo Scientific, 
Rockford, IL). Blots were analyzed with Carestream software. 
 Statistical analysis. All data are represented as means ± SE, with a criterion of P < 0.05 
and P < 0.01 and were assessed as stated using two-way ANOVAs as a means of statistical 
significance. Individual differences were calculated using Bonferroni’s post hoc test (Statistica, 
StatSoft). A t-test was also used to compare values for nondiabetic and STZ-treated rats. 
Results 
 Capillary-to-fiber content. The effect of STZ-induced diabetes on the skeletal muscle 
microvasculature was evaluated using the C:F, expressed relative to fiber number to account for 
diabetes-related muscle atrophy. There was obvious capillary rarefaction in the TA of the STZ-
SED-H2O group when compared with the nondiabetic, control group (Fig. 14.2, A and A’, P < 
0.001), which was paralleled within the soleus of the STZ-SED-H2O animals (Fig. 14.3, A and A’, 
P < 0.001). 
 Within the TA, C:F for both the STZ-SED-Praz and the STZ-EX-H2O groups were 
significantly higher from the STZ-SED-H2O group (Fig. 14.2, B and B’, P < 0.001), although they 
were not significantly different from each other. This suggests that individually, both prazosin and 
exercise were capable of improving the diabetes-induced loss of capillaries toward that observed 
in nondiabetic control rats. The STZ-EX-Praz animals had significantly higher C:F in comparison 
with the STZ-EX-H2O and STZ-SED-Praz animals (P < 0.001), signifying that cotreatment 
exerted an additive effect on angiogenesis. We also observed an increase in C:F within the soleus 
of the STZ-SED-Praz animals (P < 0.01) and the STZ-EX-Praz animals (Fig. 14.3, B and B’, P < 
0.05); however, exercise was unable to improve the diabetes-induced rarefaction independently. 
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 Circulating glucose concentrations. Hyperglycemia was evident in all STZ-treated animals 
(Fig. 14.4A). When analyzed as an AUC from day 11 onward (the date of prazosin initiation), there 
was a significant main effect of both exercise and prazosin to improve daily fed glucose 
concentrations, with the most favorable response occurring in the STZ-EX-Praz group (Fig. 
14.4A’, P < 0.01), suggesting that the cotreatment produced the most beneficial result. 
 Running distance. Daily running distance was graphed in relation to prazosin 
administration (Fig. 14.5A) and no difference was found between the average running distance in 
the two exercising groups (Fig. 14.5B). A significant negative correlation was observed between 
individual mean blood glucose concentrations and cumulative running distances (r2= -0.70; Fig. 
14.5C, P < 0.01). 
 Corticosterone and NEFAs. STZ-induced diabetes affected the concentrations of 
circulating corticosterone and NEFAs. Before prazosin administration, corticosterone and NEFA 
concentrations were not different across the STZ-treatment group, so these data were pooled 
(initial basal, Fig. 14.6, A and B). All STZ-treated animals developed significantly elevated 
corticosterone concentrations (Fig. 14.6A, P < 0.001) at the end of the treatment period, and only 
the prazosin group showed significantly decreased values (Fig. 14.6A’, P < 0.05). There was a 
significant effect of voluntary exercise, prazosin and their combination, to improve NEFA values 
(Fig. 14.6B’, P < 0.05). 
 Mdm2, VEGF-A, and TSP-1. VEGF-A and TSP-1, key pro- and antiangiogenic molecules 
in skeletal muscle, are influenced by Mdm2, and these three markers have been used to understand 
the changes observed in skeletal muscle C:F. In both the TA and soleus muscles, STZ-treated rats 
had significantly decreased Mdm2 protein content vs. nondiabetic rats (Fig. 14.7, A, A’, B, and B’, 
P < 0.05). Within the TA, Mdm2 protein content was lowest in the STZ-SED-H2O group but was 
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only significantly lower than the STZ-SED-Praz group (Fig. 14.7A”, P > 0.05). Soleus Mdm2 
protein content was not significantly modified in the four different treatment groups (Fig. 14.7B”). 
There was no significant effect of STZ treatment, prazosin, or exercise on VEGF-A protein content 
within either the TA or soleus muscles (Fig. 14.8, A, A’, A”, B, B’, and B”, P > 0.05). There was 
also no significant effect of STZ treatment, prazosin, or exercise on TSP-1 protein content within 
either the TA or soleus muscles (Fig. 14.9, A, A’, A”, B, B’, and B”, P > 0.05). 
Discussion 
Using a combined therapeutic approach, we have shown that exposure to 19 days of combined 
voluntary exercise and prazosin treatment caused improved skeletal muscle vascularization, 
through enhanced C:F within the TA muscle and a normalization of the C:F within the soleus 
muscle of STZ-treated rats. Acutely, prazosin administration is not known to improve glycemia in 
diabetes; however, we found that prazosin-induced skeletal muscle capillarization, which was 
independent of voluntary exercise, was associated with improvements in nonfasted (fed) glucose 
concentrations. When combined with voluntary exercise, prazosin treatment caused additional 
improvements in fed glucose concentrations and circulating lipid levels, thereby suggesting that 
the two treatments can act in an additive fashion to improve muscle capillarization and metabolism 
in this animal model of T1D. To our knowledge, this is the first time that these two therapeutic 
modalities have been combined in an animal model (health or disease) and suggests that there is 
likely an additive effect of both prazosin and exercise on angiogenesis and metabolic rescue in 
diabetes. 
 It is well established that endurance exercise promotes new capillary growth (22) in both 
animals and healthy humans (35); however, literature regarding the effect of exercise on the 
pathological effects of T1D within the skeletal muscle vasculature is inconclusive (20, 44). In 
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healthy rats, exercise training causes increased VEGF mRNA and protein content, which 
stimulates further enhancements in muscle capillarization (16). When examined in STZ-induced 
diabetic mice, treadmill endurance training was unable to improve quadriceps femoris cross-
sectional fiber area or C:F after 5 wk of exercise training (27). In our study, uncontrolled STZ-
induced diabetes caused significant capillary rarefaction, a decrease in the number of capillaries 
in an area of tissue, in both the TA (Fig. 14.2, A and A’) and soleus muscles (Fig. 14.3, A and A’), 
which is consistent with previous studies (28, 41). When given access to voluntary exercise wheels, 
STZ-induced diabetic rats showed a significant increase in C:F in the TA (Fig. 14.2, B and B’) and 
a slight, but not significant, tendency to increase C:F in the soleus (Fig. 14.3, B and B’) when 
compared with sedentary STZ-treated rats. The exercise modality in our study was voluntary wheel 
running and this might have elicited different muscle recruitment between the TA vs. soleus 
muscles (25), although there was no difference in volume of exercise between treatment groups 
(Fig. 14.5, A and B). Additionally, angiogenic potential appears to be inversely proportional to the 
original capillarity, i.e., it is easier to induce in fast muscle than slow or cardiac muscle (12), 
another possible explanation for the muscle type-specific differences observed in capillarity. 
 The enhancement of skeletal muscle capillarization, through nonsprouting angiogenesis 
with prazosin treatment, results in an increase in capillarity in glycolytic and oxidative skeletal 
muscles in healthy rats (3, 9, 47). However, to our knowledge, this study is the first to illustrate 
the beneficial effects of prazosin on skeletal muscle capillary rarefaction in STZ-induced diabetic 
rats. We observed a normalization of C:F in both TA and soleus muscles of sedentary, STZ-treated 
rats as their C:F values were equivalent to those measured in the control group. When coupled 
with wheel running, there was an additive effect on the angiogenic response, specifically in the 
TA. It is worth noting that the skeletal muscle angiogenesis observed within both the TA and 
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soleus (the normalization) occurred amidst significantly elevated circulating corticosterone levels 
(Fig. 14.6, A and A’), a hormone that has been linked to capillary rarefaction (42). In addition to 
the fact that both treatment modalities result in distinct forms of angiogenesis, there are data 
suggesting that the combination of high-volume, low-intensity exercise, like voluntary wheel 
running, actually elicits a more rapid angioadaptive response than what is observed after treadmill 
exercise training (35). 
 Exercise is a widely recognized strategy for improving glycemia in diabetes (6), as regular 
exercise leads to the improvement of whole body glucose and lipid metabolism and enhanced 
skeletal muscle glucose disposal (17) and insulin sensitivity (23, 24). We observed a significant 
effect of voluntary exercise to improve fed glucose concentrations in the STZ-treated rats, and this 
result was amplified when the animals were coadministered prazosin (Fig. 14.4, A and A’). These 
improvements in blood glucose, regardless of prazosin administration, were also correlated to 
running distance (Fig. 14.5C), suggesting that higher running volumes caused better fed glucose 
concentrations. In our study, sedentary STZ-induced diabetic rats treated with prazosin also 
showed improved fed glucose values throughout the experimental protocol, an unexpected but 
interesting observation, given the inconsistent findings on prazosin treatment in various models of 
hyperglycemia (4, 18, 31). As prazosin is not known to acutely lower blood glucose levels, our 
results highlight the importance of skeletal muscle capillary content on glucose homeostasis and 
demonstrate that increased capillarization likely enhances insulin sensitivity and glucose disposal, 
an observation recently seen in healthy rats (3). 
 The angiogenic response is controlled by a dynamic balance between anti- and 
proangiogenic factors (36). VEGF-A and TSP-1 are key pro- and antiangiogenic molecules (30, 
37). Interestingly, we have recently brought evidence that the E3 ubiquitin ligase Mdm2 could be 
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a central regulator of skeletal muscle angiogenesis, partly by regulating VEGF-A and TSP-1 
expression (2, 40). 
 Our current results show, for the first time, that STZ-treated rats had a significant decrease 
in Mdm2 protein levels in both the TA and soleus muscles, as summarized in Fig. 14.10A. This 
reduction in Mdm2 could explain the lowered skeletal muscle capillarization in both muscles in 
sedentary diabetic rats, as Mdm2 protein levels have been shown to be closely related to 
endothelial content within the skeletal muscle (40). It was previously observed that both 
capillarization and Mdm2 protein levels were significantly lower in a model of type-2 diabetes and 
in skeletal muscles from Zucker diabetic fatty (ZDF) rats (40). Further results demonstrated that 
voluntary running efficiently restored both the impaired skeletal muscle capillarization and Mdm2 
protein levels within the ZDF rats. In contrast to these findings, the voluntary exercise stimulus 
applied within our current study did not rescue the observed decrease in Mdm2 protein in the 
diabetic animals (Fig. 14.10B) and suggests that the physiological response of Mdm2 to exercise 
could be lost in uncontrolled, T1D muscle. 
 No significant alterations in TSP-1 or VEGF-A protein levels in response to diabetes 
induction, prazosin treatment, or voluntary exercise were observed in either the TA or soleus 
muscles. Moreover, VEGF receptor expression in soleus and TA muscle were unchanged by STZ 
treatment nor by exercise or prazosin treatment (data not shown). Kivelä et al. (27) have shown 
that STZ-induced diabetic mice had lower VEGF-A protein levels at 3 and 5 wk post-diabetes 
induction and a concomitant increase in TSP-1 expression. In that study, while exercise served to 
delay the reduction in VEGF-A levels, it was not sufficient to attenuate the elevation in TSP-1 
mRNA. The C:F is increased as early as 14 days of treadmill running in rodent skeletal muscle 
(43); therefore, we hypothesize that alterations in VEGF-A and TSP-1 protein levels could have 
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occurred at an earlier time point to stimulate the growth of capillaries. While VEGF-A protein 
could have been elevated before the measured time point to induce the angiogenic process, the 
trend for TSP-1 protein levels could indicate the stopping or slowing down of capillary growth, as 
the balance between oxygen and nutrient supply and demand had been achieved in the skeletal 
muscle. 
 In summary, the significant improvement to fed glucose concentration observed after 
cotreatment with voluntary exercise and prazosin administration could be the result of 
enhancements in insulin sensitivity and lipid metabolism, increased skeletal muscle glucose 
disposal, and possibly improved diffusion conditions for glucose in the muscle as the result of 
heightened skeletal muscle angiogenesis. These results suggest that the combination of both 
voluntary exercise and prazosin administration could lead to a cooperative improvement in 
peripheral vascular complications linked to T1D and may perhaps prevent future complications 
through the augmentation of skeletal muscle capillarization and glycemia status. 
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Figure legends 
Figure 14.1. Schematic of the experimental design. Basal saphenous vein measurement for 
corticosterone and nonesterified fatty acid (NEFA) concentrations occurred on day 1 before the 
provision of voluntary running wheels. Streptozotocin (STZ) was administered on day 7, prazosin 
on day 11 and on day 14 animals had their food reduced to 30% of their total body weight to 
improve glycemia in the diabetic animals. Animals were euthanized on day 32 (end point) with a 
final saphenous vein sample. T1D, type 1 diabetes. 
Figure 14.2. Capillary-to-fiber ratio (C:F) in the tibialis anterior in nondiabetic and STZ-treated 
rats (A and A’) and after 20 days of voluntary exercise and prazosin cotreatment (B and B’). All 
values are means ± SE (n = 3–5 per group). SED, sedentary; EX, exercise; Praz, prazosin. 
***Significantly different from nondiabetic group (P < 0.05). Different letters (a, b, and c) indicate 
a significant difference (main effect treatment and activity) between groups (P < 0.001), following 
two-way ANOVA (post hoc test). 
Figure 14.3. C:F in the soleus of nondiabetic and STZ-treated rats (A and A’) and after 20 days of 
voluntary exercise and prazosin cotreatment (B and B’). All values are means ± SE (n = 5 per 
group). ***Significantly different from nondiabetic group (P < 0.001). Different letters (a, b, and 
c) indicate a significant difference (main effect of treatment) between groups (P < 0.05), using a 
two-way ANOVA (post hoc test). 
Figure 14.4. Blood glucose values across the experimental timeline (A) and expressed as area under 
the curve (AUC; A’). AUC values are calculated from day 11 (prazosin administration) until day 
32 (end point). A main effect of both prazosin (P < 0.01) and exercise (P < 0.01) to improve daily 
glucose concentrations was found, with the cotreatment (STZ-EX-Praz) producing the most 
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significant improvement. All values are means ± SE (n = 6–10 per group). Different letters (a, b, 
and c) indicate a significant difference (main effect treatment and activity) between groups (P < 
0.05), following two-way ANOVA (post hoc test). 
Figure 14.5. Voluntary running distances over time (A) and the total mean values (B) were graphed 
from the initiation of the cotreatment (prazosin administration). Running distance was negatively 
correlated to mean blood glucose concentration (C) (r2 = -0.7015, P < 0.01). All values are means 
± SE (n = 6–10). 
Figure 14.6. Corticosterone and NEFA in nondiabetic and STZ-treated rats (A and B) and after 20 
days of voluntary exercise and prazosin cotreatment (A’) and (B’). Black and white bar represents 
combined basal value before STZ injection. All values are means ± SE (n = 6–10 per group). 
***Significantly different from nondiabetic group (P < 0.001). Different letters (a and b) indicate 
a significant difference (main effect treatment/activity for corticosterone and activity for NEFA) 
between groups (all P < 0.05), following two-way ANOVA (post hoc test). 
Figure 14.7. Skeletal muscle murine double minute-2 (Mdm2) protein levels are decreased in STZ-
induced T1D. A: murine double minute-2 (Mdm2) protein in control (nondiabetic) and STZ-treated 
rat tibialis anterior (TA) muscles. A’: Mdm2 protein in nondiabetic and STZ-treated rat TA muscle. 
*P ≤ 0.01 following unpaired Student’s t-test analysis. A”: Mdm2 protein in the TA muscles of 
sedentary, prazosin-treated sedentary, exercised, or exercised and prazosin-treated STZ-treated 
rats. Different letters indicate significant difference, P ≤ 0.05 following two-way ANOVA. B: 
Mdm2 protein in nondiabetic and STZ-treated rat soleus muscles. B’: Mdm2 protein in nondiabetic 
and STZ-treated rat soleus muscle. *P ≤ 0.05 following unpaired Student’s t-test analysis. B”: 
Mdm2 protein in the soleus muscles of sedentary, prazosin-treated sedentary, exercised, or 
exercised and prazosin-treated STZ-treated rats. All data are means ± SE (n = 6 per group). Same 
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letter (a) indicates no significant differences were found between groups following two-way 
ANOVA. 
Figure 14.8. STZ-induced diabetes does not alter skeletal muscle vascular endothelial growth 
factor (VEGF) protein levels. A: VEGF protein in control (nondiabetic) and STZ-treated rat TA 
muscles. A’: VEGF protein in nondiabetic and STZ-treated rat TA muscle. No significant 
difference following unpaired Student’s t-test analysis. A”: VEGF protein in the TA muscles of 
sedentary, prazosin-treated sedentary, exercised, or exercised and prazosin-treated STZ-treated 
rats. B: VEGF protein in nondiabetic and STZ-treated rat soleus muscles. B’: VEGF protein in 
nondiabetic and STZ-treated rat soleus muscle. No significant difference following unpaired 
Student’s t-test analysis. B”: VEGF protein in the soleus muscles of sedentary, prazosin-treated 
sedentary, exercised, or exercised and prazosin-treated STZ-treated rats. All data are means ± SE 
(n = 6 per group). Same letters indicate no significant differences between groups following two-
way ANOVA. 
Figure 14.9. STZ-induced diabetes does not alter skeletal muscle thrombospondin-1 (TSP-1) 
protein levels. A: TSP-1 protein in control (nondiabetic) and STZ-treated TA muscles. A’: TSP-1 
protein in nondiabetic and STZ-treated rat TA muscle. No significant difference following 
unpaired Student’s t-test analysis. A”: TSP-1 protein in the TA muscles of sedentary, prazosin-
treated sedentary, exercised, or exercised and prazosin-treated STZ-treated rats. B: TSP-1 protein 
in nondiabetic and STZ-treated rat soleus muscles. B’: TSP-1 protein in nondiabetic and STZ-
treated rat soleus muscle. No significant difference following unpaired Student’s t-test analysis. 
B”: TSP-1 protein in the soleus muscles of sedentary, prazosin-treated sedentary, exercised, or 
exercised and prazosin-treated STZ-treated rats. All data are means ± SE (n = 6 per group). Same 
letters indicate no significant differences between groups following two-way ANOVA. 
229
Figure 14.10. Summary of the effects of prazosin and exercise within the TA skeletal muscle of 
STZ-treated rats. A: STZ treatment causes increased fed blood glucose levels, elevations in 
corticosterone (Cort), NEFA, and decreased insulin (Ins) content. Within the TA, STZ treatment 
decreased C:F and Mdm2 protein content while both VEGF and TSP-1 were unaffected. B: STZ-
treated rats were exposed to either prazosin treatment, voluntary exercise, or a combination of 
both. Individually, prazosin and voluntary exercise increased C:F and decreased both NEFA and 
fed blood glucose concentrations. Prazosin treatment increased Mdm2 protein content while 
VEGF and TSP-1 were unaffected. Voluntary exercise caused no alterations to angiogenic 
proteins. The combination of prazosin with voluntary exercise resulted in the most improved fed 
blood glucose concentrations and C:F. Both Cort and NEFA concentrations were unaffected and 
there were no alterations to angiogenic proteins. 
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